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High throughput analytical methods based on UPLC-APCI-HRMS and/or UPLC-ESI-
HRMS were developed for the multi-residue analysis of pharmaceuticals, personal care 
products (PPCPs), brominated flame retardants (BFRs) and their 
degradation/transformation products. The PPCPs method was successfully applied to 
analysis of freshwater samples from Egypt. Target PPCPs were ubiquitous in the 
Egyptian aquatic environment and displayed relatively high concentrations in an effluent 
sample from a hospital wastewater treatment plant. The BFRs method was applied to 
screen for legacy BFRs, novel BFRs and their potential degradation/transformation 
products in simulated landfill leachate samples. In vitro bioassays were developed to 
study for the first time the metabolism of the novel BFRs TBECH by human liver 
microsomes and EH-TBB and FM550 by human skin S9 fractions. TBECH was 
metabolised by hepatic CYP450-mediated enzymes to produce a complex mixture of 
hydroxylated, debrominated and α-oxidation metabolites. EH-TBB and TPhP (in the 
FM550 mixture) underwent biotransformation by carboxylesterases in human skin S9 
fractions. Kinetic modelling of the studied hepatic and dermal human biotransformation 
reactions revealed that exposure to multiple chemicals significantly influences the 
metabolic rates of target compounds. In vitro – in vivo extrapolations were also modelled 
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In recent years, more and more chemicals of emerging concern have been discovered in 
the environment with the aid of advances in analytical science and instrumentation. These 
chemicals pose potential risks to the environment and human health. However their fate, 
toxicity and exposure pathways are not yet fully understood. An emerging contaminant 
(EC) therefore was defined by the USEPA as “a chemical or material characterized by 
a perceived, potential, or real threat to human health or the environment or by a lack of 
published health standards. A contaminant also may be "emerging" because of the 
discovery of a new source or a new pathway to humans” (USEPA, 2010). By this 
definition, ECs cover both truly new compounds that were not detected previously and 
chemicals which have been around but just recently have been brought to the attention of 
the scientific community. The list of ECs comprises at least hundreds of organic and 
inorganic pollutants belonging to numerous chemical categories. Some prime examples 
of ECs are novel brominated flame retardants (NBFRs) and pharmaceutical and personal 
care products (PPCPs). One of the important challenge of studying ECs in general and 
NBFRs and PPCPs in particular is how to simultaneously analyse a broad suit of 
chemicals in a sample. With the recent advances in mass spectrometry (MS) e.g. Orbitrap 
MS technology, this challenge can be addressed. In this chapter, the Orbitrap MS 
technology will be introduced and potential applications of UPLC-Orbitrap MS in 
environmental science will be discussed. Additionally, background information about 
NBFRs and PPCPs will also be introduced with focus on their main human exposure 
pathways and associated human and wildlife health risks. 
1.1. Orbitrap mass spectrometry 
Mass spectrometry is a powerful analytical technique that ionises chemicals into ions 
(positive or negative, singly or multiply charged) then sorts and separates them by a mass 
analyzer based on their mass to charge ratio (m/z). Such information together with other 
parameters such as ion intensities and retention time (if the MS is coupled to a 
chromatography instrument such as liquid chromatography or gas chromatography) allow 
identification and quantification of chemicals within a sample. For samples generated 
from complex matrices (e.g. environmental or food), it is extremely important for a MS 
instrument to have high selectivity in order to differentiate between a chemical of interest 
and interferences. The selectivity of an instrument is reflected by its mass resolution, 
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which is defined as the ability to distinguish between two ions with very small differences 
in their m/z (ΔM) and calculated as the ratio of ion mass over ΔM (IUPAC, 1997). An 
MS platform that is capable of delivering mass resolution power more than 10,000 is 
considered a high resolution mass spectrometer (HRMS). 
There are various types of HRMS, each with their own limitations and advantages. Some 
common types of mass spectrometry systems for environmental analysis are sector field, 
time of flight, Fourier transform ion cyctron resonance, and Orbitrap. A sector field MS 
instrument often consisted of both magnetic sector and electric sector that provide high 
reproducibility, sensitivity and resolution. However, they are bulky, expensive and has 
limited application in untargeted screening analysis. The Fourier transform ion cyctron 
resonance (FT-ICR) MS can provide extremely high resolution power up to over 
1,000,000 (Ghaste et al., 2016) but it is very expensive and performs at relatively slow 
scan rate. FT-ICR-MS is also a complex system that takes up a large laboratory space. 
The time of flight (TOF) instruments have high scan rates, dynamic range and resolution 
power (up to 60,000) but limited precursor selectivity in MS/MS experiments (Eichhorn 
et al., 2012; Ghaste et al., 2016). 
Orbitrap technology is the most recent advance in mass spectrometry that has been 
invented by Alexander Makarov in 2000 (Makarov, 2000). Schematic representation of 
an Orbitrap mass spectrometer (Q Exactive series) is shown in Figure 1.1. Samples are 
introduced into the Ion Max Atmospheric Pressure Ionization housing via a nanospray 
needle. The instrument is capable of ionizing samples by three different ionization 
technique: Electro Spray Ionization (ESI), Atmospheric Pressure Chemical Ionization 
(APCI) and Atmospheric Pressure Photoionization (APPI), each technique can be used in 
positive (+), negative (-) or alternative switching positive/negative (+)/(-) polarity. The 
ion beams enter the mass spectrometer via a S-Lens system and then it is transmitted to 
the quadrupole through a series of flatapole to remove neutral particles. The quadrupole 
can act as a precursor selection unit, which filters out unwanted ions based on a 
preselected mass range. After exiting the quarupole, the ion beam is accumulated in the 
C-Trap. After a package of ions (which can contain multiple ions beams) is trapped in the 
C-Trap (defined by AGC Target number), MS/MS fragmentation can be done in the 
Higher Energy Collisional Dissociation (HCD) cell if needed, then the ion package is 
introduced into the Orbitrap mass analyzer through the Z Lens.  
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Figure 1.1: Schematic components of the Q Exactive Orbitrap mass spectrometer 
series (Michalski et al., 2011b). 
  
The Orbitrap mass analyzer consists of an outer barrel-like electrode and a coaxial inner 
spindle-like electrode (Figure 1.1) (Qizhi et al., 2005). Once an ion package entered the 
Orbitrap, they start to oscillate back and forth around the inner electrode. This orbital 
movement creates an image current which can be converted into a mass spectrum by 
Fourier transformation (Qizhi et al., 2005, Annette Michalski et al., 2011) at up to 150,000 
FWHM in early models and 1,000,000 FWHM in some modern ones.  
Some typical scan functions can be carried out by an Orbitrap MS instrument are: Full 
Scan (FS), All Ion Fragmentation (AIF), Single Ion Monitoring (SIM), Parallel Reaction 
Monitoring (PRM) and Data Independent Analysis (DIA). Additionally, different scan 
functions can be used in one method, either each function in a different time range; or 
alternating analysis throughout a time period. In order to choose a proper MS data 
acquisition mode for a particular analysis, it is necessary to understand the mechanism of 
each mode. 
Full Scan mode provides mass spectrum of ions without any preselection in the 
quadrupole or further fragmentation. A data dependent MS/MS acquisition can be 
performed if needed after a full scan cycle. This mode is Full MS-ddMS2 or TopN 
acquisition where a full scan is obtained and then N highest intensity m/z (Top N) are 
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fragmented in subsequent N number of PRM scans, each scan feature one among N 
previously mentioned m/z in the order from highest to lowest intensity. 
All Ion Fragmentation allows fragmentation of all the ions produced by the ionization 
source. This can be done by 2 types of induction: in source collision induced dissociation 
(in source CID) and HCD. The in source CID technique utilizes the nebulizer, drying or 
sheath gas to collide with the ions formed in the atmospheric pressure region (before 
entering the entrance cone) (Parcher et al., 2017). Whereas the HCD cell fragments ion 
packages (introduced via the C-trap) with prefilled nitrogen gas (Figure 1.1), in-source 
CID and HCD can be applied together for a pseudo MS3 experiment. 
Single Ion Monitoring mode is similar to Selected Ion Monitoring mode in single quad 
and triple quad instruments where a narrow population of precursors ion (can be as narrow 
as ± 0.2 mz) was preselected by the quadrupole and analyzed in the Orbitrap. 
Parallel Reaction Monitoring is somewhat comparable to Single Reaction Monitoring 
(SRM) or Multiple Reaction Monitoring (MRM) in triple quad instruments, however, the 
HCD cell serves as Q2 and the Orbitrap serves as Q3. Basically, a precursor ion is selected 
by the quadrupole, fragmented by the HCD cell, and all the fragmentation ions are 
analyzed by the Orbitrap. 
In Data Independent Analysis, samples are often infused into the MS via syringe pump. 
A mass range of ions of interested (e.g. 400 to 1000 m/z) is then divided into smaller, 
equal mass segments (e.g. 400 to 410 mz, 410 to 420 m/z, …, 990 to 1000 m/z) and 
MS/MS experiments are done on these segments, continuously. 
Depending on the purposes of a particular experiment, different Orbitrap MS parameters 
including ionization mode, polarity and scan mode can be chosen accordingly. 
Commercially available in 2005, UPLC-Orbitrap HRMS is a state of the art platform, 
which consist of ultra performance liquid chromatography coupled to Orbitrap MS. It has 
soon become very popular in biosciences applications such as proteomics or 
metabolomics thanks to its fast separation, high resolution, accurate ion masses (up to 
less than 1 ppm mass deviation) features (Dunn et al., 2008; Lu et al., 2008; A Michalski 
et al., 2011; Yates et al., 2009). With these features, it is thought that UPLC-Orbitrap 
HRMS is also suitable to study other classes of chemicals in addition to protein and 
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metabolites such as pharmaceuticals or environmental contaminants. However, the 
potential of Orbitrap technology has not been fully explored and its capabilities are not 
fully exploited in the field of environmental analysis. Recently, a HPLC-Orbitrap MS 
method has been developed to analyze 27 brominated flame retardants (BFRs) in fish 
using Atmospheric Pressure Photoionization (APPI) (Zacs and Bartkevics, 2015). The 
method was reported to be rapid, sensitive (method limit of detections 0.001 – 0.25 ng g-
1 sample) and selective where almost no background noise was observed at quantifying 
m/z of detected BFRs in fish samples. Comparable results of BFRs in fish were achieved 
in comparison with a gas chromatography (GC)-HRMS method, which is often referred 
to as the gold standard platform to analyze this class of chemical. Additionally, in contrast 
to GC, chromatographic separation of the method was done using liquid chromatography 
that can avoid degradation of some thermal labile BFRs (Zacs and Bartkevics, 2015). This 
demonstrated the great potential of Orbitrap technology in environmental science studies. 
Therefore, in this thesis we aim to investigate the UPLC-Orbitrap-HRMS as an advanced 
platform for analysis of environmental contaminants, particularly brominated flame 
retardants and pharmaceutical and personal care products. 
1.2. Novel Brominated Flame Retardants 
1.2.1. Production, usage and physicochemical properties 
Brominated flame retardants (BFRs) have been used extensively as additive/reactive 
flame retardants (FRs) to improve the fire resistance of combustible consumer products 
such as electronic equipment, flexible foam, plastics, textiles, wood and a wide range of 
other materials. Among the various classes of BFRs, polybrominated diphenyl ethers 
(PBDEs) have attracted the most attention with respect to environmental contamination. 
In May 2009, the Penta-BDE and Octa-BDE commercial mixtures were listed under the 
United Nations Environment Programme (UNEP) Stockholm Convention on persistent 
organic pollutants (POPs) due to their toxicity, persistence, bioaccumulation and long-
range atmospheric transport. Manufacture and new use of Deca-BDE has also been 
restricted severely in Europe and the United States of America, and it is currently under 
active consideration for listing under the Stockholm Convention. Such restrictions on 
PBDEs without concomitant relaxation of fire retardancy regulations has paved the way 
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for increased use of novel or emerging brominated flame retardants (NBFRs/EBFRs), as 
alternatives for PBDEs. For example, 1,2-bis(2,4,6-tribromophenoxy) ethane (BTBPE) 
and decabromodiphenyl ethane (DBDPE) have been suggested as replacements for Octa-
BDE and Deca-BDE commercial mixtures, respectively (Brown et al., 2014). 
To date, the exact production volume of NBFRs is still unknown but it was estimated to 
be around 100,000 metric tons per year (Harju et al., 2008). This number however covered 
only 21 NBFRs. Among those, 4 additive FRs namely DBDPE, BTBPE, bis(2-
ethylhexyl) tetrabromophthalate (BEH-TEBP) and 2-ethylhexyl-2,3,4,5-
tetrabromobenzoate (EH-TBB) are produced in higher volume than others and 
consequently have attracted more attention from environmental scientists. They were all 
classified as high production volume chemical in the US (produced or imported more than 
500 tons per year) (USEPA, 2006; WHO, 1997). DBDPE is marketed under the trade 
names Saytex 8010 (Albermarle Corp.), FR-1410 (Dead Sea Bromine Co.) and Fire-
master 2100R (Chemtura Corp.) and used in high-impact polystyrene (HIPS), engineering 
and thermoset plastic (e.g. ABS, polyamides, polycarbornates, etc.), wires and cables. 
BTBPE, EH-TBB and BEH-TEBP were produced by Chemtura Chemical Corporation 
and used in different flame retardant formulations: Firemaster 680 (BTBPE), Firemaster 
550 (EH-TBB:BEH-TEBP in  4:1 ratio ), Firemaster BZ-54 (EH-TBB:BEH-TEBP in 
2.5:1 ratio)  and DP-45 (BEH-TEBP) (Davis and Stapleton, 2009; Stapleton et al., 2008). 
It is clear that the physicochemical properties of NBFRs are similar to that of legacy BFRs 
such as PBDEs, TBBPA or HBCDDs (Table 1.1). They often have high Kow (octanol-
water partition coefficient) and low water solubility values, meaning these compounds 
tend to accumulate in lipid-rich (e.g. adipose tissues) rather than in aqueous media.  Due 
to these properties, NBFRs have the potential to bioaccumulate inside living organisms 
and biomagnify from lower to higher trophic levels in a food chain. Their vapour 
pressures are usually quite low, in the range of semi volatile organic compounds.  NBFRs’ 
chemical structures also resemble closely those of legacy BFRs with many bromine 
moieties usually directly attached to an aromatic ring (Figure 1.2). It is thought that they 
are endocrine disrupting chemical (EDC) candidates (Kovarich et al., 2011; Mankidy et 
al., 2014; Saunders et al., 2015b, 2013). 
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Table 1.1: Physicochemical properties of some legacy and novel BFRs reported by U.S EPA (commercial PBDEs) or estimated by 










pressure at 25 
oC (mm Hg) 
Water 
solubility at 










C14H8Br6O2 9.15 2.38E-10 0.22 
Commercial 
Deca-BDE 
   C12Br10O 6.27
 3.2E-8 < 1 
Commercial 
Octa-BDE 





   C12H5Br5O 6.64 – 
6.97 
2.2E-7 - 5.5E-7 13.3 
DBDPE  84852-
53-9 














C15H18Br4O2 8.75 3.43E-8 3.41 
HBB  87-82-1 Hexabromobenzene C6Br6 7.33 1.68E-8 226 
HBCDDs HBCD 3194-
55-6 






C13H12Br2Cl6 7.91 1.07E-7 0.14 
PBEB  85-22-3 Pentabromoethylbenzene C8H5Br5 7.48 4.65E-6 104.7 
TBBPA  79-94-7 Tetrabromobisphenol A C15H12Br4O2 5.90 6.24E-6 1 
2,4,6-TBP  118-79-
6 










C9H7Br5O 6.34 6.22E-7 79.8 
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1.2.2. Toxicity and health effects 
Currently, the toxicological effects of NBFRs are still not very well-studied and available 
data is scarce. DBDPE administered rats showed significantly increased thyroid hormone 
Triiodothyronine (T3), Thiobarbituric acid (TBA) and decreased Creatinine (Cr) levels in 
comparison with control group (F. Wang et al., 2010a). Furthermore, DBDPE metabolites 
tended to accumulate in liver and kidney more than in adipose tissue. This indicated 
DBDPE and its metabolites have potential to influence the endocrine system and cause 
oxidative stress (F. Wang et al., 2010a). Similarly, it was also reported that DBDPE could 
inhibit antioxidant enzymes and therefore trigger oxidative stress in fish liver (Feng et al., 
2013). By using human liver subcellular fractions, Smythe et al., 2017 found DBDPE 
able to inhibit deiodinases and sulfotransferases in human liver. This was also the first 
time a non-hydroxylated contaminant was reported to express such effects.  
Mice exposed to tris(2,3-dibromopropyl) isocyanurate (TDBP-TAZTO) for 28 days 
showed severe toxic effects on mice lung, and altered lung and liver ultrastructure, 
especially mitochondria e.g. enhanced hepatocyte apoptosis and mitochondria 
degeneration in liver and mitochondria swelling in lung (J. Li et al., 2015). Using chicken 
LMH cells in conjunction with in silico modelling, Asnake et al., 2015 reported three 
NBFRs namely TBP-AE, TBP-BAE and TBP-DBPE inhibited androgen receptor (AR) 
activation, possibly by docking to the ligand binding pockets of chicken AR. The 
endocrine toxicities of other NBFRs in animal models have also been reported. For 
example, in fish, an EH-TBB and BEH-TEBP mixture and HCDBCO altered gene 
expression and decrease fecundity (Saunders et al., 2015a, 2015b), β-DBE-DBCH 
disrupted thyroid axis (Park et al., 2011), and BTBPE affected transcriptional responses 
(Giraudo et al., 2017). 
In short, NBFRs do not usually express acute toxicity (Hardy et al., 2012; F. Wang et al., 




1.2.3. Occurrence in major environmental compartments of concern 
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Non-occupational human exposure to so-called “legacy” BFRs such as PBDEs, HBCDDs 
and TBBPA occurs mainly through ingestion of indoor dust and diet with lesser 
contributions from indoor air inhalation and dermal absorption (although substantial 
uncertainty exists about the magnitude of the latter) (Abdallah and Harrad, 2014, 2011; 
Lorber, 2008). Currently, very limited data are available for NBFRs in terms of human 
exposure; however considering the fact they share quite similar physicochemical 
properties with conventional BFRs, it is plausible to hypothesise that human exposure to 
NBFRs will occur via pathways similar to those for “legacy” BFRs (Table 1.1). 
1.2.3.1. Indoor dust exposure 
For PBDEs, house dust has been highlighted as accounting for 82 % of the estimated 
intake of PBDEs in the U.S population (Lorber, 2008). Unsurprisingly therefore, an 
increasing volume of data are emerging about the presence of NBFRs especially BEH-
TEBP, EH-TBB, DBDPE, and BTBPE in indoor dust. 
As NBFRs is a general term covering a wide range of organobromine compounds with 
different physicochemical properties, most studies only focus on a limited number of 
chemicals in this group. The most common compounds analyzed and which frequently 
exhibit the highest concentrations in indoor media are: EH-TBB, BEH-TEBP, DBDPE, 
BTBPE, and HBB. More studies on other NBFRs are needed. 
Concentrations of these 5 common NBFRs in indoor dust are usually in the low ng g-1 
range. Among different non-occupational indoor microenvironment categories, houses 
have received the most attention, followed by offices and cars. Available data indicates 
that concentrations of DBDPE and BTBPE in office dust surpass those in house dust, 
while those of other NBFRs are comparable between different microenvironments. 
Harrad et al. (2008) reported median concentrations in UK house, office and car dust of 
24, 99 and 100 ng g-1 for DBDPE and 5.3 ng g-1, <MDL, and <MDL for BTBPE in the 
respective microenvironments. A recent study on house dust from Birmingham, UK 
found pentabromoethylbenzene (PBEB), EH-TBB, BEH-TEBP, BTBPE and DBDPE at 
median concentrations of 0.3, 4.1, 1.2, 36, 74 ng g-1 in kitchen dust and 0.4, 12, 75, 4.5, 
and 120 ng g-1 in living room/bedroom dust, respectively (Kuang et al., 2016). DBDPE 
concentrations in UK living room/bedroom dust sampled during 2006-07 (median, 24 ng 
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g-1) were significantly exceeded by those in dust sampled in 2015 (median, 120 ng g-1) 
(Kuang et al., 2016). Similar concentrations of EH-TBB, BTBPE and DBDPE to those 
reported by Kuang et al., 2016 in house dust collected in 2015 were found in a separate 
study conducted in Birmingham on house dust sampled in 2013 and 2014 by Al-Omran 
and Harrad, 2015. They also discovered that BEH-TEBP concentrations significantly 
increase with decreasing dust particle size, however this was not the case for other NBFRs 
in the study. House and office dust collected in Birmingham in 2015 were frequently 
detected with a broad suite of NBFRs including α- and β-4-(1-2-dibromoethyl)-1,2-
dibromocyclohexane (DBE-DBCH), pentabromobenzene (PBBz), tetrabromo-o-
chlorotoluene (TBCT), pentabromotoluene (PBT), 1,2,4,5-tetrabromo-3,6-
dimethylbenzene (TBX), 2-3-dibromopropyl-2,4,6-tribromophenyl ether (TBP-DBPE), 
hexabromobenzene (HBB), syn- and anti-dechlorane plus (DDC-CO), 
tetrabromobisphenolA bis(2,3-dibromopropyl ether (TBBPA-BDBPE), PBEB, EH-TBB, 
BTBPE, and BEH-TEBP (Tao et al., 2016). The median concentration of NBFRs in house 
and office dust samples mostly felt between <0.01 to 62 ng g-1 with some exceptions: 
TBBPA-BDBPE in house dust (1000 ng g-1) and BTBPE, BEH-TEBP, DBDPE and 
TBBPA-DBPE in office dust (160, 160, 440 and 2300 ng g-1) (Tao et al., 2016). By 
comparison with results from a previous study in the same area (Harrad et al., 2008), the 
authors suggested that restrictions on legacy FRs have increased demand for NBFRs in 
the UK (reflected by the significant higher concentrations of BTBPE and DBDPE in 
office dust and DBDPE in house dust over the time course 2007 to 2015) (Tao et al., 
2016). 
Inspection of the global database reveals clear geographical differences in the relative 
abundance of different NBFRs. Specifically, in North America, EH-TBB and BEH-TEBP 
predominate, but in Asia, especially China, BTBPE and DBDPE are the most abundant. 
In an urban area of Guangzhou, South China; Wang et al. (2010) reported BTBPE, 
DBDPE, PBT, PBEB and HBB to be present in house dust at median concentrations 
(range) of 6.47 (nd-211), 2733 (100-47000), 1.52 (0.22-12), 0.15 (nd-2.05) and 18.1 
(1.95-483) ng g-1 respectively. Significantly increased levels of BTBPE (by a factor 
between 1 and 8) and DBDPE (by between 40-400 times) between 2010 and 2015 were 
observed in dust from 3 sites in Longtang, China (Zheng et al., 2015).  
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In North America, Stapleton et al. (2008) reported geometric mean concentrations of 39.4, 
17.7, 91.1, and 65.8 ng g-1 for DBDPE, BTBPE, EH-TBB and BEH-TEBP, respectively 
in home vacuum bags collected in Boston, US in 2006 (n=19).  Another study compared 
NBFR concentrations in dust collected from the living areas of sixteen homes in northern 
California, US in 2006 with those in detected in dust collected in the same homes in 2011. 
Concentrations of BTBPE stayed relatively static over time while EH-TBB, BEH-TEBP 
and DBDPE exhibited an increasing trend over the 5 years period (Dodson et al., 2012). 
A wide range of current use BFRs were detected in house dust sampled during 2007-2008 
in Vancouver, Canada, specifically: allyl-2,4,6-tribromophenyl ether (TBP-AE), 
pentabromobenzyl acrylate (PBB-Acr), octabromotrimethylphenyl indane (OBTMPI), 2-
bromoallyl-2,4,6-tribromophenyl ether (TBP-BAE), EH-TBB, BEH-TEBP, BTBPE, 
HBB, PBB, PBT, TBP-DBPE, PBEB, TBCT, BB-101 and TBX; with EH-TBB and BEH-
TEBP present at much higher levels than others (Shoeib et al., 2012). Similar patterns 
were also observed elsewhere in Canada (Abbasi et al., 2016; Fan et al., 2016; Venier et 
al., 2016). 
A consistent finding across all studies to date is that the EH-TBB:BEH-TEBP ratio in 
dust differs markedly (in both directions) from the 4:1 value present in commercial 
Firemaster 550 (Ali et al., 2011; Stapleton et al., 2008). The implication of these 
observations is that there exist sources additional to FM-550 (e.g. use of BEH-TEBP as a 
plasticizer) and/or that there are substantial differences in the environmental behavior (e.g. 
volatility, degradation rate) of the two compounds.  
Another noteworthy observation is that dust in e-waste recycling facilities and adjacent 
houses often contains much higher concentration of NBFRs than residential dust from 
locations not impacted by e-waste recycling. Urban and suburban house dust collected in 
2008 in Vietnam showed BTBPE and DBDPE to be present at maximum concentrations 
of 100 and 150 ng g-1, respectively, while those in two Vietnamese e-waste recycling sites 
were 6 to 10 times higher: 620 ng g-1 for BTBPE and 1,600 ng g-1 for DBDPE (Tue et al., 
2013).  
Besides e-waste impacted areas, dust samples from some other less common 
microenvironments were also found to contain very high NBFRs levels.  Allen et al. 
(2013) reported a suite of NBFRs in dust from carpets and air vents on airplanes (n=40, 
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sampled in 2010) at much higher concentrations than reported elsewhere for house, car 
or office dust. Median concentrations of BTBPE, HBB, EH-TBB and BEH-TEBP were 
330, 100, 350 and 640 ng g-1 for carpet dust and 1300, 45, 740 and 1200 ng g-1 for air vent 
dust, respectively. Recently, La Guardia and Hale (2015) detected extremely high levels 
of EH-TBB and BEH-TEBP in dust from houses of 4 gymnasium coaches (averages of 
2580 and 1850 ng g-1 respectively) with even higher concentrations (averages of 40800 
and 24300 ng g-1 respectively) found in dust from their corresponding work places.
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Table 1.2: Summary median concentrations of some common novel brominated flame retardants in indoor dust (ng g-1) 
Location Sampling 
time 













Sweden 2012 Office, store, 
school, 
apartment 
27 9.1 140 12 17  1.2  Newton et 






House 30   24 5.3    Stuart et al., 
2008  
 
Office 18   99 <dl    
Car 20   100 <dl    
UK 2007 
2008 






House   39 1 13 153 2 78   
Office   6 7 64 721 19 306   
Romania 2010 House   47 5 20 170 5    Dirtu et al., 
2012  






 Car   30   98.8 <2.1    Kalachova 





House 48 16.1 132 512 8.73 1.93 1.72  Cequier et 
al., 2014  
Classroom 6 2.67 99.9 179 13.4 0.269 3.31  
Germany NA House   20 <3.0 343 146 <10    Fromme et 





House 38 409b 377b  22b    Johnson et 





House   59 337 186 82.8 22.3  0.91 0.75 Brown et 
al., 2014  





House   116 120 99  30    Shoeib et 





NA   67 220     
Devanathan 
et al., 2011  EWRS NA   120 65000    
Residential 
buildings 





2008 House  50 4a 17a 26a 3a    Ali et al., 
2012a  
Pakistan NA House 15 0.4 5.8 90 15    Ali et al., 
2013 
Car 15 0.5 6.5 65 10.5    
Kuwait NA House 15 6.6 54 220 6.8    Ali et al., 
2013 
Car 15 13 85 202 4    
Egypt 2013 
 
House 17 0.81 0.12  0.24   0.18 Hassan and 
Shoeib, 
2015 
Office 5 7.14 0.09  1.26   0.04 






25   890     Muenhor et 





House 13   40 – 46c 7.1 - 
3.1c 





20   220 – 
230c 





House    220     Mizouchi et 
al., 2015  









27   63.1 20    Wang et al., 
2010   
2007 House in 
urban area  
19   2733 6.47    
China 2010 House and 
public places 
81 130 120 1100 120    Qi et al., 
2014  
 
a : arithmetic mean                   b : geometric mean                     c : median range 
*: α+β DBE-DBCH; EWRS: E-waste recycling sites; n: sample number 
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1.2.3.2. Indoor air exposure 
The first report about BTBPE and DBDPE in household air was published by Karlsson et 
al., 2007. In 5 samples from Örebro, Stockholm and Norrköping in Sweden, the authors 
found DBDPE in one from Örebro at 22.9 pg m-3 while BTBPE was not detected in any 
samples. Recently, indoor air from twelve offices, stores, and apartments in Stockholm 
was assessed (Newton et al., 2015). Geometric mean concentrations of NBFRs in these 
samples were: DBE-DBCH (α+β) 43 pg m-3, PBT 10 pg m-3, HBB 7.2 pg m-3, BEH-TEBP 
42 pg m-3, and DBDPE 79 pg m-3. In Norway, Cequier et al., 2014 monitored a broad 
range of NBFRs in air samples from 48 households, with mean (maximum) 
concentrations of: DBE-DBCH 222 pg m-3 (4120), TBP-AE 6.69 pg m-3 (69.3), TBX 64.5 
pg m-3 (2830), PBB 9.30 pg m-3 (50.8), PBT 14.3 pg m-3 (213), PBEB 1.29 pg m-3 (30.6), 
TBP-DBPE 5.49 pg m-3 (132), DBDPE 38.2 pg m-3 (963), and HBB 12.4 pg m-3 (297). 
Saito et al. (2007) observed 2,4,6-tribromophenol (TBP) and HBB in air inside Tokyo 
homes (n=18) at concentrations in the range nd-6800 pg m-3 and nd-710 pg m-3, 
respectively. Concentrations in office buildings in the same area (n=14) also contained 
TBP (nd-2800 pg m-3) and HBB (nd-950 pg m-3) (Saito et al., 2007). In comparison, 
atmospheric concentrations of TBP in 2 houses in Hokkaido, Japan fell between 220 and 
690 pg m-3 which was an order of magnitude higher in than adjacent outdoor air 
(Takigami et al., 2009). Residential indoor air in Guangzhou, China was detected with 
DBDPE at median concentration 74.9 pg m-3 (Ding et al., 2016). In the eastern United 
States, elevated concentrations were detected of EH-TBB and BEH-TEBP in air sampled 
within a gymnasium. When air was sampled within 30 cm of a foam pit in this gymnasium, 
concentrations as high as 26100 pg m-3 of EH-TBB and 16900 pg m-3 of BEH-TEBP were 
recorded; however when samples were collected further from the pit, concentrations 
reduced to 5010 pg m-3 and 2660 pg m-3, respectively (Carignan et al., 2013). 
One of the main pathways for occupational exposure to NBFRs is through indoor air and 
dust inhalation and ingestion in working environments. As expected, air samples inside 
e-waste recycling facilities exhibited high concentrations of NBFRs. The inhalable dust 
fraction in air samples taken from an electronic recycling facility in Örebro, Sweden 
contained DBDPE (range, <20-790 pg m-3) and BTBPE (range, 130-11850 pg m-3) 
(Julander et al., 2005). Moreover, even higher concentrations were reported in air from 
21 
 
other e-waste recycling plants in Sweden, namely 10 to 1200 pg m-3 for DBDPE and 600 
to 67000 pg m-3 for BTBPE (Pettersson-Julander et al., 2004; Sjödin et al., 2001). 
Dismantling halls displayed the highest concentrations in these plants. Elsewhere in 
Scandinavia, Rosenberg et al., 2011 observed elevated concentrations of DBDPE (4500-
1,700,000 pg m-3), BTBPE (nd-57,000 pg m-3) and HBB (nd-560,000 pg m-3) in two 
Finnish waste electrical and electronic equipment recycling sites. 
The available data suggest that the sources of non-dietary human exposure to NBFRs are 
predominantly indoor but that one should also consider outdoor media if the studying area 
is impacted by industrial and/or e-waste recycling activities. With very limited data, 
however, it is hard to conclude how much these activities contribute to the total NBFR 
exposure via air inhalation of residents living in contaminated area. More research on 
indoor and outdoor air in the vicinity of industrial zones and e-waste recycling sites is 
recommended. 
1.2.3.3. Dietary Exposure 
Dietary exposure is unarguably a major human exposure pathway for legacy BFRs such 
as PBDEs and HBCDDs (Abdallah and Harrad, 2014, 2011; Lorber, 2008). Given the 
similarity between the physicochemical properties of these legacy BFRs and NBFRs, it 
is reasonable to hypothesize that the diet will also be a substantial pathway of human 
exposure to the latter. There are several approaches to dietary exposure assessment. The 
most commonly employed is the Total Diet Study (TDS) or market basket approach in 
which a sample list is generated from a total diet survey that covers categories of food 
and drink commonly consumed by the study population. Samples are ideally prepared as 
consumed for analysis rather than analyzed raw. Subsequent determination of 
concentrations of target contaminants (e.g. NBFRs) in these samples, combined with 
information on the rate at which such foodstuffs are consumed, permits estimation of total 
dietary exposure to the study population. An alternative is analysis of NBFRs in a smaller 
number of human foodstuffs such as a selection of fish and shell-fish. The limited data to 
date, suggest relatively low levels of NBFRs in the food supply. Unlike the situation in 
dust samples, PBEB appears in seafood samples at higher or comparable levels to other 
NBFRs like EH-TBB or BEH-TEBP. 
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Lake trout samples from Lake Ontario, Canada during the period 1979 to 2004 showed 
high BTBPE and PBEB concentrations up to 2.6 ± 0.3 ng g-1 l.w for BTBPE (mean, 1993 
samples) and 320 ± 156 ng g-1 l.w (mean, 1988 samples) for PBEB (Ismail et al., 2009). 
Another Canadian seafood study reported NBFRs in American eels to fall in the ranges 
(ng g-1 l.w): PBT (nd-19.1), PBEB (nd-2.7), TBP-DBPE (nd-75.9) and EH-TBB (nd-5.2) 
(Sühring et al., 2014). Further south, some common NBFRs in wildlife from San 
Francisco Bay (white croaker, shiner surfperch, cormorant egg and harbor seal) were 
analyzed for but not detected, with the exception of frequently detection of PBEB in 
harbor seal blubber (maximum 0.5 ng g-1 l.w) (Klosterhaus et al., 2012). 
In TDS studies, targeted NBFRs were only occasionally detected at low concentrations, 
mainly in fish and sometimes in meat. This suggests that at this moment, NBFRs affect 
the food chain primarily via aquatic environments. Fernandes et al., 2009 used a TDS 
approach consisting of more than 100 samples of vegetables, meats, fish, dairy products 
and processed foods to assess the presence of NBFRs in UK foods. HBB and DBDPE 
were not detected in any samples but BTBPE was occasionally detected at low levels, 
mainly in foods of animal origin such as: mackerel (0.03 ng g-1 w.w), ox kidney (0.05 ng 
g-1 w.w), chicken liver (0.04 ng g-1 w.w), lemon sole (0.04 ng g-1 w.w), and pork (0.06 ng 
g-1 w.w) (Fernandes et al., 2009). Similar findings were reported in other European 
countries (Sahlström et al., 2015; Tlustos et al., 2010; Xu et al., 2015). Recently, Tao et 
al., 2017 monitored 16 NBFRs in meat, liver, seafood, eggs and dairy products purchased 
in UK supermarket and found β-BDE-DBCH to be the predominant chemical accounting 
for 64.5 ± 23.4 % of total NBFRs. Among detected NBFRs, β-BDE-DBCH showed the 
highest detection frequency at 100% following by α-DBE-DBE (97%), EH-TBB (77%), 
BEH-TEBP (63%) and BTBPE (60%); their average concentrations ranged from <0.04 
to 85 ng g-1 lw (Tao et al., 2017). In Irish foods, HBB, DBDPE and BTBPE were not 
detected in any of 100 composite samples studied (Tlustos et al., 2010). Meat, seafood, 
and processed seafood purchased from Belgian supermarkets showed no detectable levels 
of HCDBCO, BTBPE EH-TBB, and BEH-TEBP except BTBPE and BEH-TEBP in 
smoked salmon (0.035 and 0.084 ng g-1 w.w, respectively) (Xu et al., 2015). Aggregated 
Swedish diet samples from five categories (fish, meat, dairy products, vegetable oils and 
egg) exhibited NBFR concentrations that only exceeded the limit of quantification (LOQ) 
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levels in fish samples with the exception of BTBPE in eggs which was detected at an 
average concentration of 3.9 pg g-1 w.w. (Sahlström et al., 2015).  
Monitoring programs also suggest one pathway via industrial activities have the potential 
to pollute aquatic environments may include waste water treatment plants. Molluscs along 
the northern coast of Spain showed non-detectable levels of EH-TBB, BEH-TEBP, 
BTBPE and DBDPE with the exception of EH-TBB in wild mussel (0.06±0.01 ng g-1 
w.w) and BTBPE in raft cultured mussels and clams (0.16±0.06 and 0.1±0.02 ng g-1 w.w, 
respectively) (Villaverde-de-Sáa et al., 2013). Isobe et al. (2012) also reported low 
concentrations of BTBPE and DBDBPE in mussels from coastal waters of China, Japan, 
Hong Kong, Cambodia, Vietnam, Malaysia, Indonesia, and India. However, by 
comparison, concentrations of EH-TBB, BEH-TEBP, and BTBPE observed in molluscs 
from the Yadkin River, United States, downstream from a textile manufacturing waste 
water treatment plant outfall were among the highest reported worldwide: nd to 2,220, nd 
to 1,370 and nd to 303 ng g-1 l.w, respectively (La Guardia et al., 2012).  The highest 
concentrations were all found at the outfall, with concentrations declining markedly in 
samples taken along the river at 16.8, 25.2 and 44.6 km distant from the outfall. Highly 
elevated concentrations of BB-153 in shellfish along the French coast were found at a site 
heavily impacted by chemical, petroleum and steel industries, up to 81.8 pg g-1 w.w 
(Munschy et al., 2015). In Eastern China, composite foodstuffs including fish, shrimp, 
chicken, duck, pork, livers and eggs were detected with considerable levels of PBEB, 
HBB, EH-TBB, BEH-TEBP, BTBPE, and DBDPE (Labunska et al., 2015). Their mean 
concentration ranges were: <0.17 to 6.81, <0.15 to 6.49, <0.20 to 62.2, <0.25 to 16.3, 
<0.35 to 15.0 and <0.45 to 45.3 ng g-1 l.w, respectively. In general, dietary samples from 
e-waste impacted areas often exhibited higher concentrations of NBFRs than their 
corresponding control samples (Labunska et al., 2015).  
Interestingly, BTBPE and DBDPE were also reported in commercial honey from Brazil, 
Morocco, Portugal and Spain at low concentrations (range, <LOD to 4.22 pg g-1 fresh 
weight) (Mohr et al., 2014). Moreover, Liu et al. (2014) detected PBB, HBB and DBDPE 
in baby foods (formula, cereal and puree) from the U.S and Chinese markets within the 
ranges 1.35 to 128.4, 0.75 to 11.4 and 3.34 to 48.8 pg g-1 fresh weight, respectively. 
24 
 
Besides direct exposure via food consumption, one should also pay attention to indirect 
human exposure to NBFRs which could happen through contact between foodstuffs 
(Polder et al., 2016) and kitchen dust, NBFR-containing kitchenware, kitchen utensils, 
food packaging materials and food storage containers. Kuang et al. (2016) found PBEB, 
EH-TBB, BEH-TEBP, BTBPE and DBDPE in UK kitchen dust at notable maximum 
concentrations: 25, 290, 420, 10 and 450 ng g-1, respectively. Evidence of DBDPE 
contamination was found in electric frying pans and thermo cups purchased in Europe 
(Puype et al., 2015; Samsonek and Puype, 2013). Some UK black plastic kitchen utensils 
were measured with considerable amount of BTBPE, BEH-TEBP, DBDPE and EH-TBB, 
even up to 1000 μg g-1 of BTBPE in one utensil (Kuang et al., 2018). The authors also 
estimated that 20% of NBFRs can be transfer from cooking utensils to hot cooking oil 
using a simulated cooking experiment (Kuang et al., 2018). Moreover, frequent detection 
of BATE, PBT, PBB, PBEB, HBB, TBP-DBPE, BTBPE and DBDPE with up to 560 ng 
g-1 l.w (TBP-DBPE) was observed in fat samples from kitchen hoods (n=15) which 
suggests kitchens may play an important role in NBFR exposure (Bendig et al., 2013). 
1.2.4. Human body burdens of NBFRs 
One of the very first studies about NBFRs in biological samples reported HBB in Japanese 
human adipose tissue samples at concentrations ranging between 0.35 and 0.65 ng g-1 
w.w (Yamaguchi et al., 1988a). The authors moreover suggested that PBB and 1,2,4,5-
tetrabromobenzene (TeBB) found in the tissues may be HBB metabolites as these were 
found in earlier rat metabolism studies (Yamaguchi et al., 1988b, 1986). HBB was also 
detected in Danish, Finnish and New Zealand breast milk (Mannetje et al., 2013; Shen et 
al., 2008) and in Norwegian and Northern Chinese serum samples (Cequier et al., 2015, 
2013; Zhu et al., 2009).  
Of all NBFRs, 2,4,6-tribromophenol (2,4,6-TBP) appears the most commonly detected in 
human blood. Thomsen et al. (2001) found 2,4,6-TBP  at concentrations 10-100 times 
higher than those of seven indicator PBDEs and TBBPA in plasma of three occupational 
groups in Norway. Human blood samples in U.S also contained 2,4,6-TBP at a median 
concentration of 3.0 ng g-1 l.w (median) which was hypothesised to arise from human 
exposure to 2,4,6-TBP  and/or metabolites of BDE-100 and BDE-154 (Qiu et al., 2009). 
A large scale study in Nunanvik Inuit adults in Canada revealed the presence of 2,4,6-
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TBP  (geometric mean, 58 ng L-1 w.w) in blood plasma was significantly related to 
seafood consumption (Dallaire et al., 2009). Elsewhere, Kawashiro et al. (2008) detected 
2,4,6-TBP  in Japanese umbilical cord, cord blood and maternal blood samples at mean 
concentrations of 33, 37 and 22 pg g-1 w.w, respectively. A low frequency of detection of 
TBP in blood plasma samples from Hong Kong people was reported with concentrations 
ranging from ND to 65 pg g-1 l.w (Wang et al., 2012). 
Interestingly, presenting contrast to the frequent reports of their presence in external 
media (see earlier sections), BTBPE and DBDPE have not to date been widely reported 
in biological samples. Indeed, their detection frequency in human samples is commonly 
<10 %. Such low detection rates of BTBPE and DBDPE suggest they are either efficiently 
metabolised in the human body and/or have low bioaccumulation potential (Zhou et al., 
2014a; Zhu et al., 2009). Karlsson et al. (2007) could not detect BTBPE or DBDPE in 
plasma samples of five Swedish citizens. These two NBFRs were also not detected in 
breast milk of first time Irish mothers (Pratt et al., 2013), serum of first time Swedish 
mothers and their toddlers (Sahlström et al., 2014), and the serum of Swedish aircraft 
personnel (Strid et al., 2014). Cequier et al. (2013) occasionally detected BTBPE in 10 
Norwegian serum samples at a concentration range of nd-0.99 ng g-1 l.w but no DBDPE 
was found. Similar results were reported in serum samples from Norwegian women 
(Cequier et al., 2015) or maternal serum (n=102) and milk (n=105) samples from Canada 
(Zhou et al., 2014a). On the other hand, very high DBDPE concentrations in Chinese 
serum samples have been detected: 125.2 ng g-1 l.w for workers in e-waste recycling 
facilities, 56.1 ng g-1 l.w for residents nearby and 13.8 ng g-1 l.w for residents in urban 
area (Liang et al., 2016), however detection rates were not reported. Very recently, Tao 
et al., 2017 reported low median concentrations of α-BDE-DBCH, β-BDE-DBCH, EH-
TBB, BEH-TEBP, BTBPE and DBDPE in UK human milk collected in 2010 and 2014-
2015 ranging from <LOD to 3.1 ng g-1 lw. Interestingly, their respective detection rates 
were relatively high in samples collected in 2010 at 20%, 76%, 44%, 28%, 36% and 4% 
which was even higher in 2014-2015 samples at 100%, 100%, 90%, 40%, 50% and 10%, 
respectively (Tao et al., 2017). 
He et al. (2013) targeted BEH-TEBP in pooled serum samples of Chinese living in 
Laizhou Bay area. Among 10 age-gender groups (males and female between 20 to 84 
years), the authors found BEH-TEBP only in the 30 to 39 year-old female group at a mean 
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concentration of 260 ng g-1 l.w. Low PBEB concentrations wer reported in New Zealand 
breast milk (mean 0.001 ng g-1 l.w) (Mannetje et al., 2013) and it was not detected in 
Chinese serum (Zhu et al., 2009).  
Recently, non-invasive matrices have been considered in some studies to monitor NBFRs. 
These include: hair, nail, urine or feces which are cost effective, easy to collect and most 
importantly do not require invasive sampling techniques. Zheng et al. (2011) were able 
to find HBB, BTBPE and DBDPE in hair of residents in Pearl River Delta, South China. 
The levels of BTBPE and HBB shared the same pattern: workers in e-waste workshops > 
residents in e-waste recycling area > residents in urban area ~ residents in rural area. Dust 
was proposed as a major exposure pathway for DBDPE and BTBPE as their 
concentrations in hair samples and dust samples were significantly correlated (Zheng et 
al., 2011). In a similar fashion, Liang et al (2016) reported DBDPE in human hairs from 
an e-waste recycling area southeastern China followed the aforementioned pattern of 
BTBPE and HBB: the mean concentrations were 82.5 ng g-1 d.w (workers), 29.4 ng g-1 
d.w (residents in e-waste recycling area) and 10.9 ng g-1 d.w (urban residents). These 
concentrations were significantly correlated between hair and serum samples for both 
workers and resident in e-waste recycling area (Liang et al., 2016). EH-TBB and BEH-
TEBP were frequently detected in hair and fingernail samples (n=10) from donors based 
on the Indiana University Bloomington campus ranging between <9.2-230 and <17-240 
ng g—1, respectively, whereas PBB was found in only 2 hair samples (0.63 and 4.24 ng g-
1) (Liu et al., 2015). Using faeces as a biomonitoring matrix for toddlers (n=22), 
Sahlström et al. (2015) found a broad range of NBFRs: BTBPE, BEH-TEBP, α- and β-
DBE-DBCH, BATE, PBB, PBT, PBEB, HCDBCO and OBTMPI at sub ng g-1 l.w levels. 
The above results support the idea that NBFRs display variable bio-accumulation 
potentials and metabolic rates and most importantly, do accumulate in humans. At this 
stage, it is difficult to state which NBFRs are of most concern with respect to human 
internal exposure. Therefore full understanding of their metabolic pathways is essential 
to identify the most appropriate biomarkers and thereby facilitate better-targeted 
biomonitoring programs. 
1.2.5. NBFRs metabolism 
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Currently, knowledge of the metabolic pathways of NBFRs is limited to a small number 
of in vitro and in vivo animal studies, mostly for EH-TBB, BEH-TEBP and HBB.  
Yamaguchi et al. (1988b, 1986) found rapid reductive debromination of HBB 
administered to rats, forming 1,2,4-tribromobenzene; 1,2,3,4-, 1,2,3,5-, 1,2,4,5-
tetrabromobenzene and PBB. Other HBB metabolites in rat, including pentabromophenol 
and some thiomethoxy (CH3S) and methoxy (CH3O) derivatives of tetra and 
pentabromobenzene were reported by Koss et al. (1982). Moreover, in humans, 
debrominated metabolites of HBB were detected in Japanese adipose tissue (Yamaguchi 
et al., 1988a), Swedish toddler faeces (Sahlström et al., 2015) and in Danish and Finnish 
breast milk and placenta samples (Shen et al., 2008). However, it is unclear whether these 
compounds derive from external exposure as opposed to metabolism of HBB. 
Several in vitro studies have tried to identify the metabolites of EH-TBB and BEH-TEBP 
using different models like S9 fractions, liver microsomes or liver cytosol of humans, rats 
common carp, turtles and fathead minnows (Bearr et al., 2012; Roberts et al., 2012). In 
general, while EH-TBB appears to be metabolised to 2,3,4,5-tetrabromobenzoic acid 
(TBBA) and 2,3,4,5-tetrabromomethylbenzoate (TBMB) at species-dependent rates; no 
metabolites of BEH-TEBP were identified. However, by using porcine carboxylesterase, 
BEH-TEBP was slowly transformed to mono (2-ethylhexyl) tetrabromophthalate 
(TBMEHP) (Roberts et al., 2012). No phase II metabolites (sulfation and glutathione 
conjugates) were found for both TBBA and TBMEHP using human liver microsomes and 
cytosol (Roberts et al., 2012). A later in vivo experiment also confirmed TBBA and 
2,3,4,5-tetrabromophthalic acid (TBPA) as metabolites of the flame retardant Uniplex 
FRP-45 (>95 % BEH-TEBP and <5 % EH-TBB) in rat urine and serum (Silva et al., 
2015). Based on these findings, TBBA was recommended as a biomarker of recent human 
exposure to EH-TBB (Hoffman et al., 2014; Silva et al., 2015). Indeed, TBBA was 
measured at a geometric mean of 5.6 pg mL-1 (specific gravity corrected - SGC for urine 
dilution) in 77 % of adult urine samples from North Carolina, U.S and was significantly 
correlated with EH-TBB levels in corresponding paired handwipe samples (Hoffman et 
al., 2014). TBBA was also found in the urine of mothers (range, <3.0-62.2 pg mL-1, SGC) 
and their children (range, <3.0-84.9 pg mL-1, SGC) in New Jersey, U.S but with different 
detection rates (Butt et al., 2014). The more frequent detection in children (70 %) in 
comparison to their mothers (27 %), implies higher exposure to EH-TBB in children. 
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Metabolites of NBFRs other than EH-TBB, BEH-TEBP and HBB have been studied in 
some preliminary studies. Hakk et al. (2004) analyzed faeces of male rats administered 
BTBPE and found 2 groups of metabolites: (1) those arising from debromination and 
hydroxylation of aromatic rings and (2) those arising from hydrolysis of the ether linkage. 
A total of six metabolites were identified by the authors including 2,4,6-TBP. However, 
2,4,6-TBP can be also a metabolite of other BFRs such as BDE-100, BDE-154 (Qiu et 
al., 2009), and TBP-DBPE (Von Der Recke and Vetter, 2007). For TBP-DBPE, in 
addition to 2,4,6-TBP, other potential metabolites detected were: TBP-AE (main 
metabolite), TBP-BAE and an unidentified compound formed under anaerobic conditions 
by corrinoids (Von Der Recke and Vetter, 2007). F. Wang et al. (2010) reported seven 
metabolites of DBDPE in male rats, but unlike BDE-209 (where reductive debromination 
is the primary metabolic pathway), methylsulfonyl or ethylsulfonyl substitutions were 
more likely. Also using rat as a model, Chu et al. (2012) identified OH-DBE-DBCH, 
(OH)2-DBE-DBCH and some additional unidentified compounds as metabolites of α- and 
β-DBE-DBCH. 
1.2.6. Current knowledge gaps 
To date, knowledge of human exposure to NBFRs is scant, especially with respect to 
aspects other than indoor dust exposure. Notwithstanding this, NBFRs appear ubiquitous 
in the environment. Furthermore, bio-monitoring studies, even though limited in number 
to date, demonstrate the presence of these compounds in humans albeit at low 
concentrations thus far. Moreover, as some NBFRs are potentially readily metabolised, 
internal exposure levels based on detection of the parent compounds alone might be 
underestimates. Data to date suggests dust exposure to be an important pathway of 
exposure to NBFRs. In contrast, unlike PBDEs, concentrations of NBFRs in foodstuffs 
reported to date are very low with the exception in UK food where total NBFRs were 
higher than total PBDEs concentration, mostly due to β-DBE-DBCH (Tao et al., 2017) . 
More data is needed to assess fully the extent of dietary exposure however, as it is likely 
that there will be a time lag between the emergence of indoor contamination and dietary 
exposure (Harrad and Diamond, 2006). It is noteworthy that most research to date covers 
only a limited range of NBFRs such as: EH-TBB, BEH-TEBP, DBDPE, BTBPE, and 
HBB. We therefore recommend that a wider range of NBFRs are targeted in future studies.  
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There is also a substantial gap in knowledge of NBFR metabolism. Understanding the 
metabolic pathways of NBFRs will assist assessment of their toxicity and facilitate more 
effective human biomonitoring. For example, evidence suggests TBBA to be a more 
effective biomarker of human exposure to EH-TBB, than the parent compound itself. 
Identification of the best exposure biomarkers remains difficult for some NBFRs however, 
as in many cases a metabolite may not be unique to a single compound, and/or doubts 
exist about whether external exposure to the metabolite may explain at least some of its 
presence in humans. 
1.3. Pharmaceutical and Personal Care Products 
1.3.1. Introduction 
Pharmaceuticals and personal care products (PPCPs) are an emerging contaminant group 
constituted of antimicrobials, antibiotics, stimulants, natural and synthetic hormones, 
fragrances, UV screens and many other chemicals used in daily modern life. Recently 
there have been increasing concern about their environmental fate and effects following 
confirmation of their presence in various environmental compartments (e.g. water, 
sediment and biota) at relatively high concentrations (Ali et al., 2018; Blair et al., 2013; 
Fisch et al., 2017; Mirzaei et al., 2018; Thomas and Hilton, 2004). The main sources of 
PPCPs in the environment are through sewage treatment plants (STPs) and waste water 
treatment plants (WWTPs). As the concerns about PPCPs have emerged only recently 
however, many STPs/WWTPs are not equipped with the ability to detect or efficiently 
remove these contaminants. Therefore, it is likely that large quantities of PPCPs have 
been released into our aquatic environment (Bu et al., 2013; Tarpani and Azapagic, 2018). 
Currently, there remains very limited data about PPCPs regarding their effects on human 
and wildlife health, bioaccumulation and biomagnification potential, and persistence, etc. 
1.3.2. Physiochemical properties 
PPCPs are usually well dissolved in water in ionised forms. A summary of 
physicochemical properties of some PPCPs is given in Table 1.3. 
Table 1.3: Physicochemical properties of some common PPCPs  
Chemical M.W (g/mol) Solubility (mg/L) pKa Log Kow 
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17β-Estradiol  272.2 3.6c 10.4c 3.9–4.0c 
Acetaminophen 151.2  9.7b 0.46a 
Caffein 194.2  6.1b <0a 
Carbamazepine  236.28 17.7a 7.0c 2.45a 
Diazepam 284.8 50c 3.3–3.4c 2.5–3.0c 
Diclofenac 318.1 2.4c 4.0–4.5c 4.5–4.8c 
Erythromycin  733.9 1.4c 8.9c 3.06a 
Estriol 288.4 13.25a  2.45a 
Estrone 270.4 12.42a 10.4c 3.13a 
Ethinylestradiol  296.2 4.83a 10.5–10.7c 3.67a 
Gemfibrozil 250.2  4.7b 4.77a 
Ibuprofen 206.1 21c 4.9–5.7c 3.97a 
Iopromide 790.9 23.8c  <0a 
Naproxen 230.1 16c 4.2c 3.18a 
Sulfamethoxazole  253.1 610c 5.6–6.0c 0.5–0.9c 
Testosterone 288.2 5.57a 17.4b 3.32 
Trimethoprim  290.1 400c 6.6–7.2c 0.91a 
a: Lintelmann et al., 2003; b: Westerhoff et al., 2005; c: Suárez et al., 2008 
M.W: molecular weight; Solubility: water solubility at 25oC; pKa: acid dissociation 
constant 
While many PPCPs are not persistent, they continuously being used and released into the 
environment via activities such as: dumping of unused medications, excretion of PPCPs 
and their metabolites, washing off UV screens, fragrances, medical waste treatment, etc. 
Therefore, PPCPs are not persistent per se, but considered to be “pseudo-persistent”. The 
Kow values of PPCPs are generally not high, thus few studies have reported on their 
bioaccumulative potential (Arnnok et al., 2017; F. Chen et al., 2017; Muir et al., 2017). 
1.3.3. Toxicity and health effects 
Pharmaceuticals are specifically designed to target certain biological processes at low 
doses for maximum activity. However, it is possible that these compounds can be 
bioactive in non-target organisms. As the main sources of PPCPs in the environment are 
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through STPs and WWTPs; being exposed throughout their life cycle has made aquatic 
species one of the most impacted environmental targets of these chemicals and their 
metabolites. 
It was reported that many individual PPCPs stimulated the bioluminescent activity and 
disrupted biological homeostasis of Vibrio fischeri – an aquatic bacteria (de García et al., 
2015) at environmentally relevant concentrations. This effect was even stronger when a 
PPCPs mixture was used. Yokota et al., 2015 reported the non-steroidal anti-
inflammatory drugs (NSAIDs) diclofenac sodium and mefenamic acid to express anti-
ovulatory effect in vitro in fish ovarian follicles. Diclofenac sodium also reduced 
fecundity (Yokota et al., 2015), caused oxidative stress in liver, altered testosterone levels 
(Guiloski et al., 2015), damaged or delayed hatching and altered reproduction (Lee et al., 
2011) in fish in vivo. Naproxen, mefenamic acid, acetylsalicylic acid, ibuprofen and 
diclofenac sodium reduced the testosterone concentrations in male but increased the 17β-
estradiol and testosterone levels in female zebrafish (Ji et al., 2013). Additionally, 
naproxen exhibited sex-specific alteration of hormone levels and related HPG axis gene 
transcription in fishes (Ji et al., 2013). Lysosomal damage of clam’s haemolymph has 
been reported following exposure to caffeine, ibuprofen, carbamazepine or novobiocin 
for 35 days (Aguirre-Martínez et al., 2013). 
A cytotoxic drug 5-flurouracil has been shown to be extremely toxic to aquatic organisms 
with EC50 < 0.1 mg L
-1 by daphnia madna reproduction and pseudomonas putida growth 
inhibition tests (Zounkova et al., 2010). Not only PPCPs but their metabolites might also 
express toxicity. These metabolites are formed via chemical, physical and biological 
processes such as human/animal metabolism or STP/WWTP treatment (e.g. chlorination 
or chloramination) processes. A metabolite of 5-fluorouracil: α-fluoro-β-alanine has 
shown low but pronounced toxicity to aquatic organisms and is classified as harmful 
(Zounkova et al., 2010). Both triclosan, a widely used antibacterial chemical, and its 
metabolite methyltriclosan negatively affected morphology and density of abalone 
immune cells (hemocytes) (Gaume et al., 2012). 
From an ecotoxicological perspective, exposure of living organisms to PPCPs mixtures 
is of most concern. As PPCPs are usually hydrophilic, they are very mobile in aquatic 
systems. Considering the fact that there are hundreds of PPCPs available, not to mention 
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their metabolites, it is very plausible that aquatic organisms are being exposed to a very 
complex mixture of PPCPs daily. Combined drug intoxication is a very well-known 
phenomenon in humans and therefore should not be taken lightly in aquatic species. 
However, such mixtures effects is very hard to predict/understand is the presence of 
complex mixtures of many individual contaminants. For example, exposures to binary 
mixtures of four anti-cancer drugs: 5-fluorouracil, cisplatin, etoposide and imatinib 
mesylate to Pseudokirchneriella subcapitata alga and Synechococcus leopoliensis 
cyanobacteria show different toxicities than predicted (using the concepts of 
concentration addition and independent action of individual PPCPs) (Brezovšek et al., 
2014). This difference in mixture toxicity was both compound- and species[specific 
(Brezovšek et al., 2014). Similar compound-specific  combined effects were also reported 
in fish exposed to a mix of caffeine, DEET, progesterone, gemfibrozil, ibuprofen, 
diphenhydramine, naproxen, atenolol, triclocarban and triclosan (Zenobio et al., 2014). 
1.3.4. Occurrence in major environment compartments of concern 
As previously discussed in session 1.2.3, on a toxicological perspective the major concern 
of PPCPs is negative effects to aquatic life, especially freshwater species. Therefore 
current research is often focused on PPCPs occurrence in relevant environmental 
compartments such as wastewater, surface water, sewage sludge and sediment. 
1.3.4.1. Wastewater and surface water 
In 2000, the U.S Geological Survey carried out a comprehensive investigation of 95 
organic wastewater contaminants (OWCs) most of which are PPCPs in 139 potentially 
contaminated stream sites across the U.S (Kolpin et al., 2002). Detergent metabolites, 
steroids, plasticisers and nonprescription drugs together accounted for more than 85 % of 
the total concentration of OWCs, with coprostanol and cholesterol (steroids), caffeine and 
4-nonylphenol (detergent metabolite) among the most frequently detected. Individual 
PPCP concentrations in these sites were reported at less than 1 μg L-1 in 95 % of 
observations (Kolpin et al., 2002). 
Another comprehensive study on antibiotics was carried out in Australia in 2005-2006. It 
consisted of 114 sampling sites including: hospital wastewater, WWTP influent and 
effluent, surface water and drinking water (Watkinson et al., 2009). The presence of 
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antibiotics in Australian aquatic systems is very pronounced with maximum 
concentrations up to 64 μg L-1 in WWTP influents, 14.5 μg L-1 in hospital wastewaters, 
3.4 μg L-1 in WWTP effluents and 2 μg L-1 in surface water. Predominant among detected 
antibiotics in Australian water were β-lactam, quinolone, sulphonamide group 
compounds, and macrolide (Watkinson et al., 2009). 
Carbamazepine and 6 of its metabolites have been detected in both influent and effluent 
water samples from three French STPs in concentration ranges of 86-420 ng L-1 for 
carbamazepine and nd-1500 ng L-1 for its metabolites (Leclercq et al., 2009). 
Dihydroxylated and 10-hydroxylated metabolites of carbamazepine were found at much 
higher concentrations than their parent compound, up to µg L-1 level, especially in effluent 
samples (Leclercq et al., 2009). Surface water in the Ruhr, Germany contained triclosan 
in concentration range <3 to 10 ng L-1 and that of methyltriclosan was 0.3 to 10 ng L-1 
(Bester, 2005) while triclosan in effluent of two STPs in that area was 10 to 600 ng/L 
(Bester, 2005). 
Surface water samples in the Han River, South Korea showed high average concentrations 
of cimetidine, acetaminophen, caffeine and sulfamethoxazole at 281, 268.7, 34.8 and 26.9 
ng/L  (Choi et al. 2008). The authors also suggested STPs might be the major source of 
PPCPs in downstream regions of the river by comparison with data obtained from samples 
upstream and downstream of four STPs discharging into the river. Natural and synthetic 
estrogens: estrone, 17β-estradiol, estriol, ethynylestradiol, diethylstilbestrol and 17-
valerate were found in both surface water and sediment in rivers of the Tianjin area, China 
with total concentrations ranging from 0.64-174 ng L-1 in water and 0.98-51.6 ng g-1 (dry 
weight) in sediment (Lei et al., 2009). Extremely high concentrations of PPCPs were 
found in WWTP effluent and surface waters in Hyderabad, India up to maximum 
concentrations of 14 mg L-1 (ciprofloxacin) (Fick et al., 2009). Drinking water in the same 
area was also highly contaminated with PPCPs at μg L-1 levels (Fick et al., 2009). 
In summary, effluents from STPs and WWTPs around the world have been found to 
contain PPCPs, indicating the current technologies in such facilities are not efficient in 
completely removing PPCPs. Moreover, even though often found at relatively low 
concentrations (<1 µg/L), the ubiquity of these emerging contaminants in surface water 
and drinking water is of concern for aquatic species and humans. 
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1.3.4.2. Sediment and sewage sludge 
Concentrations of PPCPs in sewage sludge and sediment are usually highly variable 
between pharmaceutical groups, possibly due to the usage/consumption pattern as well as 
adsorption capacity. Sewage sludge samples (n=45) have been collected from 20 cities 
across China and analysed for 30 pharmaceutical chemicals; of which olfloxacin, 
oxytetracylin, norfloxacin and ketoprofen predominated with maximum concentrations 
up to 24760, 5280, 5280 and 4458 μg kg-1, respectively (Chen et al., 2013). Ofloxacin 
also showed the highest average concentration in sewage sludge collected in Fijuan, 
China (2270 μg kg-1), followed by triclocarban (1440 μg kg-1) and tetracycline, 
oxytetracycline, triclosan, fenoprofen and miconazole (>100 μg kg-1) (Li et al., 2016).  
The occurrence of six parabens (methyl-, ethyl-, propyl-, butyl-, heptyl- and benzyl-
paraben) together with five paraben metabolites (4-hydroxy benzoic acid, methyl 
protocatechuate, ethyl protocatachuate, 3,4-dihydroxy benzoic acid and benzoic acid) was 
confirmed in samples collected from five Indian STPs. The maximum total paraben 
concentrations in influent, effluent and sewage sludge were 920 ng L-1, 67 ng L-1 and 
1090 ng g-1 d.w; while those of total paraben metabolites were 34,600 ng L-1, 3,800 ng L-
1 and 35,900 ng g-1 d.w, respectively (Karthikraj et al., 2017). Lower levels of parabens 
(methyl-, ethyl-, propyl-, butyl- and benzyl-paraben) were reported in fourteen WWTPs 
in the U.S at a concentration range of 21.1 to 213.2 ng g-1 d.w total parabens (J. Chen et 
al., 2017). 
Naproxen, salicylic acid, propranolol, caffeine and 17α-ethinylestradiol were found in 
surface sediment of Guadiamar River, Spain at mean concentrations of 11.2, 9.49, 3.37, 
7.21 and 48.1 μg kg-1 (Martín et al., 2010). Li et al. investigated water, sediments and 
biota samples from Baiyangdian Lake - the largest freshwater body in North China - and 
observed the ubiquity of antibiotics in the lake; 17 antibiotics were detected in sediment 
samples with norfloxacin predominant (mean concentration 267 μg kg-1) followed by 
roxithromycin and ofloxacin (mean concentration 64.9 and 21 μg kg-1, respectively) (Li 
et al., 2012). 
The natural hormones estrone and 17β-estradiol were found in New Zealand sediments 
ranging from 0.71 to 2.2 ng g-1 and 0.47 to 1.0 ng g-1 d.w, respectively while 17α-
ethynylestradiol was not detected (Stewart et al., 2014). Common natural and synthetic 
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estrogens (e.g. estrone, estriol, etc.) were not detected in Perdido Bay, Alabama, U.S, 
however glucocorticoids, androgens and progestins were all detected. Specifically, the 
concentration ranges of cortisone, cortisol and prednisolone were: 1.21-4.10, 4.9-9.05 and 
6.42-14.61 pg g-1 while those of androsterone, testosterone, epitestosterone, 5α-
dihydrotetosterone, progesterone and levonorgestrel were 39.64-128.66, 3.99-9.67, 1.94-
17.87, 56.8-136.86, 2.91-13.22 and 1.16 to 3.44 pg g-1 w.w (Mulabagal et al., 2017). 
1.3.5. PPCPs in biota 
Aquatic species near WWTP effluent discharge points have been shown to accumulate 
some select PPCPs such as fragrance components, antibiotics, antihistamines or 
antidepressants (Ramirez et al., 2009; Rüdel et al., 2006). Ramirez et al. detected 
norflouxetine, sertraline, diphenhydramine, diltiazem and carbamazepine at several ng g-
1 level in fish fillets collected near WWTP discharges in U.S while fluoxetine, 
norfluoxetine, diphenhydramine, sertraline and gemfibrozil were found in liver of the 
same fish at mean concentrations of several tens to hundreds ng g-1 (Ramirez et al., 2009). 
Species and organ selective bioaccumulation of antidepressants (e.g. sertraline, 
norfluoxetine, citalopram, etc.) and diphenhydramine were also reported in various fish 
species from upper Niagara River and in general bioaccumulation were in the order brain 
> liver > muscle > gonads (Arnnok et al., 2017). Previously, antidepressant fluoxetine, 
norfluoxetine, sertraline and desmethylsertraline also showed elevated concentrations in 
brain and liver of fish samples from Pecan Creek, U.S in comparison with muscle tissues; 
their respective mean concentrations in fish brain were: 1.58, 8.86, 4.27 and 15.6 ng g-1 
while those in liver were 1.34, 10.27, 3.59, 12.94 ng g-1 and in muscle were 0.11, 1.07, 
0.34 and 0.69 ng g-1 (Brooks et al., 2005). 
A recent national study of PPCPs in German fish fillets collected across Germany showed 
relatively low concentration of diphenhydramine (0.04-0.07 ng g-1 w.w), 
desmethylsertraline (1.65-3.28 ng g-1 w.w), tonalide (98-392 ng g-1 l.w) and galaxolide 
(268-11100 ng g-1 l.w) while 25 others PPCPs (e.g. caffeine, codeine, acetaminophen, 
triclosan, etc.) were not found (Subedi et al., 2012). Additionally, the authors found 
significant correlation between the concentrations of galaxolide or tonalide and the 
distance between sampling point and WWTP discharge (Subedi et al., 2012).  
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Antihypertensive, antibiotic, anti-inflammatory, stimulant, antihistamine, anti-seizure 
and antidepressant drugs have been detected in periphyton and snails from the North 
Bosque River, Texas, U.S near an effluent discharge at several to several tens μg kg-1 
w.w; desmethylsertraline was predominant among detected PPCPs with a maximum 
concentration of 42 μg kg-1 w.w (Du et al., 2015). Steroidal estrogen assessment in wild 
fish collected from Dianchi Lake, China showed maximum estrogen concentration at 11.3 
ng g-1 and higher bioaccumulation potential in liver than in gill and muscle (Liu et al., 
2011). Aquatic plants and animals in Baiyangdian Lake, China also contained some 
PPCPs with quinolone antibiotics predominating in aquatic plants (8.37-6532 μg kg-1) 
while quinolone (17.8-167 μg kg-1) and macrolide (<MDL-182 μg kg-1) antibiotics 
predominated in aquatic animals (Li et al., 2012). Fish samples from supermarkets in 
Guangdong, China were analyzed for 54 PPCPs, of which 22 were detected at 
concentrations less than 10 µg kg-1 (Zhang et al., 2017) 
One of the very few epidemiological studies conducted into the effect of PPCPs on 
wildlife, revealed kidney diclofenac residues were highly correlated with renal failure in 
vultures in Pakistan. It was later proposed that dietary exposure to treated livestock 
carcasses resulted in lethal diclofenac concentrations and caused renal failure in these 
birds (Oaks et al., 2004). 
In summary, PPCPs have been detected in biota globally. Commonly found chemicals 
are antidepressants, antibiotics, musks and antihistamines. 
1.3.6. Current knowledge gaps 
PPCPs are an emerging contaminant group consisting of hundreds of chemicals with 
different physicochemical properties. This makes simultaneous analysis of multiple 
PPCPs groups challenging. Despite efforts to conduct such multi-residue analysis, most 
studies conducted in aquatic environment and species have only focused on common 
PPCP groups such as: antibiotics, antidepressants, stimulants, antihistamines, and 
fragrances. Evidence of bioaccumulation of some PPCPs exists but remains very limited 
while biomagnification is currently not addressed. 
To date, studies about PPCP toxicity and ecotoxicology are still very scarce, most of 
which have investigated fish exposed to individual PPCPs. Considering that multiple 
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PPCPs are often found together, it is necessary to investigate their combined toxic effects 
on non-target organisms including humans. Additionally, little to nothing is known about 
the impact on public health of their environmental occurrence, even at sub-therapeutic 
levels, in drinking water and foodstuffs.  
Since evidence exists of fatalities in animals exposed to contaminated food, it is important 
to further study and monitor PPCPs in foodstuffs, especially fish/shellfish in 
contaminated areas. It is also necessary to investigate not only PPCPs but their 
metabolites/degradation products. Such compounds are formed via many mechanisms e.g. 
UV light, chlorination, temperature, biological processes, etc. and might pose even higher 
toxicity than the parent PPCPs. 
1.4. Aims of this thesis 
From the above, substantial research gaps exist about the environmental fate, metabolism, 
degradation and human/biota exposure to NBFRs and PPCPs. In particular, there are 
major gaps in our understanding of the pathways, rates and products of the metabolism 
of NBFRs. Moreover, our capacity to study the environmental fate and behaviour of 
PPCPs and their metabolites is currently restricted by the limitations of conventional 
analytical chemistry methods for their determination. The overall premise of this thesis, 
is that advances in analytical chemistry, specifically high resolution high accuracy mass 
spectrometry can provide tools to address these gaps. By using a UPLC-Orbitrap HRMS 
system, the objectives of this study are to: 
1. Develop an analytical method for determination of NBFRs and screen for NBFRs 
metabolites/degradation products as well as brominated contaminants in one 
chromatographic run.  
2. Develop high throughput analytical methods for simultaneous determination of a wide 
range of environmentally-relevant PPCPs in water samples. 
3. Investigate in vitro metabolic profiles of EH-TBB, BEH-TEBP and BTBPE by mouse 
liver microsomes. 




5. Assess the extra hepatic in vitro metabolism of EH-TBB and FireMaster 550 mixture 
by human skin S9 fractions. 
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2.1. Orbitrap MS tuning 
For high resolution mass spectrometry, it is extremely important to calibrate the system 
as this can greatly affect mass resolution of detected ions – one of the main QA/QC 
criteria for identifying and quantifying analytes. The instrument was externally calibrated 
using Pierce ESI Positive and Negative Ion calibration solutions (Table 2.1). Calibration 
solutions were directly infused into the system by a syringe pump at 10 µL/min. Factory 
default acceptance criteria for a good calibration was used. 
Table 2.1: Tuning ions for mass accuracy in positive and negative ESI mode on 
UPLC-Orbitrap MS instrument 




MRFA 524.26496  










Sodium Dodecyl Sulfate  265.14790 
Sodium Taurocholate  514.28444 
 
For a good mass accuracy calibration, the m/z deviation of each tuning ion (Table 2.1) 
has to be within ± 2.5 ppm (Figure 2.1.A and Figure 2.1.B). This tuning process is 
performed every other day or when needed. 
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Figure 2.1: Acceptable mass accuracy calibration in negative (A) and positive (B) 





After the instrument is calibrated, the UPLC is connected to the Orbitrap MS and an 
isocratic UPLC method was applied in order to optimise the ionization source parameters. 
The flow rate was set at 400 µL/min and the mobile phase was chosen in accordance to 
the studied analytes for each sample type. The parameters were chosen such that the total 
ion current (TIC) variation is below 10 % RSD and ion injection time (IT) less than 2 ms. 
Table 2.2 shows an example of optimised ionization parameters for the analysis of 
bisphenol A by UPLC-Orbitrap MS 
Table 2.2: Optimised ionisation parameters for the analysis of Bisphenol A by 
UPLC-Orbitrap MS (LC flow rate 400 μL/min) 
Source Parameters Setting 
Sheath gas flow rate 50 
Aux gas flow rate 15 
Sweep gas flow rate 0 
Spray voltage (kV) 4.5 
Capillary temp. (oC) 275 
S-lens RF level 50 
Aux gas heater temp (oC) 350 
 
2.2. Data Analysis 
2.2.1. Targeted Analysis 
Targeted analysis of compounds of interest was performed on Quan Browser 3.0 software 
(Thermo Fisher Scientific, USA). Pure individual standards or standard mixtures (1 ng on 
column) were subjected to analysis for identification of each target compound and their 
corresponding retention time (tR). This was acheived via different ionisation techniques 
and polarities including (+)/(-) APCI and (+)/(-) ESI.  
After the accurate masses and retention times were established for each analyte, a 5 point 
calibration was conducted. Wherever possible, the isotope dilution method was used to 
quantify target compounds. Due to the wide range of chemicals being analyzed, only a 
limited number of internal standards were used. Internal standards were chosen so that 
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they do not naturally occur in the samples (usually deuterated or 13C labelled) and their 
retention times are close to that of the target compounds. 
The concentration of target analytes were determined via relative response factor (RRF) 







     (Equation 1) 
RRFs are obtained for each calibration point and an average RRF is calculated. Before 
and after each sample batch, a calibration standard (usually the middle concentration level 
within a calibration curve i.e. calibration standard level 3 in a 5 points calibration curve) 
is injected and the average RRFs for these two standards was calculated. This average 
RRF (which must be within ±25 % of the average RRF obtained from the 5 point 
calibration) is used to calculate the concentration of the target analytes in real samples by 










   (Equation 2) 
Where CNAT,real sample is the concentration of target analyte in sample, ANAT is the peak 
area of target analyte in sample, AIS is the peak area of internal standard in sample, RRF 
is the relative response factor for the analyte, MIS is the amount of internal standard 
added to sample (ng) and SS is the sample size (mL). 
The following QA/QC criteria have to be met for confirmation of a target compound in 
a sample (Harrad, 2014): 
i. Peak signal to noise ratio (S/N) must exceed 10:1. 
ii. m/z value of the molecular ion peak must be within 5 ppm of its theoretical value 
at resolution power of 17500 FWHM (full width at half mass). 
iii. Relative retention time of the peak in the sample must be within ±0.2% of the 
value determined for that analyte in the calibration standards ran before and after 
a sample batch. 
For targeted screening of chemicals, a similar approach was carried out but no calibration 
curve was required. 
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2.2.2. Untargeted analysis 
Compound Discoverer 2.0 software (Thermo Fisher Scientific, Bremen, Germany) was 
used to assist with untargeted analysis of interested emerging contaminants and/or their 
metabolite identification process. The software was developed for liquid chromatography 
- high resolution accurate mass data with different working “nodes”, each node is 
responsible for a specific purpose. Multiple nodes can be combined in various ways to 
form work flows depending on user need. A general work flow as described in Figure 2.2 
was implemented in our studies. 
Figure 2.2: Compound Discoverer workflow for untargeted screening of emerging 
contaminants and their metabolites 
 
A detailed explanation and parameters of the workflow is provided in Table 2.3. Briefly, 
the software extracted spectra from input mass spectral data files and aligned the retention 
times of multiple LC/MS files based on mass tolerance and maximum time shift criteria. 
Compound Discoverer then attempted to elucidate the element compositions for each 
peaks in every single file using predefined settings. The detected features were grouped 
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based on their accurate masses and retention times across all files and made ready for 
further analysis nodes including background compound filter, elemental composition 
prediction, online Chemspider library search, offline mass list search and isotope pattern 
scoring. Finally, a “Differential Analysis” node was used to provide some simple 
differential statistics such as PCA and ANOVA with Tukey HSD post-hoc testing on 
detected feature’s groups. 
Compound identification was achieved via 4 successive filters established within the 
Compound Discoverer 2.0 software. Specifically, these were that the: 
iv. Peak signal to noise ratio (S/N) must exceed 10:1. 
v. m/z value of the molecular ion peak must be within 5 ppm of its theoretical value 
at resolution power of 17500 FWHM (full width at half mass). 
vi. Isotope pattern must match within 5 % of the theoretically predicted abundances 
of the predicted chemical formula (if applicable). 
vii. log2 fold change (calculated as log2 of the peak area ratio between in vitro samples 
and experiment blanks) must be > 1 (for metabolite identification), which is 
equivalent of fold change > 2 (Dalman et al., 2012). 
Additionally, the relative retention time of the peak in the sample must be within ±0.2 % 
of the value determined for that analyte in the pure standard mixture run before and after 






Table 2.2: Descriptive analysis “nodes” of Compound Discoverer 2.0 Software used in untargeted screening of chemicals and 
metabolites. 
Node Description Parameters 
Input Files LC/MS data file input NA 
Select Spectra Choose spectra to process within LC/MS files Min. Precursor Mass: 100 Da 
Max. Precursor Mass: 850 Da 
Polarity Mode: negative 
S/N Threshold: 1.5 
Align Retention 
Times 
Chromatographic alignment of samples with 
similar LC/MS method and run time 
Alignment Model: Adaptive curve 
Mass Tolerance: 5 ppm 
Maximum shift: 0.5 min 
Detect Unknown 
Compounds 
Detect compounds in a file by Compound 
Elucidator algorithm 
Mass Tolerance: 5 ppm 
S/N threshold: 1.5 
Min. Peak Intensity: 1000 
Ion: [2M-H]; [M+Cl]; [M-2H]; [M-Br+2e]; [M-Br+O]; [M-H]; 
[M-H-H2O] 
Max. Element Counts: C20 H30 Br4 O10 (for EH-TBB samples); 
C20 H30 Br6 O10 (for BTBPE samples); C30 H50 Br4 O10 (for 
BEH-TEBP samples) 
Min. # Scans per Peak: 5 
Group Unknown 
Compounds 
Group all detected compounds across all files 
by retention times and molecular weights  
Mass Tolerance: 5 ppm 




Annotate and filter background compounds in 
predefined blank samples 
Max. Sample/Blank: 3 
Hide Background = True 
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Search Mass Lists Search for compounds in offline mass list 
provided inside Compound Discoverer 
Library: Environmental and Food Safety (EFS) HRAM 
Compound Database 
Mass tolerance: 5 ppm 
Predict 
Compositions 
Predict elemental compositions for grouped 
detected compounds based on user Ion 
definition 
Mass tolerance: 5 ppm 
Max. Element Counts: similar with that in Detect Unknown 
Compounds node 
Max. RDBE: 20 
Max. # Candidates: 10 
Search 
ChemSpider 
Search for detected compounds in ChemSpider 
databases 
Databases: ACToR: Aggregated Computational Toxicology 
Resource; DrugBank; EAWAG Biocatalysis/Biodegradation 
Database; EPA DSSTox; FDA UNII – NLM 
Mass tolerance: 5 ppm 
Pattern Scoring Compare detected compounds with predefined 
isotope patterns and give matching scores 
Isotope Pattern: C8Br, C8BR2, C8Br3, C8Br4, C8Br5, C8Br6 
Mass Tolerance: 5 ppm 
Intensity Tolerance: 30% 
Fill Gaps Re-integrate a peak if it was found in more 
than one data files but not in another, trying to 
get the peak area even at noise level 
Mass tolerance: 5 ppm 
S/N Threshold: 1.5 
Retention Time Tolerance: 0.1 min 
Differential 
Analysis 
Perform basic statistical analysis: PCA and 
ANOVA 




2.2.3. Biotransformation kinetic model 
The metabolite formation rate and substrate concentration of the studied chemicals were 
fitted to different biotransformation kinetic models by nonlinear regression analysis 
using the SigmaPlot Enzyme Kinetics Module v.1.1 (Systat Software Inc., Richmond, 
CA) to determine the enzyme kinetic model that best describe the formation rates of the 
metabolites. The models used were the Michaelis-Menten equation (Equation 3), the 


















           (Equation 5) 
where 𝑣 is initial velocity of the reaction, Vmax is the maximum metabolic rate, [S] is the 
substrate concentration, Km is the Michaelis-Menten constant, K
’ is the Hill dissociation 
constant, n is the Hill coefficient and Ki is the inhibitory dissociation constant. Selection 
of the best fitted model was determined by statistical criteria to evaluate the goodness of 
the fit. The two statistical criteria used were Akaike Information Criterion corrected for 
small sample size (AICc) and the standard deviation of the residuals (Sy.x). The model 
with the lowest values for AICc and for the standard deviation of the residuals was 
considered to be the model that best fit the data. When the formation rate of a primary 
metabolite is best described by the Michaelis-Menten model (Equation 3), the part of 
the in vitro intrinsic clearance (Clint,M) due to the formation of that metabolite can be 








 If the levels of the substrate of interest in human blood are negligible compared to the 
apparent Km value associated with the formation of the metabolite, then (Km + [S]) ≈ Km 










The total Clint value of the substrate of interest can then be calculated as the sum of the 
Clint of each of its primary metabolites. 
The intrinsic in vitro clearance of a xenobiotic by an organ on kilogram human body 
weight (CLint-organ) basis can be scale up by the following equation: 
𝐶𝐿𝑖𝑛𝑡−𝑜𝑟𝑔𝑎𝑛 = 𝐶𝐿𝑖𝑛𝑡 × 𝑝 × 𝑤  (Equation 8) 
Where p is the amount of protein per gram of an organ and w is the average weight of that 
organ per kilogram body weight. 
The blood flow of an organ per kilogram body weight (kg b.w) Qh was taken into account 




   (Equation 9) 
2.3. Analysis of blanks, LODs and LOQs 
Instrument blanks (injections of methanol into the instrument) and method blanks 
(samples containing a clean matrix similar to the matrix of real samples, usually deionized 
water in this thesis) were analysed alongside each sample batch. None of the target 
compounds (with the exception of 2,4,6-TBP) were detected in any of the method or 
instrument blanks. Limit of detection (LOD) and limit of quantification (LOQ) were 
estimated using the signal to noise (S:N) approach. Instrumental detection limit (IDL) 
was calculated as the lowest concentration that gives a S:N ratio of 3:1, while Instrumental 
quantification limit (IQL) was calculated as the lowest concentration that gives a S:N ratio 
of 10:1 (Harrad, 2014).  
2.4. Statistical Analysis 
Statistical analysis was conducted using IBM SPSS Statistics for Windows, version 22 
(IBM Corp., Armonk, N.Y., USA), Excel (Microsoft Office 2013) and Compound 
Discoverer 2.0 (Thermo Fisher Scientific, Bremen, Germany). The linearity, calibration 
curves, standard deviation of the response and slope of calibration curve for target 
compounds were assessed by linear regression in Excel. Principal Component Analysis 
(PCA) was performed on in vitro samples (peak intensities were log10 transformed) by 
Compound Discoverer 2.0 for QA/QC purposes. The differences in means among study 
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factors (e.g. treated vs non-treated samples; level of chemical exposure to human liver 
microsomes, etc.) were statistically evaluated using ANOVA with Tukey HSD posthoc 
test. Kruskal Wallis test to evaluate the statistical differences between two or more groups 
of a variable (without normality assumption) was carried out using SPSS. The level of 




Chapter 3  
Method development for 
simultaneous analysis of multiple 
pharmaceuticals and personal care 





In this chapter, a high throughput analysis method for the determination of concentrations 
of 29 common PPCPs was developed by rapid alternate switching (+)/(-)ESI-LC-HRMS. 
The developed method was then applied to assess the levels of target chemicals in effluent 
and surface water samples collected from Egypt. 
3.2. Materials and methods 
3.2.1. Chemicals and standards 
All solvents used in this study were purchased from Fisher Scientific (Loughborough, 
UK) and were of HPLC grade or higher. Individual standards of 29 PPCPs (Table 3.1, 
Figure 3.1), in addition to isotope-labelled Caffeine-D9, Codeine-D3, Carbamazapine-
D10, Estone-D4 and 4-Chlorophenol-2,3,5,6-D4 used as internal (surrogate) standards 
were purchased from Sigma-Aldrich™ (Irvine, UK) at the highest possible purity (>99 %). 
13C-tetrabromobisphenol A (13C-TBBPA) and Tris (2-chloroethyl) phosphate-D12 
(TCEP-D12) used as recovery (syringe standards) were obtained from Wellington 
Laboratories (Guelph, ON, Canada). All standard stock solutions were prepared and 
further diluted in methanol. Oasis MCX and Oasis HLB cartridges (6 cc, 150 mg sorbent 
per cartridge) were obtained from Waters™ (Hertfordshire, UK). Ammonium formate 
(NH4COOH), ammonium hydroxide (NH4OH, 30 %), ammonium fluoride (NH4F) and 
formic acid (HCCOH) were obtained from Sigma-Aldrich™ (Gillingham, UK). Milli-Q 
water was used for cleaning and sample preparation purposes. 






Acetaminophen Analgesics C8H9NO2 103-90-2 








Trimethoprim Antibiotics C14H18N4O3 738-70-5 
Sulfamethoxazole Antibiotics C10H11N3O3S 723-46-6 
Erythromycin Antibiotics C37H67NO13 114-07-8 
Carbamazepine Anticonvulsants  C15H12N2O 298-46-4 
Gabapentin Anticonvulsants C9H17NO2 60142-96-
3 
Metformin Antidiabetic C4H11N5 1115-70-4 
Glyburide Antidiabetic  C23H28ClN3O5S 10238-21-
8 




Antimalarial agent C17H17ClF6N2O 51773-92-
3 
Oxazepam Benzodiazepine C15H11ClN2O2 6801-81-6 
Diazepam Benzodiazepine C16H13ClN2O 439-14-5   
Metoprolol Beta-blocker C15H25NO3 56392-17-
7 
Propranolol Beta-blocker C16H21NO2 318-98-9 







Hydrocortisone Dermatological drug C21H30O5 50-23-7 
17α-ethynylestradiol Estrogen C20H24O2 57-63-6 
DEET Insect repellent C12H17NO 134-62-3 
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Naproxen NSAID C14H14O3 22204-53-
1 
Diclofenac Sodium NSAID C14H10Cl2NNaO2 15307-79-
6 
Ibuprofen NSAID C13H18O2 15687-27-
1 
Meclofenamic Acid NSAID C14H11Cl2NO2 6385-02-0 
Codeine Opiate C18H21NO3 76-57-3 
Nicotine Stimulant C10H14N2 54-11-5 
Caffeine Stimulant C8H10N4O2 58-08-2 
17-β-estradiol (E2) Steroid C18H24O2 50-28-2 
Hydrocortisone 
(HCT) 




Figure 3.1: Names and chemical structures of PPCPs in this study 
 
3.2.2. Sample preparation and extraction 
Surface water samples were collected by the Department of Analytical Chemistry, Assiut 
University, Egypt and provided to us at Birmingham. Water samples (1 L) were collected 
from the effluent of 5 waste water treatment plants (WWTPs) at Assiut governorate, 
Egypt. These include 3 major WWTPs in Assiut city (Al Helaly, Nazalat- Abdellah and 
El Walidiyaah), the water treatment plant of Sodfa town, in addition to the water treatment 
plant of Assiut University hospitals. Furthermore, surface water samples were collected 
from the River Nile and El-Ebrahmiya canal in Assiut city. These are grab samples 
collected upstream of the WWTP discharge point in deactivated glass bottles and 
transferred immediately to the lab, where they were kept at 4 °C until extraction. 
Individual and mixture stock solutions (0.5 g/L) of the targeted PPCPs (Table 1) were 
prepared in methanol and stored in dark amber vials at -20 °C. Working solutions were 
prepared fresh daily by diluting the stock solutions to the required final concentration and 
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were stored at 4 °C for a maximum of 24 h. The isotope labelled internal standards were 
prepared and mixed separately at 1 ng/µL in methanol and kept in dark amber vials at -
20 °C.  
Environmental water samples were extracted by solid phase extraction (SPE) using Oasis 
MCX cartridges and Waters™ 20-port controlled pressure vacuum manifold equipped 
with 50 Hz vacuum pump (Waters, Hertfordshire, UK). The SPE cartridges were pre-
conditioned with 3 mL of methanol following by 3 mL of Milli-Q water. 250 mL of the 
water sample were spiked with 100 ng of isotopically-labelled internal standards mixture 
and treated with 500 mg Na2EDTA to release the free form of Tetracycline and 
Fluoroquinolone antibiotics from potential complexes with Ca+2 and Mg+2 in 
environmental waters (Kasprzyk-Hordern et al., 2007). The samples were loaded onto the 
pre-conditioned cartridges at a flow rate of 5 mL/min. The cartridges were washed with 
3 mL of 0.5 % HCOOH in Milli-Q water (3 mL/min). After drying, PPCPs were eluted 
with 5 mL of methanol following by 5 mL of 5 % NH4OH in methanol. The combined 
eluate was dried under a gentle stream of nitrogen using a TurboVap II® evaporator 
(Biotage™, Sweden) and reconstituted in 100 μL of methanol containing 25 pg/µL of 
13C-TBBPA and TCEP-D12 used as recovery (syringe) standards for QA/QC purposes. 
3.3. Instrument Analysis 
Samples were analyzed on a UPLC system (Thermo Fisher Scientific, Bremen, Germany) 
composed of a Dionex Ultimate 3000 liquid chromatography equipped with a HPG-
3400RS dual pump, a TCC-3000 column oven and a WPS-3000 auto sampler. The UPLC 
is coupled to a Q-Exactive Plus Orbitrap mass spectrometer equipped with a heated 
electrospray ionisation (HESI) ion source. 2 mM NH4COOH/2 mM NH4F in water 
(mobile phase A) and 0.5 % formic acid in methanol (mobile phase B). A gradient method 
at 400 µL/min flow rate was applied as follows: start at 2 % B, stay for 1 min; increase to 
98 % B over 11 min, held for 1 min; then decrease to 2 % B over 0.1 min; maintained 
constant for a total run time of 16 min. Injection volume was 5 μL. The Orbitrap 
parameters were set as follows: alternate switching (-)/(+) ESI, sheath gas flow rate 50 
AU (arbitrary unit), auxiliary gas flow rate 15 AU, spray voltage ± 4.5 kV, capillary 
temperature 275 oC, probe heater temperature 300 oC. The optimal MS parameters were: 
S-lens RF-level 50, resolution 17,500 FWHM (Full Width at Half Maximum) and scan 
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range 125 to 750 m/z. In each scan, the automated gain control (AGC) target in the C-
traps was set at 1 x 106 ions and the maximum injection time (IT) was 50 ms. 
3.4. Method Validation and quantification 
Method linearity was investigated via triplicate injections of 6 point calibration curve for 
each of the studied analytes over a concentration range of 1 – 1,000 ng/mL, using a fixed 
concentration of 100 ng/mL of the isotope labelled IS. Linearity was evaluated through 
the linearity coefficients (R2) of the obtained calibration curves. 
Other method validation parameters were calculated using Milli-Q water spiked with the 
target PPCPs at 3 concentration levels (10, 250 and 750 ng/mL). 
Accuracy was estimated as the percentage recovery of target analytes and evaluated 
through the percent deviation from the known spiked concentration level.  
Precision was calculated as relative standard deviation (RSD %) for inter- and intra-day 
multiple injections). Nine injections covering the 3 concentration levels (3 injections 
each) were used for assessment of precision. Further validation of method precision was 
performed via triplicate analysis of 3 different samples (spiked tap water, surface water 
from the River Nile and effluent sample A).    
Limit of detection (LOD) and limit of quantification (LOQ) were estimated using the 
signal to noise (S:N) approach. Instrumental detection limit (IDL) was calculated as the 
lowest concentration that gives a S:N ratio of 3:1, while instrumental quantification limit 
(IQL) was calculated as the lowest concentration that gives a S:N ratio of 10:1.  
Method quantification limits (MQL) were determined by repeated injection of tapwater 
samples spiked at low concentrations of target compounds.  The concentration that 
produces a S:N ratio of 10 (+2 standard deviation of 5 replicate injections) was estimated 
as the MQL.  
3.5. Quality assurance/quality control (QA/QC)   
None of the target compounds were detected in method blanks (one blank for every 5 
samples; each blank is composed of 250 mL Milli-Q water treated like a sample). 
Therefore, no blank correction of the results was required.  
58 
 
Recoveries of the isotope-labelled internal standards were calculated against the syringe 
standards in all samples and blanks. QC acceptance criteria for method accuracy and 
precision evaluation was adapted from US EPA method 1694 for PPCPs analysis in water 
by HPLC/MS/MS: RSD must be smaller than 30% and recovery must be within 55-120% 
(USEPA, 2007). High recoveries (>80 %) of all five internal standards were obtained 
indicating good overall performance of the method. 
A calibration standard containing all the target compounds and IS (25 pg/µL) was injected 
before and after each sample batch. For a given peak to be identified as a target analyte 
in a sample; the relative retention time (RRT) of the peak in the sample must be within ± 
0.2 min of the average value determined for the same analyte in the 2 calibration standards 
run before and after that sample batch (Harrad, 2004). 
3.6. Results and discussions 
3.6.1 Chromatographic separation and mass spectrometry 
Individual standards of PPCPs were infused into the Orbitrap mass spectrometer by a 
syringe pump at 20 µL/min in order to identify the most abundant ions and their respective 
ionization modes for each PPCPs and ISs. For all of the studied compounds, the most 
abundant ions were either positive or negative pseudo molecular ion: [M+H]+ or [M-H]-. 
Among the 29 PPCPs, 16 of them were ionized in positive mode and 6 of them were 
ionized in negative mode. Interestingly, 7 PPCPs were well-ionized in both positive and 
negative mode including sulfamethoxazole, naproxen, oxazepam, valsartan, diclofenac 
sodium, meclofenamic acid and glyburide. This information can be used as an additional 
confirmation tool for such compounds when analyzing real samples. For compounds 
which can be measured in both ionization modes, the mode that produced higher intensity 
ions (i.e. higher sensitivity) was chosen for quantification. The accurate masses of the 
most abundant ions were calculated using the isotope simulator function of Xcalibur 
software (Table 3.2).  
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Metformin +ve 130.10884 0.64 IS1 
Nicotine +ve 163.12318 3.43 IS1 
Acetaminophen +ve 152.07143 3.46 IS1 
Gabapentin +ve 172.13417 3.65 IS1 
Codeine D3 (IS1) +ve 303.17923 4.63  
Codeine +ve 300.16089 4.69 IS1 
Caffeine D9 (IS2) +ve 204.14500 5.03  
Caffeine +ve 195.08862 5.07 IS2 
Trimethoprim +ve 291.14540 5.40 IS1 
Sulfamethoxazole +ve 254.05949 5.50 IS2 
-ve 252.04526  
Tramadol +ve 264.19584 6.20 IS1 
Metoprolol +ve 268.19076 6.33 IS1 
Propranolol +ve 260.16433 7.97 IS1 
4 Chlorophenol-2,3,5,6 D4 (IS3) -ve 131.01939 8.05  
Clofibric acid -ve 213.03217 8.13 IS3 
Carbamazepine D10 (IS4) +ve 247.16600 8.42  
Carbamazepine +ve 237.10333 8.49 IS4 
Hydrocortisone +ve 363.21686 8.67 IS4 
Naproxen +ve 231.10198 9.05 IS4 
-ve 229.08824  
DEET +ve 192.13931 9.07 IS4 
Erythromycin +ve 734.47192 9.14 IS4 
Oxazepam +ve 287.05860 9.17 IS4 
-ve 285.04430  
Valsartan +ve 436.23466 9.38  
-ve 434.22117 IS3 
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Mefloquine Hydrochloride -ve 413.08759 9.78 IS3 
17α-ethynylestradiol -ve 295.17047 9.87 IS5 
β-estradiol -ve 271.16998 9.88 IS5 
Diazepam +ve 285.07928 9.89 IS4 
Estrone-2,4,16,16 D4 (IS5) -ve 273.18024 9.91  
Diclofenac Sodium +ve 296.02432 10.06 IS4 
-ve 294.01031  
Glyburide +ve 494.15155 10.34  
-ve 492.13818 IS3 
Ibuprofen -ve 205.12297 10.61 IS3 
Meclofenamic acid +ve 296.02432 10.78 IS4 
-ve 294.01031  
Clotrimazole +ve 345.11676 11.28 IS4 
Gemfibrozil -ve 249.15001 11.54 IS3 
 
After successful identification of quantifier ions, a standard solution containing all target 
PPCPs and ISs were subjected to UPLC-HRMS for optimization of UPLC separation and 
mass spectrometry parameters. We evaluated the effects of UPLC gradient, flow rate, 
mobile phase composition and modifiers, column temperature and injection volume on 
the peak shape and separation of 29 PPCPs. Optimal conditions for UPLC have been 
reported in section 3.3. 
The chromatogram of calibration standard level 3 following the analysis using optimal 
UPLC conditions is presented in Figure 3.2. The targeted compounds were eluted within 
the retention time range 0.64 to 11 min indicating their broad polarity range (Table 3.2). 
Due to the different accurate masses of quantifier ions for each PPCP (with the exception 
of diclofenac sodium and meclofenamic acid), it is not essential to baseline separate every 
peak. Theoretically a much shorter gradient can be applied, however a gradient with a 
total run time of 16 min was chosen to allow enough time for column equilibration and 
avoid potential ion suppression due to co-elution of analytes (to allow for possible 
addition of other target compounds to the method in future studies). Additionally, as we 
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used alternate switching ionization in this study, a 16 min gradient provided sufficient 
data points on each peak for reproducible PPCP quantification. 
The ionization and mass spectrometry parameters were optimized using spiked tap water 
extracts and peak intensities of the targeted PPCPs as well as the number of data points 
for each peak were the main evaluation criteria. The optimal ionization and mass 
spectrometric parameters are reported in section 3.3. Despite the fact that the Q Exactive 
Plus instrument can run at a resolution as high as 240,000 FWHM, a resolution of 17,500 
FWHM was chosen in this study. This was a trade-off between the ion mass accuracy and 
scan rate (or the number of data points for a peak). When the instrument runs at higher 
resolving power, a much more accurate ion mass will be recorded and consequently a 
better selectivity of analyzing compounds against isobaric matrix interferences can be 
achieved. However, in order to obtain such high resolution, the orbitrap mass 
spectrometer requires much more time to scan. For example, the scan rate for a 200 m/z 
ion at 140,000 FWHM is 1.5 Hz compared to 12 Hz at 17,500 FWHM. In other words, a 
two second chromatographic peak will contain 3 or 36 data points at a resolution of 
140,000 or 17,500 FWHM, respectively. In addition, we used alternate ionization 
switching in this study which would reduce the number of data points by half for a given 
peak in comparison with single polarity ionization mode. Therefore, a resolving power of 
17,500 FWHM was selected as it offered sufficient data points (> 10) with sufficient mass 
accuracy for identification and quantification (mass deviation < 5 ppm). 
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Figure 3.2: Extracted Ion Chromatogram of our target PPCPs and Internal Standards in calibration standard level 3 
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3.6.2. Quantification and validation 
3.6.2.1. Method linearity 
The calibration curves of the 29 PPCPs were obtained by plotting concentration of 
targeted compounds versus the peak area ratio of each compound and its corresponding 
internal standard. Calibration plots and R2 (linearity coefficient) values for each PPCP 
showed very good linearity over the calibration range (1 to 1000 ng/mL) where the 
majority of R2 values exceeded 0.99 (Table 3.3.) 
Table 3.3: Linearity coefficient and calibration equation for PPCPs analysis by 
UPLC-HRMS in this study 
Compound R2 Equation 
Nicotine 0.999 Y = 0.0145 + 0.0028*X 
Metformin 0.997 Y = 0.0108 + 0.0019*X 
Acetaminophen 0.994 Y = 0.0166 + 0.0004*X 
Gabapentin 0.995 Y = 0.0098 + 0.0021*X 
Codeine 0.998 Y = 0.0343 + 0.002*X 
Caffeine 0.995 Y = 0.0385 + 0.0018*X 
Trimethoprim 0.998 Y = 0.0494 + 0.0027*X 
Sulfamethoxazole 0.996 Y = 0.0825 + 0.0026*X 
Tramadol 0.996 Y = 0.3368 + 0.0226*X 
Metoprolol 0.999 Y = 0.1824 + 0.0201*X 
Propranolol 0.996 Y = 0.5527 + 0.0284*X 
Doxycycline 0.998 Y = -0.0595 + 0.0092*X 
Carbamazepine 0.975 Y = 0.1566 + 0.0014*X 
Hydrocortisone 0.986 Y = 0.0149 + 0.00023*X 
64 
 
Naproxen 0.963 Y = 0.0079 + 9E-5*X 
DEET 0.952 Y = 0.8109 + 0.0055*X 
Erythromycin 0.992 Y = 0.009 + 0.0009*X 
Oxazepam 0.992 Y = 0.0157 + 0.0004*X 
Valsartan 0.995 Y = 0.0009 + 0.0002*X 
Mefloquine hydrochloride 0.994 Y = -0.0025 + 0.0002*X 
17-ethynylestradiol 0.995 Y = 0.0290 + 0.0009*X   
-estradiol 0.995 Y = 0.0483 + 0.0011*X 
Diazepam 0.974 Y = 0.1909 + 0.0033*X 
Diclofenac Sodium 0.994 Y = 0.0012 + 0.0002*X 
Glyburide 0.995 Y = 0.00162 + 0.0002*X 
Ibuprofen 0.995 Y = -0.0014 + 0.0004*X 
Meclofenamic acid 0.999 Y = -0.0017 + 0.0001*X 
Clotrimazole 0.962 Y = 0.0105 + 0.0002*X 
Gemfibrozil 0.991 Y = -0.0007 + 3E-5*X 
 
3.6.2.2. Accuracy and precision 
The method accuracy was estimated as the percentage recovery of target analytes and 
evaluated through the percent deviation from three spiked concentration levels: 10 ng/mL, 
250 ng/mL and 750 ng/mL. For every concentration level, three injections of triplicate 




Table 3.4: Method accuracy expressed as % recovery at 3 spiked concentration 
levels of PPCPs in Milli-Q water 
 Compound 10 ng/mL 250 ng/mL 750 ng/mL 
Nicotine 91.2 ± 7.2 93.1 ± 8.6 95.3 ± 2.7 
Metformin 91.5 ± 6.6 90.8 ± 8.0 94.2 ± 2.9 
Acetaminophen 93.4 ± 7.8 98.1 ± 2.8 97.6 ± 2.8 
Amoxicillin 88.1 ± 3.1 88.2 ± 3.3 89.5 ± 2.8 
Gabapentin 90.7 ± 7.6 88.1 ± 3.7 92.6 ± 6.0 
Codeine 92.7 ± 3.2 92.2 ± 3.8 91.2 ± 2.5 
Caffeine 103.4 ± 5.9 101.1 ± 4.6 99.7 ± 4.2 
Trimethoprim 95.6 ± 6.6 96.8 ± 2.6 96.4 ± 3.1 
Sulfamethoxazole 93.2 ± 3.1 92.3 ± 3.1 93.0 ± 2.8 
Tramadol 89.6 ± 5.8 93.8 ± 2.5 92.2 ± 3.5 
Metoprolol 92.0 ± 2.9 93.6 ± 3.6 93.6 ± 3.3 
Propranolol 95.2 ± 9.4 93.7 ± 5.6 97.8 ± 2.6 
Doxycycline 86.3 ± 4.2 85.1 ± 4.0 85.7 ± 4.1 
Carbamazepine 87.7 ± 2.8 88.0 ± 3.5 88.7 ± 3.3 
Hydrocortisone 82.4 ± 5.1 84.0 ± 5.8 84.2 ± 3.7 
Naproxen 89.0 ± 5.4 90.2 ± 4.2 91.4 ± 4.6 
DEET 87.1 ± 8.1 95.8 ± 3.0 99.3 ± 2.1 
Erythromycin 81.9 ± 4.2 85.6 ± 3.8 83.1 ± 3.2 
Oxazepam 92.6 ± 6.8 96.5 ± 4.2 94.9 ± 4.8 
Valsartan 86.6 ± 9.3 92.8 ± 8.0 98.2 ± 4.5 
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Mefloquine hydrochloride 85.7 ± 4.3 87.2 ± 5.1 87.2 ± 4.2 
17α-ethynylestradiol 79.0 ± 6.2 78.4 ± 5.0 79.2 ± 3.9 
β-estradiol 77.8 ± 5.1 76.6 ± 4.9 76.2 ± 5.7 
Diazepam 93.4 ± 9.7 93.7 ± 7.1 97.5 ± 3.5 
Diclofenac Sodium 89.9 ± 3.4 88.2 ± 4.3 89.9 ± 3.9 
Glyburide 86.5 ± 4.8 87.9 ± 3.9 90.5 ± 4.7 
Ibuprofen 91.7 ± 2.9 90.4 ± 3.5 90.7 ± 3.5 
Meclofenamic acid 86.7 ± 5.7 85.7 ± 4.6 85.9 ± 3.9 
Clotrimazole 102.4 ± 4.9 100.7 ± 3.5 102.4 ± 3.5 
Gemfibrozil 89.0 ± 8.0 92.1 ± 7.6 95.8 ± 4.2 
 
As can be seen in Table 3.4, our method showed very good accuracy ranging from 76.2 
to 103.4 % recovery for all targeted compounds across three concentration levels. The 
relative standard deviations (RSD) of the recoveries were all below 10 %. These 
recoveries are similar to those previously reported for PPCPs analysis by (-)/(+)APCI-
UPLC-Orbitrap HRMS (Huysman et al., 2017) and better than some LC-MS/MS methods 
(Al-Odaini et al., 2010; Caldas et al., 2016). 
The precision was evaluated by RSD for repeatability (intra-day precision) and 
reproducibility (inter-day precision). The RSD for repeatability and reproducibility 
ranged between 0.4 to 13.5% and 2.2 to 10.8%, respectively (Table 3.5). 
Table 3.5: Intra- and inter-day precision expressed as RSD% for targeted PPCPs 













Nicotine 3.2 9.1 1.8 7.9 9.2 2.8 
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Metformin 2.3 6.8 3.2 7.2 8.8 3.1 
Acetaminophen 3.1 3.1 3.8 8.4 2.8 2.9 
Amoxicillin 1.6 3.7 1.1 3.5 3.8 3.1 
Gabapentin 8.8 6.0 8.4 8.4 4.2 6.5 
Codeine 2.8 1.7 3.6 3.4 4.1 2.7 
Caffeine 2.2 4.8 5.1 5.7 4.6 4.2 
Trimethoprim 2.3 4.1 4.3 6.9 2.7 3.2 
Sulfamethoxazole 1.4 1.5 4.2 3.3 3.3 3.1 
Tramadol 2.2 2.8 5.4 6.5 2.7 3.8 
Metoprolol 2.1 0.4 3.5 3.1 3.8 3.6 
Propranolol 13.5 5.6 1.2 9.8 5.9 2.6 
Doxycycline 4.6 4.1 5.2 4.8 4.7 4.8 
Carbamazepine 2.2 5.6 3.9 3.1 4.0 3.8 
Hydrocortisone 6.1 4.8 4.4 6.2 6.8 4.3 
Naproxen 2.8 3.3 4.0 6.1 4.6 5.0 
DEET 7.4 3.5 2.5 9.3 3.1 2.2 
Erythromycin 5.4 1.8 2.4 5.1 4.4 3.9 
Oxazepam 11.0 2.3 5.5 7.3 4.4 5.0 
Valsartan 12.9 10.5 4.0 10.8 8.7 4.6 
Mefloquine 
hydrochloride 
5.2 8.0 5.8 5.0 5.9 4.8 
17α-
ethynylestradiol 
8.2 2.9 4.8 7.9 6.4 4.9 
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β-estradiol 7.9 2.0 4.0 6.5 6.4 7.4 
Diazepam 3.7 6.7 3.6 10.4 7.6 3.6 
Diclofenac Sodium 2.4 6.5 5.9 3.8 4.9 4.3 
Glyburide 2.6 3.4 6.6 5.5 4.4 5.2 
Ibuprofen 2.6 3.8 4.0 3.2 3.9 3.9 
Meclofenamic acid 1.3 6.1 4.3 6.5 5.3 4.6 
Clotrimazole 6.8 3.3 1.1 4.8 3.5 3.4 
 
As Milli-Q water is ultrapure, this might underestimate the matrix effects of real samples 
on the method’s performance. Therefore, we further evaluated the precision for some 
aquatic matrices including spiked tap water (at 500 ng/L), river water and effluent from a 
waste water treatment plant. Among the three investigated matrices, spiked tap water 
showed the lowest RSDs while the effluent sample had higher RSDs than river water for 
most of the detected PPCPs (Table 3.6). This is reasonable as effluent samples usually 
contain more chemicals and organic matter than river water. The results in Table 3.6 
demonstrated that similar precision values were obtained in comparison with spiked 
Milli-Q water experiment. Therefore, it is projected that this method can be extended to 
other complex aquatic matrices e.g. leachate, influent and effluent of waste water 
treatment plants or river water without losing the precision and accuracy. 
Table 3.6: Precision for complex matrices expressed as RSD% for triplicate analysis 
of target PPCPs 
Compounds Spiked tap water  Effluent Surface water 
Nicotine 6.8 9.3 10.9 
Metformin 5.6 11.6 6.9 
Acetaminophen 2.1 5.1 5.9 
Amoxicillin 3.8 12.2 7.4 
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Gabapentin 9.5 <MQL 9.9 
Codeine 6.0 <MQL 9.7 
Caffeine 8.2 5.4 8.3 
Trimethoprim 1.5 11.2 7.6 
Sulfamethoxazole 4.9 13.4 3.3 
Tramadol 4.2 10.8 9.9 
Metoprolol 4.8 <MQL <MQL 
Propranolol 8.0 15.1 11.9 
Doxycycline 4.0 <MQL <MQL 
Carbamazepine 5.2 16.3 13.8 
Hydrocortisone 6.2 12.6 7.5 
Naproxen 5.4 <MQL <MQL 
DEET 3.6 <MQL <MQL 
Erythromycin 5.1 8.5 <MQL 
Oxazepam 3.4 <MQL <MQL 
Valsartan 4.5 10.3 8.2 
Mefloquine hydrochloride 6.0 <MQL 12.1 
17-ethynylestradiol 6.3 <MQL <MQL 
-estradiol 4.9 <MQL <MQL 
Diazepam 6.3 <MQL <MQL 
Diclofenac Sodium 4.7 8.9 6.9 
Glyburide 6.2 3.5 3.6 
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Ibuprofen 8.7 11.3 <MQL 
Meclofenamic acid 8.8 6.3 6.8 
Clotrimazole 6.9 13.5 8.9 
Gemfibrozil 8.7 <MQL 9.6 
3.6.2.3 Detection and quantification limits. 
The instrument detection and quantification limits were determined by analysis of pure 
standards. A wide range of IDLs and IQLs was acquired (Table 3.7). The IDLs ranged 
from 0.02 to 1.21 ng/mL while IQLs ranged from 0.07 to 4.05 ng/mL. The big differences 
in IDLs and IQLs of targeted chemicals were possibly due to: 1. variable ionization 
efficiency for different analytes and/or polarity mode; and 2. matrix effects or co-elution 
at a particular retention time, which affected the sensitivity of the instrument. 
Table 3.7: IDLs, IQLs and MQLs for the developed PPCP analysis method by 
UPLC-HRMS 
Compounds IDL (ng/mL) IQL (ng/mL) MQL (ng/L) 
Nicotine 0.50 1.67 13.3 
Metformin 0.10 0.33 9.5 
Acetaminophen 0.10 0.33 2.8 
Amoxicillin 1.10 3.67 22.4 
Gabapentin 0.28 0.93 5.2 
Codeine 0.23 0.77 5.0 
Caffeine 0.80 2.80 7.2 
Trimethoprim 0.04 0.12 2.4 
Sulfamethoxazole 0.06 0.20 3.4 
Tramadol 0.17 0.56 4.6 
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Metoprolol 0.02 0.07 2.7 
Propranolol 0.04 0.14 4.7 
Doxycycline 0.24 0.79 22.9 
Carbamazepine 0.02 0.07 2.5 
Hydrocortisone 0.34 1.13 37.8 
Naproxen 0.09 0.30 4.7 
DEET 0.11 0.37 5.7 
Erythromycin 0.25 0.84 22.0 
Oxazepam 0.15 0.49 6.3 
Valsartan 0.32 1.05 8.6 
Mefloquine hydrochloride 0.30 0.99 24.7 
17α-ethynylestradiol 1.21 4.05 83.8 
β-estradiol 1.16 3.87 81.0 
Diazepam 0.13 0.43 4.7 
Diclofenac Sodium 0.15 0.50 9.8 
Glyburide 0.30 0.99 12.9 
Ibuprofen 0.12 0.41 8.9 
Meclofenamic acid 0.17 0.57 10.3 
Clotrimazole 0.36 1.19 16.3 
Gemfibrozil 0.31 1.05 14.5 
MQL values were obtained by analysis of spiked tap water containing target PPCPs at 
concentrations that ranged from 2.4 to 83.8 ng/L (Table 3.7). Among our 29 target PPCPs, 
the hormones β-estradiol and 17α-ethynylestradiol showed the highest MQLs at 81 and 
83.8 ng/L, respectively. The MQLs for other chemicals were less than 37.8 ng/L. 
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3.6.3. Application to surface water samples 
After successful validation, the method was applied to effluent and surface water samples 
collected in Egypt. The effluent was sampled at 5 waste water treatment plants (WWTPs) 
at Assiut governorate, Egypt. These include 3 major WWTPs in Assiut city (Al Helaly, 
Nazalat- Abdellah and El Walidiyaah), the water treatment plant of Sodfa town, in 
addition to the water treatment plant of Assiut University hospitals. The surface water 
samples were collected from the River Nile and El-Ebrahmiya canal in Assiut city 
upstream of the WWTP discharge point. 
Among the targeted PPCPs, two of them (mefloquine hydrochloride and DEET) were not 
found in any samples; ten of them (nicotine, metformin, acetaminophen, caffeine, 
tramadol, metoprolol, hydrocortisone, valsartan, glyburide and ibuprofen) were detected 
in all of the samples while the rest was occasionally detected (Table 3.8). Effluent samples 
also showed generally higher concentrations of PPCPs than surface water samples. 




Table 3.8: PPCPs concentrations in Egyptian effluent and surface water samples. 
 Effluent samples (ng/L) Surface water (ng/L) 
1A 1B 1C 1D 1E Median 2F 2G 2H 2I 2J Median 
Acetaminophen 1510 978 16000 3040 1580 1580 954 144 207 392 776 392 
Ibuprofen 1500 1660 6700 812 1090 1500 51 26 91 62 34 51 
Glyburide 2120 798 4160 550 1440 1440 333 628 393 365 253 365 
Metformin 219 589 5610 1110 168 589 32 63 23 21 36 32 
Trimethoprim 1060 271 2740 459 650 650 230 116 210 224 175 210 
Diclofenac Sodium 269 79 3614 172 201 201 35 <9.8 77 44 <9.8 44 
Nicotine 365 736 567 835 419 567 116 90 269 378 98 116 
Caffeine 84 1740 855 121 70 121 12 41 15 7 54 15 
Tramadol 353 508 1100 192 282 353 41 93 56 32 58 56 
Amoxicillin <22.4 129 2040 <22.4 29 129 <22.4 24 <22.4 <22.4 28 <22.4 
Valsartan 107 258 594 318 290 290 63 55 104 59 36 59 
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Metoprolol 34 218 1100 67 57 67 17 8 5 9 12 9 
Codein 63 <5 466 29 <5 63 <5 18 14 21 15 16.5 
Carbamazepine 63 151 342 <2.5 <2.5 151 <2.5 6 <2.5 8 1 6 
Erythomycin-H2O 52 <22 275 106 <22 106 <22 <22 <22 33 61 <22 
Hydrocortizone 43 83 128 77 46 77 36 43 64 42 40 42 
17α-ethynylestradiol <83.8 <83.8 219 <83.8 104 <83.8 <83.8 <83.8 <83.8 <83.8 <83.8 <83.8 
Gabapentin <5.2 40 279 <5.2 <5.2 <5.2 <5.2 8 <5.2 12 <5.2 <5.2 
Clotrimazole 31 <16.3 231 <16.3 43 43 <16.3 23 <16.3 18 <16.3 20.5 
Propranolol 8 19 187 62 <4.7 40.5 <4.7 6 <4.7 7 <4.7 <4.7 
β-estradiol <81 <81 165 <81 <81 <81 <81 <81 <81 <81 <81 <81 
Gemfibrozil <14.5 <14.5 105 44 <14.5 74.5 <14.5 17 <14.5 16 21 17 
Naproxen <4.7 29 89 <4.7 13 29 <4.7 6 <4.7 <4.7 8 7 
Diazepam <4.7 17 58 <4.7 <4.7 <4.7 <4.7 <4.7 <4.7 9 <4.7 9 
Meclofenamic acid 17 <10.3 52 <10.3 <10.3 <10.3 <10.3 12 <10.3 <10.3 <10.3 <10.3 
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Oxazepam <6.3 <6.3 39 <6.3 10 24.5 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 
Doxycycline 22.9 22.9 29 22.9 22.9 22.9 22.9 22.9 22.9 22.9 22.9 22.9 
Sulfamethoxazole <3.4 <3.4 19 <3.4 <3.4 19 <3.4 <3.4 <3.4 <3.4 <3.4 <3.4 
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As can be seen in Table 3.8, acetaminophen, ibuprofen, glyburide, metformin, 
trimethoprim, nicotine, caffeine, tramadol, valsartan, metoprolol and hydrocortisone were 
detected in all of the samples, indicating their ubiquity in the Egyptian fresh-water aquatic 
environment. In effluent samples some analgesics, NSAIDs, antidiabetics and antibiotics 
were found at very high abundances (Table 3.8 and Figure 3.3). In particular, 
acetaminophen showed the highest concentrations ranging from 978 to 16,000 ng/L, 
following by ibuprofen (812-6,700 ng/L), glyburide (550-4,160 ng/L), metformin (168-
5,610 ng/L), trimethoprim (271-2,740 ng/L) and diclofenac sodium (79-3,610 ng/L). 
Caffeine and nicotine also showed relatively high concentrations ranging from 365 to 835 
ng/L and 70 to 1,740 ng/L, respectively.  
Figure 3.3: Concentrations of PPCPs (ng/L) in effluent samples from waste water 
treatment plants in Assiut city, Egypt 
 
While the concentrations of PPCPs effluent samples from locations 1A, 1B and 1D-E 
were similar or lower than reported previously e.g. in German municipal sewage 
treatment plants (STPs) (Ternes, 1998), Chinese WWTPs (Zhou et al., 2009) or 
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Malaysian STPs (Al-Qaim et al., 2014); the detected levels of some PPCPs in location 1C 
were much higher. This sample was effluent from a hospital WWTP and showed the 
highest concentrations for most PPCPs (Figure 3.3). For example, in sample 1C, 
acetaminophen, ibuprofen and metformin were measured at 16,000, 6,700 and 5,610 ng/L, 
respectively. On the other hand, the highest nicotine and caffeine concentrations were not 
present in this 1C sample. This is reasonable as high consumption of pharmaceuticals is 
expected at hospitals while nicotine and caffeine are related to daily habits.  
Figure 3.4: Concentrations (ng/mL) of PPCPs in surface water samples collected 
from Assiut city, Egypt 
 
In surface water sample, analgesics, antidiabetics, antibiotics and nicotine showed higher 
concentrations than other detected PPCPs (Figure 3.4). Specifically, acetaminophen was 
detected at maximum concentration of 954 ng/L, followed by glyburide (628 ng/L), 
trimethoprim (230 ng/L) and nicotine (378 ng/L). High levels of acetaminophen were 
reported previously in effluent-dominated stream in Japan (up to 682 ng/L) (Tamura et 
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al., 2017) or in US streams (up to 10,000 ng/L) (Kolpin et al., 2002). Oxazepam, 
doxycycline, sulfamethoxazole, β-estradiol and 17α-ethynylestradiol were not detected 
while other PPCPs were measured at concentrations less than 100 ng/L. In contrast to 
effluent samples, detected PPCPs in surface water samples did not largely differ between 
sampling locations with the exception of acetaminophen.  
As effluent from WWTPs will be diluted after reaching fresh water streams, it is expected 
that PPCPs levels in effluent are higher than that in surface water. Therefore, we applied 
a non-parametric statistical method to test whether this hypothesis holds true for detected 
chemicals in this study. The results of a Kruskal-Wallis test indicated that nicotine, 
metformin, acetaminophen, trimethoprim, caffeine, tramadol, metoprolol, hydrocortisone, 
valsartan, glyburide, diclofenac sodium and ibuprofen were significantly higher in 
effluent samples than surface water samples at the 95 % confidence level. 
3.7. Conclusions 
In summary, a rapid, reproducible and accurate method for analysis of multiple PPCPs in 
various aquatic matrices by UPLC-Orbitrap HRMS system has been developed. The 
proposed method was sensitive, robust and high throughput in character, which allowed 
the detection of 29 compounds, with the possibility to extend the target list. The method 
has been successfully applied to assess the levels of 29 targeted chemicals in effluent and 
surface water samples collected in Egypt. Our data showed that PPCPs were ubiquitous 
in Egyptian aquatic samples. Among the detected compounds, analgesics, NSAIDs, 
antidiabetics, antibiotics, caffeine and nicotine were predominant. It is suggested that 
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It is reported that there are more than 75 BFRs currently available in the market (Covaci 
et al., 2011).This estimate might be inaccurate as chemical companies do not always 
publicize the exact chemicals used in their flame retardant mixture formulae. However, 
simultaneous monitoring of these chemicals is extremely difficult due to the large 
variation in physicochemical properties. Currently analysis of BFRs is often performed 
on GC or LC coupled with mass spectrometers (Papachlimitzou et al., 2012). Some 
advantages of LC over GC are that LC allows analysis of hydrophilic compounds without 
the need for derivatization, while thermal degradation/isomerization is minimized. In this 
chapter, we aimed to develop a UPLC-HRMS method for screening of BFRs, and 
potentially unknown BFRs and associated transformation products in environmental 
samples with focus on NBFRs. The method was then applied to screen for BFRs in 
samples generated from a leaching test (Section 2.1.1) as well as provide preliminary 
information about in vitro biotransformation of EH-TBB, BEH-TEBP and BTBPE by 
mouse liver microsomes (MLM) (Section 2.1.3). 
4.2. Experiments 
4.2.1. Chemicals 
All solvents and reagents used in this study were purchased from Fisher Scientific 
(Loughborough, UK) and were of HPLC grade or higher. EH-TBB, BEH-TEBP and 
BTBPE for dosing solutions was obtained as neat solutions/powders from Accustandard, 
Inc. (New Haven, CT, USA). High purity standards of BFRs and internal standards (Table 
4.2) were purchased from Wellington Laboratories (Guelph, ON, Canada). RapidStart 
NADPH regenerating system was purchased from XenoTech (Kansas, KS, USA), 
William’s E medium was obtained and mouse liver microsomes were purchased from 
Thermo Fisher Scientific (Paisley, UK). 
Individual EH-TBB, BEH-TEBP and BTBPE dosing solutions at 1000 μM were prepared 





4.2.2. Leachate sample preparation and extraction 
Simulated samples generated by a series of leachate experiments carried out by Danish 
Waste Solutions ApS were provided to us at Birmingham. The experiments involved 
different types of Waste Electrical and Electronic Equipment (WEEE) undergoing 
leaching for 24 hours in a container using deionized water. Three different groups of 
WEEE items were studied, each in a separate experiment:  
1. Mixed WEEE including small household items, computers, electrical tools, etc. in a 
1,000 L High-density polyethylene (HDPE) container.  
2. Whole liquid-crystal displays (LCDs) or cathode ray tube monitor (CRTs) in a 1,000 
L HDPE container. 
3. Whole fridges/freezers in a 10,000 L metal container. 
Samples were provided as crude leachate without pre-filtering and stored in glass bottles 
in a temperature controlled room (15 oC) until analysis. 
We aimed to develop an untargeted method for screening of NBFRs in leachate samples. 
This was performed using a liquid/liquid extraction method. The samples were filtered 
through a 0.7 μm pore size glass fibre filter (Whatman, USA) to remove any visible 
particles or fibres. Because there was no information about what NBFRs might be present 
in the sample, we selected some 13C-labelled BFRs as internal standards (ISs). These 
standards would help to quantify and semi-quantify detected NBFRs, if needed. The 
advantages of isotope labelled internal standards are that they do not naturally occur in 
the environment and behave in a similar manner with the analytes during extraction, 
sample preparation and instrument analysis. Liquid chromatography coupled to mass 
spectrometry (LC-MS) is well known to susceptible to matrix effects (e.g. ion suppression 
or ion enhancement) especially in Electrospray Ionization mode (ESI) but also to a lesser 
extent in Atmosphetic Pressure Chemical Ionization mode (APCI) (Helga et al., 2011). 
The introduction of isotope labelled ISs can compensate for extraction and sample 
preparation losses as well as matrix effects in LC-MS analysis.  
Six samples of each leachate test category (M, L and F) together with one field blank (BF) 
and transportation blank (BL) were extracted and screened for BFRs (Table 4.1). Only 
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one M sample needed to be filtered before extraction to remove visible particles or fibers. 
For extraction of semi volatile chemicals in water, there are several common organic 
solvents that can be used: hexane, benzene, toluene, dichloromethane (DCM) and ethyl 
acetate. Benzene and toluene are suitable for extraction of aromatic compounds but are 
more toxic than other solvents. Hexane is good for extraction of non-polar chemicals e.g. 
aliphatic hydrocarbons while ethyl acetate works best with semi polar compounds (e.g. 
ester, ether). DCM on the other hand is a polar aprotic solvent and efficient to extract both 
non-polar and polar compounds. Fast evaporation is also an advantage of DCM. 
Therefore, DCM was chosen as the solvent of choice for extraction of BFRs in our 
samples (Chandra, 2015). 
Table 4.1: Different sample categories in stimulated leachate test 
Sample types Description 
M Mixed wasted electrical and electronic equipment 
L Whole LCDs/CRTs 
F Whole fridges/freezers 
BF Field blank (deionized water) 
BL Transportation blank (deionized water) 
Twenty nanograms each of 13C-BDE-28, 13C-BDE-209 and 13C-BTBPE were added as 
internal standards to 250 mL of leachate samples. Additionally, in order to decrease 
hydration power of water (meaning decrease the solubility of slightly soluble organic 
compounds), 5 mL of 2 % NaCl solution was added. However, if an undesirable emulsion 
in the sample was formed likely due to an excess amount of dissolved humic materials, a 
new portion of that sample was used for extraction without adding NaCl solution. The 
samples were then extracted with 50 mL of DCM by ultrasonication in 30 min following 
by mechanical shaking twice for 3 hours with 50 mL DCM. In each steps, the organic 
layers were kept and combined together. PTFE caps were used to prevent spillage and 
leakage of samples during the extraction process. Each sample batch consisted of 6 
samples taken from at least 2 different sample categories. 
The combined extracts were concentrated to 0.5 mL on a Zymark Turbovap® II 
(Hopkinton, MA, USA) then loaded onto a layered SPE cartridge consisted of (by order, 
top to bottom) 2 g Na2SO4, 6 g 22 % acid silica and 2 g Na2SO4 pre-conditioned with 2 x 
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2 mL of hexane. The cartridge was eluted with 20 mL hexane following by 20 mL DCM. 
The eluent was evaporated to dryness under a gentle nitrogen stream, reconstituted in 100 
µL methanol ready for analysis. 
4.2.3. In vitro incubation experiments 
The following exposure protocol was applied in triplicates for two levels of exposure to 
the studied NBFRs (1 and 10 µM): 0.5 mg of mouse liver microsomes, William’s E 
medium and 10 µL of an NBFR dosing solution (final concentration of 1 and 10 µM) 
were pre-incubated for 10 minutes at 37 oC. NADPH regenerating system (final 
concentration: 2.0 mM nicotinamide adenine dinucleotide phosphate, 10.0 mM glucose-
6-phosphate and 2 units/mL glucose-6-phosphate dehydrogenase) was added to make a 
final volume of 1 mL. The samples were then incubated at 37 oC, 5 % CO2 and 98 % 
relative humidity for 60 min. At the end of the incubation, 1 mL of ice-cold methanol was 
added to stop the reaction prior to sample extraction. Negative control samples were also 
carried out. These included: 1, a non-enzymatic blank in which no NADPH regenerating 
system was added. 2, a heat-inactivated blank featuring rat liver microsomes heated above 
80 0C for 10 min and 3, a solvent blank which contained only William’s E medium were 
performed and analyzed alongside the sample batch. 
4.2.4. Extraction of in vitro samples 
Samples were mixed with 3 mL of hexane:DCM mixture (1:1 v/v) by vortexing for 30 s, 
followed by ultrasonication for 5 min and centrifuged at 4000 g for 5 min. The organic 
layer was collected and the extraction procedure was repeated twice. The combined 
extracts were evaporated to dryness under a gentle stream of nitrogen then reconstituted 
in 100 µL of methanol prior to instrument analysis. 
4.3. Method development 
4.3.1. Analysis of pure BFR standards 
In order to create a mass spectrometric library for BFRs screening, available authentic 
standards of some BFRs and NBFRs (1 ng/μL) were injected into the Orbitrap MS to 
explore their HRMS spectra. The analysis of standards was carried out in both ESI and 
APCI full scan mode with positive and negative polarity (APPI was unavailable). In ESI 
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mode, mass spectrum of chemicals are usually easier to interpret with common pseudo-
molecular ions being formed: [M-H]- in negative polarity and [M+H]+ in positive mode. 
However, a well-known issue of ESI is its liability to ion suppression due to matrix effect 
(Dams et al., 2003). This phenomenon can largely affect analysis results and therefore a 
very good sample cleanup is required. In APCI mode, ion suppression effect is much less 
but mass spectrum interpretation is more difficult than in ESI mode (Dams et al., 2003). 
As expected for hydrophobic chemicals, almost all of the analyzed BFRs were only 
detected in (-)APCI mode with the exception of TBBPA and HBCDDs (ionized well in 
both (-)APCI and (-)ESI. A common ionization mechanism for BFRs in (-)APCI is via 
the formation of the pseudomolecular ion [M-Br+O]- where M is the chemical formula of 
the BFR; but there are exceptions (Table 4.2). The most intense ion was evaluated from 
obtained spectra for each compound and its accurate mass was calculated from the isotope 
simulation (Xcalibur 3.0, Thermo Fisher Scientific) (Figure 4.1). 
Almost all of the BFRs were well ionized in (-)APCI mode with the exception of DBE-
DBCH. A maximum intensity of 2E2 was observed for DBE-DBCH using the ion 
[M+O2]
- and the isotope pattern of this ion cluster was not clear (Figure 4.1.DBE-DBCH). 
Additionally, [M+O2]
- and Br- were the only ions observed for DBE-DBCH. Br- is not a 
selective ion considering the fact that there are potentially several brominated chemicals 
in real samples. Hence, ion [M+O2]
- was still used as qualification ion for DBE-DBCH 
screening purposes, with an important note that the LOD for this compound might be 
quite high compared to other studied BFRs.
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Table 4.2: BFR standards used in this chapter and their accurate ion masses analyzed by LC-(-)APCI-HRMS. 
Compound Abbreviation Chemical  
Formula 
Ion Type M/Z Intrument LOD 
(pg/uL) 
2,4,4'-Tribromodiphenyl ether BDE-28 C12H7Br3O [M-Br+O]
- 342.87923 5.8 
2,2′,4,4′-Tetrabromodiphenyl ether BDE-47 C12H6Br4O [M-Br+O]
- 420.78975 0.7 
2,2′,4,4′,5-Pentabromodiphenyl ether BDE-99 C12H5Br5O [M-Br+O]
- 500.69821 0.9 
Tetrabromobisphenol A TBBPA C15H12Br4O2 [M-H]
- 542.74516 0.2 
2,2',4,4',5,5'-Hexabromodiphenyl ether BDE-153 C12H4Br6O [M-Br+O]
- 578.60872 0.2 
Hexabromocyclododecanes HBCDDs C12H18Br6O [M-H]
- 640.63691 0.2 
2,2′,3,4,4′,5′,6-Heptabromodiphenyl ether BDE-183 C12H3Br7O [M-Br+O]
- 658.51719 0.2 
2,2',3,3',4,4',6,6'-Octabromodiphenyl ether BDE-197 C12H2Br8O [M-Br+O]
- 736.42825 0.9 
2,2′,3,3′,4,4′,5,5′,6-Nonabromodiphenyl ether BDE-206 C12HBr9O [M-Br+O]
- 816.33672 0.3 
Nonabromo-4'-chlorodiphenyl ether 4PC-BDE-208 C12Br9ClO [M-Br+O]
- 850.29720 1.0 
Decabrominated diphenyl ether BDE-209 C12Br10O [M-Br+O]
- 894.24668 0.03 
Cl10 Dechlorane Plus aCl10DP C18H14Cl10 [M-Br+O]
- 564.81824 1.0 
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Dechlorane 602 Dec-602 C14H4Cl12O [M-Br+O]
- 592.67261 1.0 
Cl11 Dechlorane Plus aCl11DP C18H13Cl11 [M-Br+O]
- 598.77927 1.2 
Dechlorane 604 Dec-604 C13H5Br3Cl6 [M-Br+O]
- 628.58836 1.0 
Dechloraneplus DDC-CO C18H12Cl12 [M-Br+O]
- 632.74029 1.0 
Dechlorane 603 Dec-603 C17H8Cl6 [M-Br+O]
- 638.68883 1.0 
2,4,6-Tribromophenyl allyl ether TBP-AE C9H7Br3O [M-Br+O]
- 306.87923 0.5 
1,2-Bis(2,4,6-tribromophenoxy)ethane BTBPE C14H8Br6O2 [C6Br3H2O]
- 328.76408 0.5 
2,4,6-Tribromophenol 2,4,6-TBP C6H3Br3O [M-H]
- 328.76408 0.1 
2,4,6-Tribromophenyl allyl ether TBP-BAE C9H6Br4O [M-Br+O]
- 384.78975 0.5 
Pentabromoethylbenzene PBEB C8H5Br5 [M-Br+O]
- 436.7033 1.2 
1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane DBE-DBCH C8H12Br4 [M+O2]
- 459.75299 27 
2,3-Dibromopropyl 2,4,6-tribromophenyl ether TBP-DBPE C9H7Br5O [M-Br+O]
- 466.71386 1.0 
2-Ethylhexyl 2,3,4,5-tetrabromobenzoate EH-TBB C15H18Br4O2 [M-Br+O]
- 484.87856 0.8 
Hexabromobenzene HBB C6Br6 [M-Br+O]
- 486.58251 0.5 
Brominated biphenyl 153 BB153 C12H4Br6 [M-Br+O]
- 562.61381 0.2 
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Dibromocyclooctane HCDBCO C18H12Br4 [M+O2]
- 571.72852 12 
Bis(2-ethylhexyl) tetrabromophthalate BEH-TEBP C24H34Br4O4 [M-Br+O]
- 640.99359 0.6 
Octabromotrimethylphenyl indane OBTMPI C18H12Br8 [M-Br+O]
- 802.51190 2.0 
Decabromodiphenyl ethane DBDPE C14H4Br10 [M-Br+O]
- 906.28307 11 
Labelled 13C 2,4,4'-tribromodiphenyl ether 13C-BDE-28 13C12H7Br3O [M-Br+O]
- 354.91949 5.5 
Labelled 13C Decabrominated diphenyl ether 13C-BDE-209 13C12Br10O [
13C6Br5O]



























4.3.2. LC-(-)APCI/(-ESI)-HRMS analysis for targeted and untargeted analysis of 
BFRs 
Even though the Orbitrap MS can provide very accurate mass for scanned ions, due to the 
similarity in chemical structures of BFRs e.g. TBP-AE and TBP-BAE or EH-TBB and 
BEH-TEBP (Figure 1.2), it is not possible to separate and identify complex mixtures of 
target compounds through direct infusion analysis. Additionally, we aimed to develop a 
method for targeted and untargeted analysis of BFRs and other brominated compounds 
in one run; hence LC separation was needed to provide another layer of separation and 
identity confirmation via retention time. Internal standards were added for retention time 
reference, semi-quantify target chemicals if possible and assess the extraction efficiency. 
We chose 13C-BDE-28, 13C-BTBPE and 13C-BDE-209 as internal standards to represent 
low, medium and high M.Wt. brominated compounds with the numbers of bromines in 
each standard of 3, 6 and 10, respectively.  
Chromatographic separation of BFRs and internal standards was performed on an 
Accucore RP-MS column (100 x 2.1 mm, 2.6 µm) (Thermo Fisher Scientific Bremen. 
Germany). Previously, it has been reported that a water-methanol mobile phase system 
generate highest sensitivity for BFRs analysis by LC-APCI-MS in comparison with other 
common mobile phases (Zhou et al., 2010). Therefore, we chose a simple water and 
methanol mobile phase gradient for our analysis without any modifiers to minimize 
complicated mass spectra due to adduct ions formation. Details of the gradient elution 
programme are shown in Table 4.3. The injection volume was 5 µL and the column oven 
was set at 30 ˚C. 
Table 4.3: LC gradient for the analysis of BFRs standard mixture 
Time (min) % Water (A) % Methanol (B) 
0 80 20 
9 0 100 
12 0 100 
12.1 80 20 




The APCI source was used to ionize samples in full scan negative ion mode and the 
optimized Orbitrap MS parameters are shown in Table 4.4 
Table 4.4: Optimized (-)APCI Orbitrap MS parameters for targeted and untargeted 
analysis of BFRs 
Parameter Value 
MS resolution (FWHM) 17500 
Shealth gas flow (a.u) 25 
Auxiliary gas flow (a.u) 5 
Source heater temperature (oC) 250 
Capillary temperature (oC) 375 
Voltage (kV) 5 
S-lens frequency (Hz) 50 
Maximum injection time (ms) 100 
Automatic gain control (ions) 1x106 
Scan range 300-1000 
 
Target BFRs and IS were identified in Quan Browser using accurate mass of identify ions 
at 5 ppm mass deviation and general knowledge of reversed phase liquid chromatography 
elution order: i) the more hydrophilic a compound is, the earlier it elutes and ii) higher 
molecular weight chemicals tend to elute later. The retention times of target compounds 
and internal standards were obtained as described in Table 4.5. 
Table 4.5: Retention time of BFR standards analyzed by (-)APCI-LC-HRMS on 
Accucore RP-MS column 
Compound Retention time 
(min) 
Compound Retention time 
(min) 
2,4,6-TBP 7.75 BDE-153 10.50 
TBBPA 8.4 Dec-603 10.57 
DBE-DBCH 8.97 BDE-183 10.63 
TBP-AE 9.25 EH-TBB 10.74 
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HBCDDs 9.34, 9.53, 9.63 13C-EH-TBB 10.74 
BDE-28 9.41 aCl10DP 10.77 
13C-BDE-28 9.44 BTBPE 10.78 
TBP-BAE 9.58 13C-BTBPE 10.81 
TBP-DBPE 9.75 DP 10.87 
BDE-47 9.9 BDE-197 10.90 
BDE-99 9.97 BDE-206 11.01 
HCDBCO 10.08 OBTMPI 11.34 
HBB 10.2 BDE-209 11.35 
Dec-602 10.31 13C-BDE-209 11.39 
BB153 10.37 4PC-BDE-208 11.71 
aCl11DP 10.39 BEH-TEBP 11.78 
PBEB 10.46 13C-BEH-TEBP 11.78 
Dec-604 10.47 DBDPE 12.7 
 
In addition to (-)APCI mode, (-)/(+) switching ESI analysis was also employed to study 
in vitro biotransformation of EH-TBB, BEH-TEBP and BTBPE with the same LC 
gradient but different Orbitrap MS parameters as follow: 
Table 4.6: Optimized (-)ESI Orbitrap MS parameters for metabolite identification 
of EH-TBB, BEH-TEBP and BTBPE by MLM in vitro 
Parameters Value 
Polarity Pos/Neg switching 
Sheath gas flow rate 25 
Aux gas flow rate 5 
Sweep gas flow rate 0 
Spray voltage (kV) 4.5 
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Capillary temp. (oC) 320 
S-lens RF level 50 
Aux gas heater temp (oC) 350 
Resolution (FWHM) 17500 
AGC target (ions) 1E6 
Maximum ion injection time (ms) 100 
Scan mode Full scan 
Scan range 70-800 
 
For untargeted screening of potential brominated contaminants, a Compound Discoverer 
approach as described in Section 2.3.2 was used with the settings in the main working 
nodes as following: 
Table 4.7: Compound Discoverer parameters of main working nodes for screening 




Min. Precursor Mass: 300 (Da) 
Max. Precursor Mass: 1000 (Da) 
Polarity Mode: negative and positive 




Alignment Model: Adaptive curve 
Mass Tolerance: 5 ppm 






Min. Peak Intensity: 5000 
Ion: [2M-H]; [M+Cl]; [M-2H]; [M-Br+2e]; [M-Br+O]; [M-H]; [M-H-
H2O]; [M+H] 
Max. Element Counts: C30 H50 Br15 Cl8 O10 






Max. Sample/Blank: 3 
Hide Background = True 
Predict 
Compositions 
Max. Element Counts: C30 H50 Br15 Cl8 O10 
Max. RDBE: 20 
Max. # Candidates: 20 
Search 
ChemSpider 
Databases: ACToR: Aggregated Computational Toxicology Resource; 
DrugBank; EAWAG Biocatalysis/Biodegradation Database; EPA 




Isotope Pattern: C8Br; C8Br2; C8Br3; C8Br4; C8Br5; C8Br6; C8Br7; 
C8Br8; C8Br9; C8Br10; C8Br11; C8Br12; C8BrCl; C8Br2Cl; 
C8Br3Cl; C8BrCl6; C8Br3Cl6; C8Br3Cl 
Intensity Tolerance: 30% 
 
For descriptive analysis (e.g. peak area ratio), PCA and ANOVA analysis, leachate 
samples were divided into 4 groups based on their sample categories: M, F, L and blank 
while in vitro samples were divided into 4 groups: treated with 1µM, treated with 10 μM, 
non-treated and blank. “Blank” group included (where applicable) field blank, 
transportation blank, solvent blank and instrument blank samples where 5 μL of methanol 
was injected. “Non-treated” group consisted of individual EH-TBB, BEH-TEBP and 
BTBPE samples as well as heated inactivated samples and non-enzymatic samples. 
4.4. BFRs screening in leachate samples 
4.4.1. Targeted screening of BFRs 
Among 31 target BFRs, only a few were detected including BDE-47, BDE-99, BDE-183, 
BDE-209, DBDPE, BTBPE, TBP, TBP-AE, HBCDDs and TBBPA. Figure 4.2 shows the 
peak area heat map of detected BFRs in the studied leachate samples. 
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Figure 4.2: Peak area heat map of detected BFRs in leachate samples 
 
As can be seen on Figure 4.2, legacy BFRs namely BDE-209, DBDPE, TBBPA were 
detected in almost every sample including blanks with much higher peak area than other 
BFRs. This indicates the ubiquitous distribution of these BFRs in the environment. Some 
other PBDEs were also occasionally detected, mostly in leachate from fridges/freezers (F 
samples) especially BDE-99. BTBPE, TBP-BAE and 2,4,6-TBP were the only NBFRs 
found in this leachate test. 2,4,6-TBP has the highest detection frequency, nearly 100% 
and also found in blanks while BTBPE mainly presented in M samples. Nearly 30% of 
samples contained TBP-BAE at quite low levels. 
Statistical tools were applied to compare the level of each detected contaminant in three 
different sample types: L, M and F. Shapiro-Wilk normality test revealed non-normal 
distribution for all the compounds with the exception of DBDBE (p = 0.77). To simplify 
the statistical analysis process, we then applied non-parametric tests for all the compounds 
including DBDPE. Kruskal–Wallis test was used to determine if the levels of each 




Table 4.8: Nonparametric Kruskal-Wallis Test result for distribution of each 
detected BFR across all sample categories 
Hypothesis Test Summary 
  Null Hypothesis Test P 
value 
Decision 
1 The distribution of TBP is the 




0.002 Reject the null 
hypothesis. 
2 The distribution of TBBPA is 




0.001 Reject the null 
hypothesis. 
3 The distribution of TBPBAE 




0.549 Retain the null 
hypothesis. 
4 The distribution of BDE47 is 




0.04 Reject the null 
hypothesis. 
5 The distribution of BDE99 is 




0.002 Reject the null 
hypothesis. 
6 The distribution of BDE183 is 




0.917 Retain the null 
hypothesis. 
7 The distribution of BTBPE is 




0.022 Reject the null 
hypothesis. 
8 The distribution of BDE209 is 




0.016 Reject the null 
hypothesis. 
9 The distribution of DBDPE is 








10 The distribution of HBCDDs 




0.575 Retain the null 
hypothesis. 
The results (Table 4.8) indicated that the abundances of TBP-BAE, BDE-183, DBDPE 
and HBCDDs did not differ significantly between the 3 sample groups. In contrast, the 
abundances of TBP, TBBPA, BDE-47, BDE-99, BTBPE and BDE-209 were significantly 
different between M, F and L samples. Thence Dunn post hoc analysis was carried out to 
assess the exact statistical relationship between contaminant levels in any two sample 
categories. 
Table 4.9: P value for pairwise comparison of contaminant levels in each sample 
category via Dunn post hoc after significant Kruskal-Wallis Test. 
Categories TBP TBBPA BDE-47 BDE-99 BTBPE BDE-209 
F-L 0.017 0.052 0.012 0.002 0.355 0.004 
F-M 0.001 0.000 0.122 0.003 0.073 0.094 
L-M 0.279 0.052 0.334 0.821 0.007 0.234 
 
At a 95 % confidence level, Dunn post hoc analysis results (Table 4.9 and Figure 4.3) 
showed that TBP and TBBPA were significantly higher in M samples than F samples 
while BTBPE was significantly higher in M than L samples. The amount of TBP was also 
significantly higher in L samples than F samples. For BDE congeners, F samples 
statistically contained higher levels of BDE-47 and BDE-209 than L and BDE-99 than M 
samples. It is clear from the Kruskal-Wallis plot (Figure 4.3) that brominated diphenyl 
ethers were present at higher concentrations in leachate samples stemming from 
fridges/freezers than other electrical waste items while leachate samples derived from 
mixed WEEE contained much more phenolic BFRs such as TBBPA. 
102 
 





4.4.2. Untargeted screening of brominated contaminants 
A total of 16335 potential chemicals across all our samples were flagged by Compound 
Discoverer. We applied some filters to narrow down the list of pur compounds of interest: 
i, Pattern matches is true in any pattern (Pattern Scoring – Table 4.7) 
ii, The maximum peak area ratio of that compound in any sample against blanks must be 
greater than 2 
iii, P value of per group ratio calculated by ANOVA and Tukey HSD post hoc is less than 
0.1 between samples and blanks 
iv, Maximum peak area has to be greater than 1000 
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Using these successive filters, only 31 potential brominated compounds were left, down 
from 16335. After carefully examining their retention times, peak shapes and ion masses, 
we highlighted five unknown compounds of interest (Table 4.10). 
Table 4.10: Some potential brominated contaminants list found by Compound 
Discoverer 
Name Ion mass (da) Elucidated Ion formula RT (min) Found in samples 
A 382.93953 C15H13Br2O2 7.55 L2, M6 
B 460.84070 C15H12Br3O2 8.04 M2-5, L2-3, L6 
C 380.95001 C16H15Br2O 9.02 L1-6, F3-6 
D 552.76654 C16H13Br4O2 9.27 M3-4. L1-3 
E 494.80075 C15H12Br3ClO2 8.38 M3, M5, L1-2 
 
The ion mass of unknown compound A was 382.93953 with a proposed ion formula of 
C15H14Br2O2 (Figure 4.4). ChemSpider screening found one match for A as 4,4'-(2,2-
propanediyl)bis(3-bromophenol). As the exact position of bromines and hydroxyl groups 
were not possible to elucidate just based on accurate mass, only the chemical structure of 
the ChemSpider match was used as a reference for compound identification. Compound 
A was then tentatively identified as dibromobisphenol A (DBBPA) (C15H14Br2O2) which 
underwent the (-)APCI ionization M-H similar to TBBPA. It is important to note that the 
exact chemical configuration of A might not be the same as DBBPA. This also applies 
for any other compound tentatively identified in this study. Unknown compound B had 
an ion mass of 460.84070 and was present in many samples (Table 4.10). It showed a 3 
bromine pattern in its mass spectra, with a predicted ion formula of C15H12Br3O2 (Figure 
4.5). If this ion was formed via M-H mechanism, the chemical formula for A was 
C15H12Br3O2. There was one match from ChemSpider for this formula as 2,6-Dibromo-
4-[2-(3-bromo-4-hydroxyphenyl)-2-propanyl]phenol or tribromobisphenol A (TriBBPA). 
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Figure 4.4: Overlay chromatogram of Unknown Compound A in leachate samples 
and its isotopic pattern 
 
Figure 4.5: Overlay chromatogram of Unknown Compound B in leachate samples 





Figure 4.6: Overlay chromatogram of Unknown Compound D in leachate samples 
and its isotopic pattern 
 
Similarly, D had an ion mass of 552.76654 and showed an isotopic pattern of 4 bromines 
in the mass spectra (Figure 4.6). It was later elucidated as C16H14Br4O2 with one match 
from ChemSpider being 4,4'-(2,2-butanediyl)bis2,6-dibromophenol. However, an 
alternative identification of a methoxylated derivative of TBBPA was noted. Indeed, 
methoxylated TBPPA (MeO-TBBPA) has been identified as a transformation product of 
TBBPA by microorganisms or in oxic soil (George and Häggblom, 2008; F. Li et al., 
2015b; Sun et al., 2014). Therefore we tentatively identified compound D as MeO-
TBBPA. 
DBBPA, TriBBPA and MeO-TBBPA have been identified as the main environmental 
transformation products of TBBPA (Liu et al., 2017). Their detection is plausible as they 
were found in many M and L samples where TBBPA presented at high levels. The 
detection rate of TriBBPA in this study is higher than MeO-TBBPA and in good 
agreement with previous studies, which demonstrated that debromination on a benzene 




For unknown compound C, since it shares a similar chemical composition with unknown 
compound D, we hypothesize it is methoxylated dibromobisphenol A (MeO-DBBPA). 
The retention time of C also supports this hypothesis: shorter than MeO-TBBPA, which 
contains the same functional groups and two more bromine atoms, and longer than 
TBBPA which is more polar due to one more hydroxyl group in its structure. 
Compound E had an ion mass of 494.80070 and showed very distinctive isotope pattern 
of 3 bromine atoms in the structure. Compound Discoverer elucidation node predicted the 
composition of E as C15H12Br3ClO2, which is very similar to TBBPA with the exception 
of one chlorine atom instead of bromine. The retention time of E was earlier but also very 
close to TBBPA (8.38 vs 8.46 min). Therefore, we hypothesized E to be chlorinated 
TriBBPA (Cl-TriBBPA). 
Figure 4.7 showed the structures of tentatively identified unknown brominated 
contaminants in leachate testing samples. They are all structurally related to TBBPA and 
might be environmental degradation/transformation products of this widely used BFR. 
Figure 4.7: Chemical structures of tentatively identified TBBPA-related 





4.5. Screening of biotransformation products of EH-TBB, BEH-TEBP and BTBPE 
following in vitro incubation with mouse liver microsomes (MLM) 
4.5.1. Characterisation of parent compounds 
Parent NBFRs were determined by the (-)APCI-LC-HRMS method described previously 
in this chapter. The exact ion masses of EH-TBB, BEH-TEBP and BTBPE (Table 4.2) 
were used for identification of each individual NBFR in dosing solutions and samples 
generated from in vitro experiments. Reconstructed chromatograms of EH-TBB, BEH-
TEBP and BTBPE in MLM exposed to individual NBFRs are shown in Figure 4.8. 
Figure 4.8: (-)APCI-LC-HRMS extracted ion chromatograms of BEH-TEBP (A), 
EH-TBB (B) and BTBPE (C) in in vitro MLM samples exposed to 10 µM of 
individual NBFRs for 60 min 
 
Interestingly, some brominated impurities were detected in (-)APCI analysis of EH-TBB 
and BEH-TEBP dosing solutions prepared from a 95 % purity standard (Accustandard, 
New Haven, USA),  but not in their high purity standards (>99 %, Wellington Lab, 
Ontario, Canada). In EH-TBB dosing solution, a small amount (~ 0.3 %) of BEH-TEBP 
was found together with a brominated impurity (~1 %) with the exact ion mass of 
404.97057. The impurity showed the unique pattern of two bromine atoms in the chemical 
formula (Figure 4.9) with the proposed molecular ion formula was [C15H19Br2O3]
-. The 
common ionization mechanism for organobrominated compounds in (-)APCI mode is 
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[M-Br+O] , therefore the impurity was tentatively identified as mono debrominated EH-
TBB (EH-TriBB) with the chemical formula C15H19Br3O2. This was further supported by 
the earlier retention time of the tri-brominated compound compared to EH-TBB, as well 
as a good match of the Br isotope cluster with the simulated accurate mass isotope pattern 
for the suspect molecule (Figure 4.9).   
In the BEH-TEBP dosing solution, only one brominated impurity with an exact molecular 
ion mass of 561.08512 was found at relative high percentage (~4 %). (-)APCI-LC-HRMS 
analysis of the impurity showed an isotopic pattern of two bromine atom in the impurity 
(Figure 4.10). Compound Discoverer proposed the ion formula to be [C24H35Br2O5]
-. 
Similar to the case of the EH-TBB dosing solution, we hypothesize this impurity to be 
BEH-TriBP, a debrominated product of BEH-TEBP, which was also supported by 
retention time and isotope cluster simulation (Figure 4.10) 
The detection of such impurities in EH-TBB and BEH-TEBP dosing solutions suggested 
that: (i) extra attention is needed when studying biotransformation of these chemicals by 
biological assays. They might appear as potential metabolites despite originating from 
dosing solutions, and. 
(ii) even though the impurities were detected at substantially lower concentrations than 





Figure 4.9: BEH-TEBP and EH-TriBB as impurities in EH-TBB dosing solution 
analyzed by (-)APCI-LC-HRMS 
 






4.5.2. Metabolite identification 
The Compound Discoverer work flow as described in Table 4.7 was employed to study 
the potential metabolites of individual EH-TBB (C15H18Br4O2), BEH-TEBP 
(C24H34Br4O4) and BTBPE (C14H8Br6O2) in vitro by mouse liver microsomes with some 
slight modification. Specifically, the Maximum Element Counts parameter in “Detect 
Unknown Compound” and “Predict Compositions” nodes were set as C30 H50 Br6 O10 
to cover possible reactions can take place during phase I metabolism (e.g. hydroxylation). 
A very large number of features were detected in two groups: “treated” and “untreated” 
for all three compounds. In order to narrow down the metabolite candidates, we applied 
the following successive filters: 
i, Pattern matches is true in any pattern (Pattern Scoring – Table 4.7) 
ii, P value of per group ratio calculated by ANOVA and TukeyHSD post hoc is less than 
0.1 between treated and untreated samples 
iii, Log2 fold changes (log2 of peak areas ratio of a feature between treated and untreated 
samples) is greater than 1 which is equivalent to fold change > 2 (Dalman et al., 2012). 
Additionally, we also looked at the feasibility of proposed chemical formulae, the 
difference between log2 fold change of 1 µM and 10 μM exposure level as well as visual 
inspection of retention time, peak shape and S/N ratio before confirming a metabolite 
candidate. 
It was reported that porcine carboxylesterase can slowly metabolize BEH-TEBP into its 
monoester form (Roberts et al., 2012). However such a metabolite was not identified in 
any in vitro BEH-TEBP bioassays by human liver microsomes (Roberts et al., 2012) or 
carp, mouse and fathead minnow S9, cytosol and microsomes (Bearr et al., 2012). A 
significant depletion of BEH-TEBP was observed in the later study in all of the bioassays, 
indicating potential metabolism of the substrate by the subcellular fractions into 
unidentified metabolites. The results from Compound Discoverer in this study also 
showed no monoester or identifiable oxidation metabolites of BEH-TEBP in either 
(-)APCI mode or (+)/(-)ESI mode. 
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Similarly, there were no measurable biotransformation products of BTBPE by MLM in 
any analysis mode. To our knowledge, there is only one in vivo metabolism study of 
BTBPE in male rats following a single oral dose at 2 mg/kg of 14C radiolabeled BTBPE 
(Hakk et al., 2004). BTBPE reportedly persisted against liver metabolism with less than 
4 % of the dose undergoing biotransformation via oxidation, oxidative debromination and 
ether cleavage mechanisms (Hakk et al., 2004). Despite our extensive efforts, no similar 
BTBPE metabolites could be positively identified following our rigorous protocol. There 
was however a strong signal for 2,4,6-tribromophenol in all samples including blanks. 
Since the metabolic rate of BTBPE was reported to be very low in vivo in rat, we cannot 
exclude the possibility that 2,4,6-tribromophenol, a potential metabolite of BTBPE, was 
formed in vitro at low concentrations that were indistinguishable from its blank level. 
Analysis of in vitro EH-TBB samples by Compound Discoverer revealed two potential 
metabolites in (-)APCI mode with accurate ion masses of 354.76151 (M1) and 384.77164 
(M2). In (-)ESI mode there was one potential metabolite (M3, accurate ion mass of 
434.66636) that eluted at the same retention time as M1. 
M1 eluted at around 6.3 min (Figure 4.11) and had the isotopic pattern of three bromines 
in its proposed formula. The proposed ion composition for M1 was [C7H2Br3O3]
- and log2 
fold change in 1 and 10 μM samples were 2.12 and 6.80, respectively. We hypothesized 
M1 to be tetrabromobenzoic acid (TBBA, C7H2Br4O2) formed via common (-)APCI 
ionization mechanism [M-Br+O]-. This is plausible because M1 eluted quite early in the 
chromatogram in comparison with EH-TBB (10.75 min), implying it to be of higher 
polarity than the parent compound. Since M3 (identified in negative ESI mode) eluted at 
the same time as M1 (in negative APCI mode) and also showed a three bromines isotopic 
pattern, we hypothesized that M3 is the ion form of TBBA in (-)ESI. TBBA is an organic 
acid and expected to be ionized in (-)ESI to form a [M-H]- ion. Indeed, the proposed ion 
formula for M3 was C7HBr4O2. In order to confirm our hypothesis, authentic standards 
of TBBA and TBBA-spiked in vitro samples were analyzed. An increase in intensities of 
both M1 and M3 was observed. The mass spectrum of TBBA in (-)APCI and (-)ESI also 
matched with that of M1 and M3, respectively. Therefore, M1/M3 was confirmed to be 




Figure 4.11: Overlay chromatogram of M1 (M3) and its chromatogram in MLM 
samples exposed to 10µM of EH-TBB in vitro 
 
M2 eluted at around 8.84 min and showed an isotopic pattern of three bromines (Figure 
4.12). The proposed molecular ion for M2 was [C8H4O3Br3]
- which likely corresponds to 
2,3,4,5-tetrabromomethylbenzoate (C8H4O2Br4) after common (-)APCI ionization 
mechanism [M-Br+O]-. An increase in log2 fold change between 1 µM (2.59) and 10 µM  
samples (9.71) was also observed. In addition to retention time and isotope cluster 
simulation, the identity of M2 as 2,3,4,5-tetrabromomethylbenzoate (TBMB) was 
confirmed via comparison of an authentic reference standard for the nominated compound. 
It could be formed via methylation of TBBA (M1).  TBMB was reported as an in vitro 
metabolite of EH-TBB by fathead minnow S9 fractions but not mouse liver subcellular 
fractions (Bearr et al., 2012). A potential source for TBMB could be the non-enzymatic 
methylation of TBBA upon addition of ice-cold methanol to stop the enzymatic reaction, 
which may lead to false positive identification of this compound as an in vitro metabolite.  
To test this hypothesis and confirm the authenticity of TBMB as a metabolite of EH-TBB, 
we carried out a series of in vitro exposure experiments (section 3.2), using different 
methods to stop the enzymatic reaction: ice-cold acetonitrile, ice-cold ethyl acetate and 
thermal deactivation at 70 °C. Additionally, a mixture of pure TBBA standard and 
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methanol were incubated at the same conditions as the in vitro experiments. No TBMB 
was observed in any of these samples. Hence, it was concluded that TBMB was not an 
authentic in vitro metabolite of EH-TBB by MLM. The exact mechanism of TBMB 
formation under the applied experimental condition is unknown but it is important to note 
that such methylation processes occurred only when there was MLM, NADPH, EH-TBB 
substrate and methanol added to stop the reaction. It is plausible that ice-cold methanol 
did not immediately stop the enzymatic activity of MLM resulting in an enzyme-mediated 
methylation reaction of TBBA. Since methyl transferase enzymes are active in 
mammalian hepatocytes, further confirmation of the metabolic fate of TBBA and its 
potential methylation to produce TBMB requires an in vivo model. 
Figure 4.12: Overlay chromatogram of M2 and its spectrum in MLM samples 
exposed to 10µM of EH-TBB in vitro 
 
4.6. Conclusions 
In this chapter, we have successfully developed a LC-(-APCI)/(-ESI)-HRMS method that 
allows both targeted and untargeted analysis of BFRs and their potential 
metabolites/degradation products. The method utilized the high mass accuracy of UPLC-
Orbitrap MS instrument, an in-house mass library and a powerful bioinformatics software 
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package, Compound DiscovererTM. This was demonstrated using simulated leachate 
samples derived from waste electrical and electronic equipment and samples generated 
from in vitro experiments of mouse liver microsomes exposed to EH-TBB, BEH-TEBP 
and BTBPE. 
In simulated leachate samples, BDE-47, BDE-99, BDE-183, BDE-209, DBDPE, BTBPE, 
TBP, TBP-AE, HBCDDs and TBBPA were detected via our targeted approach. Among 
these detected BFRs: BDE-209, DBDPE, TBBPA and 2,4,6-TBP were present in almost 
every sample. PBDEs other than BDE-209 were occasionally found - mostly in leachate 
from fridges/freezers - while BTBPE was mainly detected in samples from mixed waste 
electrical and electronic equipment. Untargeted analysis of the same samples revealed 5 
potential degradation products of TBBPA: dibromobisphenol A, tribromobisphenol A, 
methoxylated TBPPA, methoxylated dibromobisphenol A and chlorinated TriBBPA. 
Via an untargeted analysis approach, 2,3,4,5-tetrabromobenzoic acid was identified as an 
in vitro metabolite of EH-TBB by mouse liver microsomes while no potential metabolites 
were identified for BEH-TEBP and BTBPE under the same experimental conditions. It is 
also important to note that chemical impurities and in vitro experiment quenching agents 
can introduce false positive metabolite identification. 
In conclusion, our method provides a universal framework to study BFRs (including 
NBFRs) and their metabolites/degradation products in various environmental matrices 
that can be adjusted on a needed basis. The method was applied for our NBFR studies in 
Chapter 5 and 6. 
116 
 
Chapter 5  
In vitro metabolism of 1,2-Dibromo-4-
(1,2-dibromethyl)cyclohexane by 




Some material in this chapter is taken verbatim from the following publication: 
Nguyen, K.-H.; Abou-Elwafa Abdallah, M.; Moehring, T.; Harrad, S. Biotransformation 
of the Flame Retardant 1,2-Dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) in 
Vitro by Human Liver Microsomes. Environ. Sci. Technol. 2017, 51 (18), 10511–10518. 
5.1. Sypnosis 
1,2-Dibromo-4-(1,2-dibromethyl)cyclohexane (DBE-DBCH or, as used in this chapter to 
facilitate easier metabolite abbreviation, TBECH) is one of the NBFRs that has been 
widely detected recently in UK foods and indoor air and dust, which warrants human 
exposure to this chemical (Tao et al., 2017, 2016). However, very little is known about 
its toxicokinetics and fate following human exposure which is necessary to fully 
understand its toxic implications and assess the risk arising from this exposure. In this 
study, the technical mixture of TBECH and the pure β-TBECH isomer were subjected to 
in vitro biotransformation by human liver microsomes (HLM) for the first time. After 60 
mins of incubation, 5 potential metabolites of TBECH were tentatively identified in 
microsomal assays of both the TBECH mixture and β-TBECH using UPLC- Q-Exactive 
Orbitrap™ mass spectrometry. The metabolic profile of TBECH indicated potential 
hepatic biotransformation of this chemical via Cyctochrome P450-catalyzed 
hydroxylation, debromination and α-oxidation. Kinetic studies revealed monohydroxy-
TBECH as the major metabolite of TBECH by human liver microsomes. The estimated 
intrinsic clearance (Clint) of TBECH mixture was slower (P<0.05) than that of pure β-
TBECH. While the formation of monohydroxy-TBECH may reduce the bioaccumulation 
potential and provide a useful biomarker for monitoring TBECH exposure, further studies 
are required to fully understand the levels and toxicological implications of the tentatively 
identified metabolites. 
5.2. Introduction 
1,2-Dibromo-4-(1,2-dibromethyl)cyclohexane (TBECH or DBE-DBCH) is an additive 
EFR produced by Albermarle Corp., U.S.A under the trade name Saytex BCL-462. The 
flame retardant is used in extruded polystyrene and polyurethane foam, electrical cable 
coatings, adhesive in fabric and construction materials (Arsenault et al., 2008; Tomy et 
al., 2008). In the U.S, TBECH production volume in 2002 was 230 tons (Covaci et al., 
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2011). The technical mixture of TBECH contains equimolar concentrations of two 
diasteroisomers, named α and β-TBECH.  Although no other isomers could be detected 
in the technical mixture, thermal conversion into γ- and δ-TBECH was reported during 
incorporation into flame-retarded products at temperature of 123 ˚C or higher (Arsenault 
et al., 2008). TBECH isomers have been globally detected in environmental samples 
including indoor air and dust (Cequier et al., 2014; Hassan and Shoeib, 2015; Newton et 
al., 2015), outdoor air (Shoeib et al., 2014), herring gull eggs (Chen et al., 2012; Gauthier 
et al., 2009), blubber of Canadian Arctic whale (Tomy et al., 2008) and toddler’s faeces 
(Leena M O Sahlström et al., 2015). Recently, Tao et al. reported TBECH as the 
predominant emerging flame retardant detected in all indoor air (n=35) and dust (n=92) 
samples from UK houses (mean = 173 pg/m3 and 21.4 ng/g in air and dust) and offices 
(mean = 320 pg/m3 and 41 ng/g in air and dust) (Tao et al., 2016). Not only in indoor air 
and dust, TBECH was also the predominant NBFRs in UK foods with mean concentration 
ranged from 1.43 to 86.1 ng g-1 l.w, which was even higher than total PBDEs 
concentration found in many samples (Tao et al., 2017). Consequently, the compound 
was detected in 100% UK human milk samples collected in 2014-2015 at mean 
concentration of 3.37 ng g-1 l.w (Tao et al., 2017). TBECH also showed the highest levels 
of all detected EFRs in Norwegian (mean = 209 pg/m3) and Swedish (mean = 43 pg/m3) 
indoor air samples (Cequier et al., 2014; Newton et al., 2015) indicating its wide 
application, especially in Europe.  
This is of concern due to its potential toxicological effects on humans and wildlife. 
Several toxicological in silico, in vitro (human and chicken cell lines) and in vivo (birds, 
fishes and rats) studies show TBECH is a strong androgen receptor agonist and endocrine 
disruptor (Asnake et al., 2015; Curran et al., 2017; Khalaf et al., 2009; Kharlyngdoh et 
al., 2016; Larsson et al., 2006; Marteinson et al., 2017, 2015; Park et al., 2011; Pradhan 
et al., 2013). TBECH also displayed potential to disrupt thyroid and sex hormones in 
American kestrels (Marteinson et al., 2017), modulate thyroid axis in juvenile Brown 
Trout (Park et al., 2011) and alter androgen receptor regulation in human ductal breast 
cancer and prostate cancer cell lines (Kharlyngdoh et al., 2016). However, very little is 
known about the biotransformation and fate of TBECH in humans. 
Previous studies have shown some BFRs can be metabolized to more toxic lower 
brominated congeners (Abdallah et al., 2014; Feng et al., 2015; Xie et al., 2014). Two of 
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the primary in vivo debrominated metabolites of BDE-209 in rainbow trout were 
identified as BDE-47 and BDE-99 (Feng et al., 2015), which are more bioaccumulative 
and showed much higher toxic potential than the parent compound in goldfish and 
zebrafish liver cell lines (Xie et al., 2014; Yang and Chan, 2015). Similarly, HBCDDS 
was metabolized by rat and trout liver S9 fractions into pentabromocyclododecenes 
(PBCDs), which showed higher affinity for binding to the thyrotropin receptor (TSH) 
than the parent compound (Abdallah et al., 2014). Therefore, improved understanding of 
the biotransformation pathways, rates and products of TBECH is essential for assessment 
of the risk arising from human exposure to this flame retardant.  
To our knowledge, only one study has investigated the potential metabolites of TBECH 
and moreover used in vitro rat liver microsomes (Chu et al., 2012). Results revealed that 
after 60 min, 40 % of the exposure dose was metabolized by Cytochrome P450 enzymes 
into mono and dihydroxylated TBECH, together with some unidentified metabolites (Chu 
et al., 2012). However, this study did not provide information on the metabolic/hepatic 
clearance rate of TBECH. Moreover, extrapolation of results from metabolic studies in 
rat to human is subject to uncertainty due to inter-species variations in metabolic 
pathways and products. To illustrate, bioconversion from α-, β- and γ-HBCDD mixture 
into δ-HBCDD was observed in trout but not rat S9 fractions (Abdallah et al., 2014). 
Furthermore, EH-TBB was metabolized significantly faster in RLM compared to HLM 
(Roberts et al., 2012).  
Against this background, the aims of this chapter are to: (a) investigate the phase I 
metabolic pathways and products of TBECH following in vitro exposure to human liver 
microsomes (HLM); (b) compare the in vitro HLM metabolic profile of the TBECH 
technical mixture to that of the pure β-isomer and (c) assess the in vitro metabolic rate 
and intrinsic clearance of TBECH by HLM. 
5.3. Experiments 
5.3.1. Chemicals and Standards 
All solvents and reagents used in this study were purchased from Fisher Scientific 
(Loughborough, UK) and were of HPLC grade or higher. Technical TBECH was obtained 
as a neat powder from Accustandard, Inc. (New Haven, CT, USA). A dosing solution was 
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prepared by dissolving technical TBECH in dimethyl sulfoxide (DMSO). High purity 
standards of β-TBECH, α- and β- TBECH mixture (equimolar concentrations), PBDE-77, 
and 13C-BDE-100 were purchased from Wellington Laboratories (Guelph, ON, Canada). 
RapidStart NADPH regenerating system was purchased from XenoTech (Kansas, KS, 
USA) while human liver microsomes and William’s E medium were obtained from 
Thermo Fisher Scientific (Paisley, UK). 
5.3.2. In Vitro Incubation Experiments 
Pre-incubations were performed at different HLM concentrations and different times. 
After optimization of the reaction parameters, the following general exposure protocol 
was applied: 0.5 mg of human liver microsomes, William’s E medium and 10 µL of 
TBECH dosing solution (final concentration 10 µM) were pre-incubated for 10 minutes 
at 37 oC. NADPH regenerating system (final concentration: 2.0 mM nicotinamide adenine 
dinucleotide phosphate, 10.0 mM glucose-6-phosphate and 2 units/mL glucose-6-
phosphate dehydrogenase) was added to make a final volume of 1 mL. The samples were 
then incubated at 37 oC, 5 % CO2 and 98 % relative humidity for 60 min. At the end of 
the incubation, 1 mL of ice-cold methanol was added to stop the reaction prior to sample 
extraction. In all incubation experiments, experiment blanks including a non-enzymatic 
blank in which no NADPH regenerating system was added, a heat-inactivated blank 
featuring liver microsomes heated above 80 0C for 10 min and a solvent blank which 
contained only William’s E medium were performed and analyzed alongside the sample 
batch. 
5.3.3. Sample extraction 
Due to the unavailability of isotopically-labelled TBECH, incubated samples were spiked 
with 20 ng of 13C-BDE-100 as internal standard and extracted according to according to 
a previously reported method (Abdallah et al., 2014). Briefly, samples were mixed with 
3 mL of hexane:DCM mixture (1:1 v/v) by vortexing for 30 s, followed by ultrasonication 
for 5 min and centrifuged at 4000 g for 5 min. The organic layer was collected and the 
extraction procedure was repeated twice. The combined extracts were evaporated to 
dryness under a gentle stream of nitrogen then reconstituted in 100 µL of methanol 
containing 20 ng of BDE-77 as a syringe standard for QA/QC purposes. 
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5.3.4. Instrumental analysis 
5.3.4.1. UPLC-Orbitrap MS analysis 
Samples were analyzed in accordance to section 4.2.2. Briefly, chromatographic 
separation was performed on an Accucore RP-MS column (100 x 2.1 mm, 2.6 µm) with 
water (mobile phase A) and methanol (mobile phase B). A gradient programme at 400 
µL/min flow rate was applied as follows: start at 20 % B; increase to 100 % B over 9 min, 
held for 3 min; then decrease to 20 % B over 0.1 min; maintained constant for a total run 
time of 15 min.  
The parent compound was analyzed in negative APCI mode. The Orbitrap parameters 
were set as follows: (-) APCI full scan mode, resolution 17500, AGC target 1E6, 
maximum injection time 100 ms, scan range 75 to 700 m/z, sheath gas flow rate 25 AU, 
aux gas flow rate 5, discharge current 30 µA, capillary temperature 250°C and S-lens RF 
level 50. 
Accurate masses of 80.91629, 512.73847 and 420.78975 were used to monitor TBECH, 
13C12-BDE-100 (internal standard) and BDE-77 (syringe standard), respectively. The 
more universal, softer electrospray ionisation (ESI) mode was used for screening and 
identification of the produced metabolites. The optimised parameters were: (-) ESI full 
scan mode, resolution 17500, AGC target 1E6, maximum injection time 100 ms, scan 
range 75 to 750 m/z, sheath gas flow rate 20 AU, discharge voltage 2.5 kV, capillary 
temperature 320 0C.  
5.3.4.2. GC x GC TOF-MS analysis 
GCxGC-TOF MS analysis to screen for potential debrominated metabolites of TBECH. 
The samples were analysed by an Agilent 7890A gas chromatogram equipped with a 
Agilent 7693 Autosampler  (Agilent Technologies, Wilmington, DE, USA) and a Zoex 
ZX2 GC × GC cryogenic modulator (Houston, TX, USA), coupled with a Almsco 
BenchToFdx™ time of flight mass spectrometer (Almsco International, Llantrisant, UK). 
The first dimension column was 30 m x 250 µm x 0.25 µm SGC BPX 5 (SGC Analytical 
Science, Victoria, Australia) and the second dimension column was 4 m x 100 µm x 0.1 
µm SGC BPX 50. Injection volume was 1 µL using split mode (1:50) at 300 °C. Helium 
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was used as a carrier gas at a constant flow rate of 1 mL min-1. The primary oven was 
programmed as 120 °C for 4 min, heated at 2.5 °C min-1 to 210 °C increased to 325 °C at 
2 °C min-1 hold for 2 min. Modulation time was 4 sec. Ion source temperature was 320 
oC and transfer line temperature 325°C. The mass spectrometer was operated in positive 
EI mode (70 eV) with a mass scan range of 45-800 m/z at 50 Hz scan speed. Subsequent 
data processing was carried out using GC Image™ v2.1 (Zoex) 
5.3.5. QA/QC 
Quality control samples where the William’s E medium was spiked with TBECH at all 
dosing concentration levels were analyzed, with recoveries of TBECH falling between 96 
to 113 % of the theoretical dosing concentration. In incubation experiments, internal 
standard recoveries were within 60-110 %. 
No parent compounds or metabolites were found in instrument and solvent blanks. 
Additionally, no metabolites were found in the non-enzymatic and heat-inactivated blanks. 
Principal component analysis results from Compound Discoverer 2.0 software also 
showed very distinctive separation between LC/MS chromatograms of samples generated 
by our in vitro experiments compared to those of experimental and instrument blanks 
(Figure 5.1). This analysis was performed using the identified peaks and their 
corresponding peak area in each data files. It shows the difference/similarity in chemical 
information contained within the samples being analyzed. As shown in Figure 6.1, the 
preliminary samples (HLM exposed to 10 µM of the technical TBECH) were grouped 
together while heat-inactivated blank (HI-blank) and non-enzymatic blank (NEB-blank) 
were grouped on the opposite side of PC2 to the preliminary samples. The solvent blank 
and instrument blank were also grouped very closely together which implied negligible 
difference in the detected peaks between the two samples. In other words, lab 
contamination during the whole in vitro experiment and extraction process was minimal. 
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Figure 5.1: Principal component analysis score plot of negative control blanks and 
human liver microsomes samples exposed to 10 µM TBECH mixture for 60 minutes 
 
The isotopic patterns of the proposed chemical formula for detected metabolites were also 
matched with those of the accurate mass isotope simulations provided by Xcalibur™ 
software (Figure 5.2). With the assumption that the measured compounds contain 
naturally distributed isotopes, a match in isotopic pattern of a measured compound and 
simulated pattern greatly increase the confidence in elemental composition prediction of 
the proposed chemical formula. 
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Figure 5.2: Isotopic pattern of metabolites 1-5 recorded by LC-Orbitrap MS in 













5.4. Metabolic profile of TBECH 
Analysis of the UPLC-Orbitrap™ MS chromatograms obtained for samples derived from 
the in vitro experiments, revealed a minimum of three monohydroxylated and three 
dihydroxylated metabolites of the parent TBECH following exposure of HLM to 10 µM 
of the technical mixture for 1 h (Figure 5.3). Bearing in mind the lack of reference 
standards for these metabolites, the isobaric nature of TBECH isomers in the technical 
mixture and the large number of theoretical isomers, co-elution of one or more 
metabolites in the same group (e.g. monohydroxylated TBECHs) could not be excluded. 
Similarly, the specific position of the hydroxyl groups could not be elucidated.  
It is well known that cytochrome P450-catalyzed hydroxylation usually retains the 
stereochemical configuration at the substrate’s reaction site (Ortiz De Montellano, 2010). 
Therefore, we carried a parallel strand of experiments, where HLM were exposed to pure 
β-TBECH (the only purified isomer available commercially) in order to gain further 
information on the metabolic hydroxylation process. Comparisons of LC/MS 
chromatograms between β-TBECH and technical TBECH exposure experiments (Figures 
5.3a and 5.3b) revealed peak M1-2 as monohydroxy-β-TBECH (β-OH-TBECH). Since 
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the applied commercial mixture contained α- and β-TBECH isomers, it can be concluded 
that peaks M1-1 and M1-3 are α-OH-TBECH isomers (Figures5.3a and 5.3b). Similarly, 
peak M2-4 was identified as α-(OH)2-TBECH, while peaks M2-5 and M2-6 originated 
from the β-isomer (Figures 5.3c and 5.3d). 
Our findings are generally in agreement with those reported using rat liver microsomes 
(RLM), where two monohydroxy- and two dihydroxy- isomers were identified following 
exposure to the TBECH technical mixture (Chu et al., 2012). While the difference in the 
number of isomers in each metabolite group may be attributed to inter-species variations, 
this hypothesis cannot be confirmed in the absence of authentic metabolite standards. 
Figure 5.3: Selected UPLC-ESI-Orbitrap/MS chromatograms of monohydroxy (M1, 
peaks 1, 2 and 3) and dihydroxy (M2, peaks 4, 5 and 6) metabolites formed by HLM 
exposure to 10 µM of technical TBECH (a and c) and β-TBECH (b and d) for 60 
minutes 
 
In addition to the hydroxylated metabolites of the parent TBECH, we also tentatively 
identified hydroxylated biotransformation products of debrominated TBECH with the 
formulae: C8H13Br3O (M3), C8H13Br3O2 (M4), C8H11Br3O2 (M5). 
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Table 5.1: Potential metabolites of technical TBECH mixture produced via 
incubation with human liver microsomes 
Code Accurate 


























M5 378.82054 2.620 C8H11Br3O2 
 
DBCBA 




Metabolites M3 and M4 were assigned the chemical structures of mono- and dihydroxy- 
triBECH (Table 5.1). While dihydroxy-triBECH (M4; (OH)2-triBECH) was previously 
reported in in vitro RLM experiments (Chu et al., 2012), this is the first study to identify 
monohydroxy-triBECH (M3; (OH)-triBECH). It is reasonable to believe that M3 can be 
formed by direct debromination of M1 and/or through debromination of parent TBECH 
followed by hydroxylation (Figure 5.6). This is similar to previously reported in vitro 
metabolic pathways for hexabromocyclododecane isomers (HBCDD) in rat (Abdallah et 
al., 2014) and human (Erratico et al., 2016), where both hydroxylation and debromination 
were observed. 
Interestingly, two separate peaks were identified for M3 following HLM exposure to 
technical TBECH (Figure 5.3a), while one peak (M3-7) was observed upon exposure to 
pure β-TBECH. Therefore, peak M3-7 was assigned as β-OH-triBECH and peak M3-8 
was attributed to α-OH-triBECH. We hypothesized that the observed M3 metabolites may 
be produced – at least partially - from hydroxylation of a tribrominated metabolite (i.e. a 
tribromoethyl cyclohexane derivative or triBECH) with a molecular formula of C8H13Br3. 
However, such triBECH metabolites could not be detected in our samples even using the 
high separation and resolution power of a GC x GC-ToF/MS platform in an independent 
analysis dedicated specifically to identify this potential metabolite (Figure 5.4). Similar 
observations were reported in muscle and liver samples of juvenile brown trout exposed 




Figure 5.4: GC x GC - TOFMS total ion current chromatogram of HLM sample exposed to 10 µM TBECH mixture for 60 minutes. 





Figure 5.5: Selected UPLC-Orbitrap/MS chromatograms of metabolites M3 (peaks 
7 and 8), M4 (peaks 9, 10, 11, 12, 13 and 14) and M5 (peaks 15 and 16) formed by 
HLM following exposure to 10 µM technical TBECH (a, c and e) and β-TBECH (b, 
d and f) for 60 minutes 
 
While our experimental approach could not confirm the formation of triBECH, the 
hypothesis cannot be refuted as triBECH might be produced then transformed quickly to 
its hydroxylated metabolites (M3, Figure 5.5a) before the reaction is stopped after 60 min. 
Four distinctive peaks of M4 (Figure 5.5c) were detected when HLM were exposed to 
either technical TBECH or pure β-TBECH. However, two additional peaks, designated 
as M4-13 and M4-14 were observed upon exposure to pure β-TBECH only (Figure 5.5d). 
Hence, M4-13 and M4-14 were tentatively identified as β-(OH)2-triBECH. Due to the 
lack of a pure authentic standard for α-TBECH, it was not possible to address the 
stereochemistry of peaks M4-9, M4-10, M4-11 and M4-12 (Figure 5.5c).  
Peaks 15 and 16 of metabolite M5 were detected in both technical TBECH and β-TBECH 
assays at an accurate mass of 378.81864 with predicted chemical formula of C8H11Br3O2
 
(Figures 5.5e and 5.5f). As their retention times were shorter than that of most other 
monohydroxylated and dihydroxylated metabolites, we hypothesized they were 
carboxylated TriBECH metabolites (i.e. bromo-(1,2-dibromocyclohexyl) acetic acid or 
DBCBA) formed via α-oxidation mechanism (Figure 5.6). The oxidative reaction starts 
at Cα, transforming the terminal bromomethyl group initially to an aldehyde with 
subsequent oxidation to the carboxylic acid. This mechanism is similar to previous reports 
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of metabolic α-oxidative dehalogenation of structurally-similar halogenated compounds 
such as halothane (Kharasch et al., 1996) and tris-2-chloroethyl phosphate (TCEP) 
(Abdallah et al., 2015). The aldehyde intermediate (Figure 5.6) however could not be 
identified in our samples. This is similar to the results of a previous metabolic study on 
TCEP using human hepatocyte cell lines, where the inability to identify the aldehyde form 
was attributed to potential rapid oxidation to the corresponding carboxylic acid (Abdallah 
et al., 2015). 
Based on the tentatively identified metabolites, we propose here the CYP450 mediated 
metabolic pathways of TBECH by HLM (Figure 5.6): (1) hydroxylation, (2) 
debromination, and (3) α-oxidation. 
Figure 5.6: Proposed metabolic pathways of TBECH by Human Liver Microsomes 
 
 
5.5. Kinetics of TBECH metabolism by HLM  
Following metabolite identification, a series of assays with different technical TBECH 
and pure β-TBECH concentrations (1, 2, 5, 10 and 15 µM) were performed. Due to the 
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lack of authentic standards for the metabolites, they were semi-quantified using the 
response factor of the parent compound. The concentrations obtained were subjected to 
metabolic rate modelling (including Michaelis-Menten, Hill and substrate inhibition 
approaches) by nonlinear regression analysis using SigmaPlot Enzyme Kinetics Module 
v1.1 (Systat Software Inc., Richmond, CA). We considered two statistical criteria: Akaike 
Information Criterion corrected for small sample size (AICc) and standard deviation of 
the residuals (Sy.x) to evaluate the goodness of fit. The best fit model was chosen as the 
one with lowest values for both AICc and Sy.x. SigmaPlot results indicated that non-linear 
regressions of monohydroxy-TBECH, dihydroxy-TBECH and monohydroxy-TriBECH 
as well as their β isomer counterparts were best fitted to a Michaelis-Menten model 
(Figure 5.7).  
It should be noted that while monohydroxy-TBECH is a primary metabolite of the 
TBECH substrate, the lack of authentic metabolite standards precludes the confirmation 
of whether dihydroxy-TBECH and monohydroxy-TriBECH are primary and/or 
secondary metabolites. Therefore, the estimated kinetic parameters for dihydroxy-
TBECH and monohydroxy-TriBECH should be treated with caution as they were derived 
assuming a primary metabolite status only. 
Table 5.2: Kinetic parameters derived from non-linear regression (Michaelis-
Menten model) of the formation of metabolites resulting from incubation of the 
TBECH mixture and β-TBECH with human liver microsomes 
Metabolite Km (µM) ± SD 
Vmax (pmol/min/mg 




OH-TBECH 11.78 ± 4 162.5 ± 29.6 13.8 
(OH)2-TBECH 2.2 ± 1 0.64 ± 0.08 0.3 
OH-TriBECH 3.4 ± 0.82 10.1 ± 0.8 3 
β-TBECH 
OH-β-TBECH 16.5 ± 7.1 4991.7 ± 1339.8 302.5 
(OH)2-β-TBECH 12.3 ± 7.5 14.1 ± 4.9 1.1 




The model parameters derived from non-linear regression provided useful insights into 
the metabolic fate of TBECH in humans (Table 5.2). Apparent Vmax values (maximum 
metabolic rate) for the formation of monohydroxy-TBECH, dihydroxy TBECH and 
monohydroxy-TriBECH were 162.5, 0.64 and 10.1 pmol/min/mg protein, respectively 
(Table 5.2). This indicates monohydroxy TBECH is the major metabolite formed in vitro 
by human liver microsomes. The only available information on toxicokinetics of this 
flame retardant suggested rapid in vivo metabolism of β-TBECH in brown trout. 
Depuration of the β-isomer obeyed first order kinetics with half-lives of 22.5 ± 10.4 (low 
dose), 13.5 ± 5.9 (medium dose) and 13.8 ± 2.2 (high dose) days (Gemmill et al., 2011). 
In the present study, the observed in vitro metabolic clearance rate for β-TBECH was 
significantly higher (P < 0.05) than that of the TBECH mixture. 
Maximum metabolic formation rates of OH-β-TBECH, (OH)2-β-TBECH and (OH)-β-
TriBECH were 4991.7, 14.1 and 66.1 pmol/min/mg protein, respectively (Table 5.2); 
equivalent to 31, 22 and 6.5 times the corresponding metabolite formation rate resulting 
from exposure to the technical TBECH mixture. There are several plausible reasons for 
this observation including: (a) slower metabolism of the α-TBECH in the technical 
mixture and (b) alteration of the stereoselective enzymatic metabolism process by the 
presence of a larger number of stereoisomers, or even other chemicals/impurities in the 
TBECH mixture. Nevertheless, β-TBECH was metabolized by in vitro HLM at a faster 
rate than the TBECH mixture. Given the simultaneous exposure of hepatic cells to a large 
number of xenobiotics under real-life conditions, the in vivo metabolic and clearance rates 




Figure 5.7: Kinetic analysis of TBECH mixture (A) and β-TBECH (B) metabolite formation rate by human liver microsomes using 
the Michaelis-Menten model. 
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As the rates of OH-TBECH, (OH)2-TBECH and OH-TriBECH formation were best described 
by the Michaelis Menten model, we used the corresponding equations in section 2.4.3 to 
estimate the intrinsic in vitro hepatic clearance of TBECH and β-TBECH as following: 
𝐶𝐿𝑖𝑛𝑡−𝑜𝑟𝑔𝑎𝑛 = 𝐶𝐿𝑖𝑛𝑡 × 𝑝 × 𝑤  
Where CLint-organ is the intrinsic in vitro clearance of a xenobiotic by an organ on kilogram 
human body weight, p is the amount of protein per gram of an organ and w is the average 
weight of that organ per kilogram body weight. For human liver microsomes, p = 52.5 mg 
protein/g liver and w = 25.7 g liver/kg b.w (Manevski et al., 2014). 
The hepatic blood flow per kilogram body weight (kg b.w) Qh = 20.7 ml/min/kg. bw (Manevski 
et al., 2014) was taken into account for extrapolation of in vitro clearance to in vivo clearance 




   
The intrinsic in vitro hepatic clearance (CLint) of the TBECH mixture due to the formation of 
OH-TBECH, (OH)2-TBECH and OH-TriBECH were estimated as 13.8, 0.3 and 3 µL/min/mg 
protein, respectively. By comparison, those of β-TBECH were 302.5, 1.1 and 18.4 µL/min/mg 
protein, respectively. The total CLint-liver from metabolic formation of all three major 
metabolites was then calculated: 23 mL/min/kg body weight (b.w) for the TBECH mixture and 
434.45 mL/min/kg b.w for β-TBECH.  
Despite the lack of authentic standards for TBECH metabolites, leading to the semi-
quantitative nature of these measurements, the calculated hepatic clearance rates clearly show 
that β-TBECH was biotransformed at a much faster rate than the TBECH mixture. Despite 
reservations on the accuracy of direct extrapolation from in vitro to in vivo clearance due to 
simultaneous exposure to a large number of chemicals in vivo, we applied Equation 9 (section 
2.4.3) to shed some light on the in vivo hepatic clearance of TBECH in humans. Our model 
calculations revealed an in vivo hepatic clearance (CLh ) of 13.5 mL/min/kg b.w for the TBECH 
mixture, while the rapid hepatic clearance of β-TBECH was dependent on the hepatic blood 
circulation (Qh) (i.e. flow limited). 
5.6. Conclusions 
To our knowledge, this is the first study of TBECH metabolism by human liver microsomes. 
Our results demonstrated that TBECH was metabolized by human liver microsomes forming 
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a complex mixture of metabolites via cytochrome P450 enzyme-catalyzed hydroxylation and 
debromination. This is the first time that a monohydroxylated debrominated metabolite of 
TBECH has been detected in vitro. The other detected metabolites were OH-TBECH, (OH)2-
TBECH, (OH)2-TriBECH and DBCBA. substrate concentration-dependent assays showED 
OH-TBECH to be the major primary metabolite. The differences in TBECH metabolite profiles 
resulting from incubation with HLM (this study) and RLM (Chu et al., 2012) underscore inter-
species variation in xenobiotic metabolism. In general, higher levels of all metabolites were 
observed in our HLM experiments than reported previously using RLM. The metabolic rates 
of OH-TBECH, (OH)2-TBECH and OH-TriBECH were found to best fit to the Michaelis-
Menten model by non-linear regression analysis. Separate pure β-TBECH microsomal assays 
also demonstrated that β-TBECH was metabolized much faster than the technical TBECH 
mixture. However, authentic standards of α-TBECH and the metabolites are needed to 











Chapter 6  
EH-TBB and Firemaster 550 






EH-TBB and a mixture of EH-TBB, BEH-TEBP and TPhP (prepared in a ratio similar to 
that in the FireMaster 550 commercial mixture – FM550) were exposed to human skin 
S9 fractions to evaluate their extra-hepatic in vitro metabolism for the first time. After 60 
mins of incubation, one metabolite of EH-TBB and one metabolite of TPhP were 
identified. The metabolic profile of EH-TBB and TPhP indicated extra-hepatic 
biotransformation of these chemicals was catalyzed by esterases rather than cytochrome 
P450 enzymes. The metabolite formation rate of EH-TBB both as an individual standard 
and as a component of the FM550 mixture followed the Michaelis Menten model. In vitro 
– in vivo organ clearance extrapolation implied that metabolism of EH-TBB by human 
skin is marginal in comparison with that in human liver. However, further studies are 
required to understand the importance of metabolism by skin in the context of human 
dermal exposure to organic pollutants. 
6.2. Introduction 
2-ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB or TBB) is an additive flame 
retardant produced by Chemtura Chemical Corporation. It is available in 2 commercial 
mixtures: Firemaster 550 and Firemaster BZ-54. In Firemaster 550 (FM550) it was mixed 
with bis(2-ethylhexyl) tetrabromophthalate (BEH-TEBP or TBPH), triphenyl phosphate 
(TPhP) and assorted isopropyl triphenylphosphate (ITP) isomers in the ratio: 14 % BEH-
TEBP, 36 % EH-TBB, 18 % TPhP and 32% ITPs by weight (Belcher et al., 2014). As 
additive FRs, EH-TBB and other components of FM550 may leach out from treated 
consumer goods and contaminate the environment. They have been detected globally in 
many environmental matrices including indoor dust (Carignan et al., 2013; Sjödin et al., 
2001; Stapleton et al., 2009), indoor air (Cequier et al., 2014; Takeuchi et al., 2014; Tao 
et al., 2016), outdoor air (Ma et al., 2012), chicken eggs (Zheng et al., 2016), aquatic biota 
(Strid et al., 2013) and foodstuffs (Xu et al., 2015). 
Similar to other NBFRs (as discussed in section 1.1.3), their environmental occurrence is 
expected to be mainly in indoor dust. Residential dust in the UK contained median 
concentrations of EH-TBB and BEH-TEBP at 5.8 and 320 ng/g, respectively (Al-Omran 
and Harrad, 2016). In the U.S, house dust samples from California collected in 2011 
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showed higher levels of FM550 components than those collected in 2006. Specifically, 
concentration ranges of EH-TBB, BEH-TEBP and TPhP in 2011 were 45-5900, <2-3800 
and 790-36000 ng/g, respectively while those in 2006 were 4-740, 36-1900 and 580-
14000 ng/g, respectively (Dodson et al., 2012). Extremely high concentrations of EH-
TBB and BEH-TEBP were reported in dust from an American gymnasium ranging from 
20.8 to 85.6 μg/g for EH-TBB and 17.3 to 44.9 µg/g for BEH-TEBP (Carignan et al., 
2013). 
This is of concern due to the potential toxicity of FM550 components to humans and 
wildlife. Both EH-TBB and BEH-TEBP expressed in vitro antiestrogenic and 
antiandrogenic effects in the yeast estrogen screen and yeast androgen screen assays 
(reflected in inhibition of β-galactosidase production by the assays), as well as increased 
oestrogen production in the human H295R steroidogenesis assays (Saunders et al., 2013). 
By use of primary porcine testicular cells, Mankidy et al., 2014 also observed effects of 
EH-TBB and BEH-TEBP on steroidogenesis, however by different mechanisms; EH-
TBB induced the production of cortisol and aldosterone while BEH-TEBP promoted sex 
hormones synthesis. FM550-administered rats showed many negative health effects e.g. 
advanced female puberty, weight gain, altered exploratory behaviours, hepatic 
carboxylesterases activity, etc (Patisaul et al., 2013). FM550 (mainly driven by the TPhP 
component) was found to bind to human peroxisome proliferator-activated receptor γ 
(PPARγ1) and subsequently induced PPARγ1 transcription activity (Pillai et al., 2014). 
The same study also reported adipogenesis induction in primary mouse bone marrow 
cultures by FM550 and TPhP. 
It is thought that dust ingestion is a major exposure pathway of humans to EH-TBB, BEH-
TBP and TPhP (Christia et al., 2018; Tao et al., 2017). However, recently Abdallah et al., 
2016 reported the importance of dermal absorption as a pathway of human exposure to 
chlorinated organophosphate flame retardants which might even exceed exposure via dust 
ingestion or inhalation exposure. We therefore hypothesised that dermal exposure to 
FM550 components is also significant. Consequently, understanding of the skin 
metabolism pathways, rates and products of EH-TBB and FM550 is important for risk 
assessment of human exposure to these chemicals. In this study, we aim to investigate the 
extra-hepatic biotransformation of EH-TBB and FM550 in vitro by human skin S9 




6.3.1. Chemicals and Standards 
All solvents and reagents used in this study were purchased from Fisher Scientific 
(Loughborough, UK) and were of HPLC grade or higher. 2-Ethylhexyl-2,3,4,5-
tetrabromobenzoate (EH-TBB) and  bis(2-ethylhexyl) tetrabromophthalate (BEH-TEBP) 
for dosing solutions was obtained as neat solutions from Accustandard, Inc. (New Haven, 






13C-BEH-TEBP), tetrabromobenzoic acid (TBBA), 13C-
labelled tetrabromobenzoic acid (13C-TBBA ) and α-1,2,5,6,9,10-hexabromo[13C12-
]cyclododecane] (13C-α-HBCDD) were purchased from Wellington Laboratories (Guelph, 
ON, Canada). Triphenyl phosphate-d15 (TPhP-d15) was purchased from Sigma Aldrich 
(Dorset, UK). RapidStart NADPH regenerating system was purchased from XenoTech 
(Kansas, KS, USA), William’s E medium was obtained from Thermo Fisher Scientific 
(Paisley, UK) and human skin S9 fractions (HS-S9) was purchased from Biopredic 
International (Saint Grégoire, France). The HS-S9 was prepared from the skin of a 45 
years old Caucasian female (the specific skin location, area or thickness was not provided). 
Liquid nitrogen was used to deliver and store HS-S9. 
Individual EH-TBB dosing solution was prepared by dissolving EH-TBB in dimethyl 
sulfoxide (DMSO). The FireMaster 550 (FM550)-equivalent mixture was prepared by 
dissolving EH-TBB, BEH-TEBP and TPhP in the ratio 53:20.5:26.5 by weight in DMSO, 
which was similar to that reported for the technical FM550 mixture (Belcher et al., 2014). 
FM550 solutions were prepared such that each dosing level contained similar 
concentrations of EH-TBB as that in the pure EH-TBB dosing solutions. 
6.3.2. In vitro Incubation Experiments 
Pre-incubations were performed at different HS-S9 concentrations and different times. 
After optimisation of the reaction parameters, the following general exposure protocol 
was applied: 0.11 mg of HS-S9, William’s E medium and 10 µL of EH-TBB/FM550 
dosing solutions (final concentration 10 µM of EH-TBB) were pre-incubated for 5 
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minutes at 37 ˚C. NADPH regenerating system (final concentration: 2.0 mM nicotinamide 
adenine dinucleotide phosphate, 10.0 mM glucose-6-phosphate and 2 units/mL glucose-
6-phosphate dehydrogenase) was added to make a final volume of 1 mL. The samples 
were then incubated at 37 ˚C, 5 % CO2 and 98 % relative humidity for 60 min. At the end 
of the incubation, 1 mL of ice-cold ethyl acetate was added to stop the reaction prior to 
sample extraction. Ethyl acetate was chosen as the quenching reagent instead of methanol 
to minimise false positive metabolite identification for EH-TBB (see section 4.5.2). In all 
incubation experiments, a solvent blank which contained only William’s E medium was 
performed and analysed alongside the sample batch. 
6.3.3. Sample extraction 
Incubated EH-TBB samples were spiked with 20 ng each of 13C-EH-TBB and 13C-TBBA 
while FM550 samples were spiked with 20 ng each of 13C-EH-TBB, 13C-TBBA, 13C-
BEH-TEBP and TPhP-D15 as internal standards. Briefly, samples were mixed with 3 mL 
of ethyl acetate by vortexing for 30 s, followed by ultrasonication for 5 min and 
centrifuged at 4000 g for 5 min. The organic layer was collected and the extraction 
procedure was repeated twice. Ethyl acetate is a very good solvent for esters (i.e. the 
chemicals studied here) as well as relatively polar organic compounds (i.e. potential 
metabolites of EH-TBB, BEH-TEBP and TPhP) and therefore was chosen as extraction 
solvent. The combined extracts were evaporated to dryness under a gentle stream of 
nitrogen then reconstituted in 100 µL of methanol containing 20 ng of 13C-α-HBCDD as 
a syringe standard for QA/QC purposes. 
6.3.4. Instrumental analysis 
The instrumental analysis method was similar to that deployed for NBFRs determination 
and the screening method described in section 3.2.2 with slightly modified MS parameters. 
The optimised MS parameters for the analysis of EH-TBB, FM550 and their potential 





Table 6.1: Optimized Orbitrap parameters for the analysis of EH-TBB, FM550 and 
their potential metabolites by UPLC-Orbitrap MS (LC flow rate 400 μL/min) 
Parameters APCI ESI 
Polarity Neg Pos/Neg switching 
Shealth gas flow rate 25 25 
Aux gas flow rate 5 5 
Sweep gas flow rate 0 0 
Discharge current (μA) 30   
Spray voltage (kV)  4.5 
Capillary temp. (oC) 275 320 
S-lens RF level 50 50 
Aux gas heater temp (oC) 350 350 
Resolution (FWHM) 17500 17500 
AGC target (ions) 1E6 1E6 
Maximum ion injection time (ms) 100 100 
Scan mode Full scan Full scan 
Scan range (m/z) 70-800 70-800 
 
MS data from both ionisation modes was acquired for each sample. Negative APCI was 
used for determination of EH-TBB, 13C-EH-TBB, BEH-TEBP, 13C-BEH-TEBP and 
screening for potential metabolites. The more universal, softer electrospray ionisation 
(ESI) mode was used in positive/negative alternative switching mode for screening and 
identification of the produced metabolites, as well as determination of TPhP and TPhP-
d15. Table 6.2 shows accurate ion masses for monitoring parent compounds and internal 
standards. 
Table 6.2: Monitoring ions for parent compounds and internal standards in 
different ionisation modes of the UPLC-HRAM Orbitrap/MS 
Chemical Mode Ion Type Accurate Mass 
(amu) 
EH-TBB (-)APCI [M-Br+O]- 484.87856 
13C-EH-TBB (-)APCI [M-Br+O]- 508.00539 
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BEH-TEBP (-)APCI [M-Br+O]- 640.99359 
13C-BEH-TEBP (-)APCI [M-Br+O]- 681.22768 
13C-α-HBCDD (-)APCI, (-)ESI [M-H]- 652.67717 




Compound Discoverer 2.0 software (Thermo Fisher Scientific, Bremen, Germany) was 
used to detect potential metabolites and elucidate their chemical formulae, while 
quantification of target compounds was performed using Quan Browser 3.0 (Thermo 
Fisher Scientific, Bremen, Germany). 
6.4. QA/QC 
Metabolic activity of phases I enzymes including NADPH-cytochrome C reductase, 
carboxyl esterase and FMO3 were measured by the provider prior to the HS-S9 batch 
release. Results provided by Biopredic International showed normal activities of all 
enzymes after HS-S9 thawing. 
Quality assurance samples where the William’s E medium was spiked with EH-TBB and 
FM550 at all dosing levels were analyzed, with recoveries of dosing chemicals falling 
between 80 to 115 % of the theoretical dosing concentrations. In incubation experiments, 
internal standard recoveries were within 50-115 %. 
No parent compounds or metabolites were found in instrument and solvent blanks with 
the exception of TPhP at negligible levels (< 1.05% of the lowest dosing level). Therefore, 
no blank correction was needed. Additionally, no metabolites were found in the non-
enzymatic and heat-inactivated blanks. 
6.5. Results 
6.5.1. Metabolic profiles of EH-TBB and FM550 
Due to the structure of EH-TBB, BEH-TEBP and TPhP, we hypothesised that their 
metabolism by HS-S9 would be catalysed by carboxyesterases and/or cyctochrome P450. 
Full scan mode with either negative APCI or ion switching positive/negative ESI were 
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used to screen for EH-TBB and FM550 metabolites. No potential metabolites were found 
in (+)ESI or (-)APCI mode.  
For EH-TBB samples, in (-)ESI mode there was one potential metabolite with the ion 
mass of 436.66814 and the proposed ion formula C7HBr4O2. By comparing with the 
authentic standard, this was confirmed as the [M-H]ˉ molecular ion for TBBA (Figure 
6.1). This is in agreement with a previous study, which reported TBBA as the only in 
vitro metabolite of EH-TBB by human and rat liver microsomes (Roberts et al., 2012). 
Figure 6.1: TBBA and MTBBA in a Human S9 Skin fraction (HS-S9) sample 
exposed to 10 µM of EH-TBB 
 
Similar to HS-S9 exposure to pure EH-TBB, TBBA was also detected as the sole 
metabolite of EH-TBB when HS-S9 was exposed to FM550 mixture.  
In addition, another potential metabolite with the ion mass of 249.03204 was detected in 
(-)ESI mode. The proposed chemical structure for this ion was [C12H10O4P]
-. In order to 
elucidate the chemical structure of this compound, a MS/MS experiment was carried out 
in (-)ESI-SIM-MS2 mode. The ion source parameters were the same as those described 
in section 6.4.3 for (-)ESI mode while MS parameters are described in Table 6.3. 
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Table 6.3: SIM-MS2 parameters for ion 249.03204 by (-)ESI-UPLC-Orbitrap 
HRMS 
MS Parameters Value 
Scan mode SIM-MS2 
SIM 
Inclusion ion (m/z) 249.03204 
Isolation window (m/z) 0.4 
Resolution (FWHM) 17500 
AGC target (ions) 5E4 
Maximum ion injection time (ms) 100 
MS2 
Resolution (FWHM) 17500 
AGC target (ions) 5E4 
Maximum ion injection time (ms) 100 
Stepped Normalised Collision Energy 15, 20, 30 
A combination of low, medium and high collision energies were applied stepwise to 
achieve a diverse range of fragmentation ions. The results from this experiment are shown 
in Figure 6.2 




The ion 249.03204 was fragmented mainly into three ions: 154.98895, 93.03284 and 




-, respectively. Based on the proposed parent ion formula and the 
MS/MS fragment data, this metabolite is identified as diphenyl phosphate (DPhP), which 
is a primary metabolite of TPhP. This was further confirmed via comparison and 
augmentation with an authentic standard of DPhP.  
It was reported that in vitro metabolism of TPhP by human liver microsomes or chicken 
embryo hepatocytes formed DPhP, hydroxylated TPhP (OH-TPhP) and dihydroxylated 
TPhP ((OH)2-TPhP) (Su et al., 2014; Van den Eede et al., 2013). In vivo metabolism of 
TPhP in fish produced DPhP, OH-TPhP, (OH)2-TPhP and monophenyl phosphate 
(MPhP) among which DPhP was the major metabolite (Wang et al., 2016). However in 
this study, we only detected DPhP as the sole metabolite of TPhP by HS-S9. No potential 
metabolites of BEH-TEBP were identified in HS-S9 exposed to FM550 mixture which 
was in line with reported HLM and RLM in vitro studies (Roberts et al., 2012). 
By comparison of the dermal (this study) and hepatic metabolic profiles (Roberts et al., 
2012; Van den Eede et al., 2013) of EH-TBB and TPhP, it was obvious that the oxidative 
metabolites were not observed in the human skin S9 fractions. The metabolic profile of 
dermal S9 fractions show that both CYP450 and carboxylesterases are active, albeit at 
much lower levels than in the liver cells. This is in agreement with previous studies on 
the metabolic activity of human skin cells in comparison with liver cells. The functional 
activity of a CYP450 enzyme on the substrate benzyl-O-methyl-cyanocoumarin was 
reported to be twice as much in human liver than that in the skin (Smith et al., 2018). 
Similarly, hydrolysis rate of p-nitrophenyl acetate by carboxylesterase was 4 times slower 
in human skin than that in human liver (Fu et al., 2016). 
In order to test our hypothesis, we performed the NADPH independent experiment. 
Incubations of EH-TBB and FM550 without NADPH cofactor were carried out with the 
same conditions as described in section 6.3.2. The absence of NADPH did not result in 
significant changes in the formation rates of TBBA, DPhP concentrations or depletion 
rates of the parent compounds (p>0.05). Our results show differences from hepatic 
metabolism as dermal carboxylesterases seem to be more involved in the metabolism of 
the target FRs than CYP450. Therefore it is likely that not CYP enzymes but NADP-
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independent enzymes (e.g. carboxylesterases) catalysed EH-TBB and TPhP metabolism 
in HS-S9 (Figure 6.3). While, this does not eliminate the possibility of oxidative 
metabolite formation upon dermal contact under real-life situations (i.e.e upon exposure 
to larger doses) but if formed, they are likely to be at lower rates and concentrations than 
de-esterified metabolites. Indeed, proteomic profiling of xenobiotic metabolism enzymes 
revealed that the levels of CYP450 enzymes in human skin were at least 300 folds lower 
than that in human liver (van Eijl et al., 2012). In contrast, the relative level of 
carboxylesterase 1 (CES1) in human skin and liver was 0.62 with no significant level 
difference (p=0.21) (van Eijl et al., 2012). Such low level of CYP450 enzymes and similar 
level of CES1 in the skin in comparison with liver might explain why no oxidative 
metabolites were observed in our study. 
Figure 6.3: Proposed metabolic pathways of EH-TBB and TPhP by human skin S9 
fraction 
 
6.5.2. Metabolic kinetics of EH-TBB and FM 550 metabolism by HS-S9 
As discussed in chapter 5, the metabolic rates of TBECH were largely dependent on 
whether the human liver microsomes were challenged with pure β-TBECH isomer or 
technical TBECH mixture (containing both α- and β-TBECH as well as other potential 
chemical residues). Therefore, following metabolite identification, a series of assays with 
different concentrations of EH-TBB and FM550 (Table 6.4) were performed. With this 
experiment, we aimed to investigate whether the metabolic rate will be different upon 
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challenging the HS-S9 with a multi-component mixture representing FM550 formula (i.e. 
mimicking real-life situation) than upon exposure to a single compound (EH-TBB) and 
what is the effect of the multi-components (e.g. synergistic or antagonistic) on the kinetics 
of dermal metabolism of these compounds. The concentrations of TBBA and DPhP were 
quantified using an isotope dilution series method with 13C-TBBA as internal standard.  




EH-TBB (μM) FM550 
EH-TBB (μM) BEH-TEBP (μM) TPhP(μM) 
1 1 1 0.3 0.84 
2 2 2 0.6 1.68 
3 5 5 1.5 4.2 
4 10 10 3 8.4 
5 15 15 4.5 12.6 
 
The results from enzymatic kinetic modelling in Sigmaplot indicated that the formation 
of TBBA in both pure EH-TBB and FM550 mixture experiments was best described by 
Michaelis Menten model (Figure 6.4). 
Figure 6.4: Kinetic analysis of TBBA formation of EH-TBB (A) and FM550 mixture 




Table 6.5: Kinetic parameters derived from non-linear regression (Michaelis-
Menten model) of the formation of TBBA resulting from incubation of HS-S9 with 
pure EH-TBB and FM550 mixture in this study and comparison with EH-TBB 
incubation with HLM (Roberts et al. 2012) 
Substrate Model Km (µM) ± 
SD 
Vmax (pmol/min/mg protein) ± 
SD 
Reference 
EH-TBB HS-S9 25.7 ± 12.2 15.2 ± 5 This study 
FM550 HS-S9 0.84 ± 0.19 1.08 ± 0.05 This study 
EH-TBB HLM 11.1 ± 3.9 644 ± 144 Roberts et al., 
2012 
The metabolic parameters derived from the Michaelis-Menten model are presented in 
Table 6.5. Estimated maximum metabolic rate Vmax for the formation of TBBA by HS-
S9 exposed to FM550 were significantly lower (p<0.05) than to individual EH-TBB (1.08 
and 15.2 pmol/min/mg protein, respectively). However in both cases, Vmax was still much 
smaller than what observed previously in HLM (644 pmol/min/mg protein) (Roberts et 
al., 2012). It is also important to note that the Michaelis constant Km for FM550 is much 
lower than Km for EH-TBB metabolism by HS-S9 (Table 6.5). Such significant decreases 
in both Km and Vmax suggested that the formation of TBBA from FM550 by HS-S9 has 
potentially been inhibited by competitive inhibitor(s). Such inhibitors could be BEH-
TEBP, TPhP or impurities in the FM550 dosing solution. 
The formation rate of DPhP, on the other hand, did not fit into any assessed enzyme 
kinetic model (Michaelis-Menten, Hill or substrate-inhibition). Indeed, it did not show 
any signs of reaching a plateau to indicate a steady state was reached (Figure 6.5). Another 
series of bioassays with higher doses of FM550 were carried out at equivalent TPhP 
concentrations of 16.8, 25 and 33.6 μM. Close to linearity increment of DPhP formation 
rate was still observed (data not shown). Such observation is in agreement with previous 
study on kinetic profile of TPhP biotransformation in human serum where formation rate 
of DPhP did not reach a plateau even up to 100 μM of TPhP was used (Van den Eede et 
al., 2016). This precluded the estimation of metabolic kinetic parameters for TPhP under 
the applied experimental conditions. 
151 
 
Figure 6.5: Kinetic analysis of DPhP formation from FM550 mixture by human skin 
S9 fractions 
 
6.5.3. In vitro – in vivo extrapolation for clearance of EH-TBB 
As the formation rates of TBBA were best described by the Michaelis Menten model, the 
equations in section 2.4.3 were employed to estimate in vivo extra-hepatic clearance and 
compare with estimated in vivo hepatic clearance of EH-TBB (data for hepatic clearance 
estimation were obtained from Roberts et al., 2012). Metabolic clearance was estimated 
for an adult with average body weight (70 kg). The following parameters were applied: 
24.84 mg protein/g skin for HS-S9 (Jewell et al., 2007, calculated as total of microsomes 
and cytosol), 37 g skin/kg b.w, 52.5 mg protein/g liver for HLM, 25.7 g liver/kg b.w, Qh 
= 20.7 mL/min/kg b.w and Qskin = 4.37 mL/min/kg b.w (Manevski et al., 2014). The 
results for estimated in vitro and in vivo clearance of EH-TBB are shown in Table 6.6. 
Table 6.6: Estimated in vitro and in vivo clearance of EH-TBB by human skin (this 
study) and human liver (Roberts et al., 2012) 
Chemical Organ CLint-organ (in vitro, 
mL/min/kg b.w) 
CLorgan (in vivo, 
mL/min/kg b.w) 
EH-TBB Skin 0.54 0.48 
EH-TBB in FM550 Skin 1.18 0.92 




























Our model calculations estimated in vivo extra-hepatic clearance of individual EH-TBB 
and EH-TBB in FM-550 by human skin to be 0.48 and 0.92 mL/min/kg b.w, respectively. 
It was much smaller than the skin blood flow (4.37 mL/min/kg b.w), suggesting EH-TBB 
was not efficiently cleared by dermal metabolism. Indeed, the extraction ratios (defined 
as the ratio between the in vivo clearance of a xenobiotic to the blood flow for a specific 
organ) of EH-TBB by human skin were only 11 % and 21 % for individual and mixture 
exposures respectively. In contrast, human liver showed excellent EH-TBB extraction 
ratio up to 80 % with in vivo hepatic clearance of 16.4 mL/min/kg b.w. These results 
suggested that dermal metabolism contributed marginally to the clearance of internal EH-
TBB body burden in comparison with liver metabolism. 
6.5.4. Implications for human exposure 
Even though the outermost layer of skin (stratum corneum) serves as a barrier to prevent 
unwanted chemicals from entering our body, recent studies have confirmed the dermal 
uptake of many lipophilic pollutants such as HBCDDs, TBBPA, chlorinated 
organophosphate flame retardants or novel brominated flame retardants via contact with 
skin (Abdallah et al., 2015; Abdallah et al., 2016; Frederiksen et al., 2016; Knudsen et al., 
2017). Frederiksen et al. reported roughly 10 % dermal absorption and 0.1 %-0.2 % 
penetration of several FRs including EH-TBB following a single dose (of several hundred 
nanograms) onto ex vivo human skin for 72 h (Frederiksen et al., 2016). Higher skin 
absorption at 20 % with 0.2 % penetration into receptor fluid (mimicking blood flow) of 
administered 14C-labelled EH-TBB onto in vitro human skin after 24 h were observed 
(Knudsen et al., 2017). Nevertheless, it is proven that EH-TBB as well as other organic 
contaminants could pass by the skin barrier and be “trapped” in the skin without reaching 
the blood circulation. In such an event, skin metabolism may play an important role in 
the clearance of the trapped dose within the skin tissue, yet it may also help create a 
concentration gradient through the different layers of the skin tissue to facilitate further 
uptake of the parent flame retardant. Abdallah et al., 2016 highlighted the significance of 
the dermal pathway of human exposure to dust-bound organophosphate contaminants, 
which might be even more significant if dermal metabolism is considered. As EH-TBB 
is found mainly in indoor dust (see section 1.1.3), it is believed dermal uptake via contact 
with indoor dust is also an important human exposure pathway to this compound. 
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However, the slow in vitro clearance rates in the skin could translate into slow EH-TBB 
in vivo percutaneous metabolism and subsequently results in inefficient EH-TBB 
elimination from the skin, which explains the reported dermal penetration of 0.2 % of 
applied EH-TBB unchanged through human skin (Knudsen et al., 2017). Therefore, more 
studies about dermal exposure and metabolism of emerging contaminants and specifically 
EH-THB are recommended. 
6.6. Limitations of this study 
It is important to note that the skin HS-S9 was prepared from a single donor. There might 
be a large bias in metabolic activity depending on the skin location, age, race and gender. 
Additionally, our calculations were based on several assumptions which may introduce 
uncertainties to the study. Firstly, the unbound fraction of the pollutant to blood proteins 
was equal to 1, meaning all EH-TBB in the blood was free and available for metabolism. 
This might cause overestimation of xenobiotics clearance. Secondly, the hematic 
concentration of a substrate was much smaller than its corresponding Km. Finally, TBBA 
was the only metabolite of EH-TBB. While our findings and data in literature support this 
assumption, it is possible that other metabolites were formed but not detected (e.g. 
debrominated EH-TBB or debrominated TBBA). 
6.7. Conclusions 
To our knowledge, this is the first study of EH-TBB and FM550 metabolism by human 
skin S9 fractions. Our in vitro experiments demonstrated that extra-hepatic dermal 
metabolism occurs for EH-TBB and TPhP, mainly via NADPH-independent 
carboxylesterases forming TBBA and DPhP, respectively. The rate and efficiency of 
metabolism of EH-TBB by human skin is much smaller than reported for the human liver. 
This implies that in vivo clearance of EH-TBB is marginal via dermal metabolism in 
comparison with hepatic metabolism. Additionally, the dermal metabolic rate observed 
when exposure is to individual chemical components, is altered when exposure occurs 
via a multi-component mixture of chemicals. Specifically, we observed a higher rate of 
clearance for EH-TBB alone compared to EH-TBB when applied as a mixture reflecting 
FM550, which might be partially explained by the very high metabolic rate for TPhP (i.e. 
competitive substrate inhibition). Finally, the dermal metabolism of EH-TBB and FM550 
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is likely to have implications for the human dermal exposure to these FRs via contact with 
contaminated dust or consumer items (e.g. furniture upholstery, toys, etc.) in real-life 




Chapter 7  





Novel brominated flame retardants (NBFRs), pharmaceutical and personal care products 
(PPCPs) are two of the emerging contaminant groups that have been brought to the 
attention of the public and scientific community recently. NBFRs are a group of 
brominated organic pollutants widely added to polyurethane foam, textiles, plastics and 
electronic equipment to increase their fire resistance. Their ubiquity in the environment 
together with their persistent, bioaccumulative and toxic potential have caused great 
concern (Feng et al., 2013; Harrad et al., 2008; La Guardia et al., 2012; Saunders et al., 
2015a, 2015b; Tao et al., 2017). To date, there are very few data on human exposure to 
NBFRs and those data are limited to some common NBFRs such as EH-TBB, BEH-TEBP, 
DBDPE and BTBPE. Additionally, there is a substantial gap in knowledge of NBFRs 
metabolism in humans. PPCPs on the other hand are designed for human and/or animal 
use and therefore their biosafety profiles are often available. However, they have recently 
attracted attention due to their detection in various environmental compartments at 
relatively high concentrations (Ali et al., 2018; Blair et al., 2013; Fisch et al., 2017; 
Mirzaei et al., 2018; Thomas and Hilton, 2004). PPCPs consist of hundreds of chemicals 
and consequently pose a substantial analytical chemistry challenge to study their 
environmental fate.  
Given the above, the main objective of this work was to develop analytical methods using 
advanced mass spectrometry (ultra performance liquid chromatography couple to 
Orbitrap high resolution mass spectrometry in particular) for simultaneous determination 
of a wide range of NBFRs or PPCPs in environmental samples in one run. NBFR 
metabolites/degradation products screening was also included in the NBFRs method. 
Secondary objectives were to apply the developed analytical methods to real 
environmental samples to provide novel insights into the levels, profiles and 
biotransformation/degradation products of the studied emerging contaminants in the 
environment and humans.  
The main achievements and outcomes of this research are summarised below:  
 A high throughput analytical method (PPCPs method) was developed for 
determination of 29 PPCPs by alternate switching (+)/(-)ESI-UPLC-Orbitrap 
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HRMS in one run, with possibility to extend the target list upon availability of 
authentic standards. Excellent method accuracy, precision, repeatability and 
reproducibility were obtained.  
 The PPCPs method was applied to assess the level of these contaminants in 
effluent and surface water samples collected in Assiut city, Egypt. Our results 
revealed that multiple PPCPs are ubiquitous in Egyptian water samples. In 
effluent samples, analgesics, NSAIDs, antidiabetics and antibiotics were found at 
high concentrations: acetaminophen ranged from 978 to 16,000 ng/L, followed by 
ibuprofen (812-6,700 ng/L), glyburide (550-4,160 ng/L), metformin (168-5,610 
ng/L), trimethoprim (271-2,740 ng/L) and diclofenac sodium (79-3,610 ng/L). 
The effluent sample collected from a hospital wastewater treatment plant showed 
extremely high level of acetaminophen, ibuprofen and metformin at 16,000, 6,700 
and 5,610 ng/L, respectively which implied more efficient water treatment 
processes are needed to remove PPCPs at this location. In surface water sample, 
analgesics, antidiabetics, antibiotics and nicotine showed higher concentrations 
than other detected PPCPs: acetaminophen was measured at a mean concentration 
of 495 ng/L, followed by glyburide (394 ng/L), trimethoprim (191 ng/L) and 
nicotine (190 ng/L).  
 An analytical method (NBFRs method), which combined both targeted and 
untargeted approaches to both determine NBFRs and screen for NBFRs 
metabolites/degradation products together with brominated contaminants in one 
run, was developed using (-)APCI-UPLC-Orbitrap HRMS. This method utilized 
the high mass accuracy of the Orbitrap platform coupled with the power of 
bioinformatic software (i.e. Compound Discoverer™) to screen for brominated 
contaminants including NBFRs metabolites/degradation products while the native 
manufacturer software Xcalibur was used for targeted analysis. 
 The NBFRs method was applied to the study of simulated leachate samples 
derived from mixed waste electrical and electronic equipment, whole LCDs/CRTs 
and whole fridges/freezers. BDE-47, BDE-99, BDE-183, BDE-209, DBDPE, 
BTBPE, TBP, TBP-AE, HBCDDs and TBBPA were detected in these samples 
via our targeted approach. Among the detected BFRs, BDE-209, DBDPE, 
TBBPA and 2,4,6-TBP were present in almost every sample. PBDEs other than 
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BDE-209 were occasionally found - mostly in leachate from fridges/freezers - 
while BTBPE was mainly detected in samples from mixed waste electrical and 
electronic equipment. Untargeted analysis of the same samples revealed 5 
potential degradation products of TBBPA: dibromobisphenol A, 
tribromobisphenol A, methoxylated TBPPA, methoxylated dibromobisphenol A 
and chlorinated TriBBPA.  
 In vitro bioassays were successfully designed and applied to provide new insights 
into the metabolism of EH-TBB by mouse liver microsomes, TBECH by human 
liver microsomes and EH-TBB and Firemaster 550 (comprising EH-TBB, BEH-
TEBP and TPhP) by human skin S9 fractions. The in vitro samples were extracted 
by a QuEChERS method then analysed by the NBFRs method. 
 TBECH metabolism by human liver microsomes was studied for the first time. 
TBECH was metabolized in vitro by HLM via cytochrome P450 enzyme-
catalyzed hydroxylation and debromination to produce mono- and di-
hydroxylated TBECH, mono- and di-hydroxylated TriBECH as well as an α-
oxidation metabolite bromo-(1,2-dibromocyclohexyl)-acetic acid with mono-
hydroxylated TBECH the major metabolite. The metabolic rates of OH-TBECH, 
(OH)2-TBECH and OH-TriBECH were found to best fit to the Michaelis-Menten 
model by non-linear regression analysis. Separate pure β-TBECH microsomal 
assays showed that β-TBECH was metabolized much faster than the technical 
TBECH mixture possibly due to slower metabolism of the α-TBECH in the 
technical mixture and/or alteration of the stereoselective enzymatic metabolism 
process by the presence of a larger number of stereoisomers, or even other 
chemicals/impurities in the TBECH commercial mixture. The in vitro and in vivo 
hepatic clearance of the TBECH mixture and the β-TBECH isomer was also 
estimated. Our model calculations revealed an in vivo hepatic clearance rate of 
13.5 mL/min/kg b.w for the TBECH mixture, while the rapid hepatic clearance 
rate of β-TBECH (20.7 ml/min/kg. bw) was dependent on the hepatic blood 
circulation.  
 EH-TBB was metabolized to TBBA in vitro by mouse liver microsomes. It is 
important to note that methylation of TBBA to produce TBMB can take place 
when ice-cold methanol is used as stopping agent in the presence of mouse liver 
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microsomes and NADPH. This may refer to methylation of TBBA as a phase II 
metabolic reaction in vivo via methyl transferase enzymes. However, this cannot 
be confirmed via our in vitro protocol, using only mouse liver microsomes to 
investigate phase I metabolic reactions.  
 Human skin S9 fractions metabolized EH-TBB into TBBA and TPhP to DPhP in 
vitro via carboxylesterase not CYP450. Enzymatic kinetic modelling revealed that 
the metabolic rate of EH-TBB was significantly inhibited by the presence of other 
chemicals e.g. BEH-TEBP, TPhP or chemical impurities. The formation rate of 
TBBA from EH-TBB by HS-S9 was best fitted to the Michaelis-Menten model 
by non-linear regression analysis. On the other hand, the formation rate of DPhP 
showed close to linearity increment with increasing TPhP dosing concentration. 
In vitro – in vivo extrapolation suggested that extra-heptatic clearance rates of 
individual EH-TBB and EH-TBB in FM-550 by human skin were 0.48 and 0.92 
mL/min/kg b.w, respectively and were much smaller than the skin blood flow 
(4.37 mL/min/kg b.w). The extraction ratios of EH-TBB by human skin were 
calculated as 11 % and 21 % for individual and mixture exposures respectively. 
The slow in vivo clearance rates in the skin could translate into slow EH-TBB 
percutaneous metabolism and subsequently results in inefficient EH-TBB 
elimination from the skin. 
7.2. Research gap and future perspectives. 
We developed analytical methods for simultaneous analysis of multiple emerging 
contaminants and their potential degradation/transformation products in one run by 
UPLC-Orbitrap HRMS which provides a great analytical tool for assessment of such 
contaminants in the environment. Additionally, new insights into hepatic and extra-
hepatic biotransformation of TBECH, EH-TBB and TPhP were also revealed. 
However, there remain significant research gaps that need to be addressed as follows: 
 A wider range of contaminants should be included into the target list of the 
developed methods. 
 A HRMS library for environmental contaminants, especially in APCI 
ionization mode, is needed for more effective contaminant screening. 
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 More data on concentrations and profiles of various NBFRs and PPCPs in 
various environmental matrices is required to fully assess their risk to the 
environment and humans. 
 More knowledge about human biotransformation pathways/rates of NBFRs, 
both hepatic and extra-heptatic, is required to fully understand their 
implications for human exposure to these chemicals through multiple 
pathways and the potential toxicity arising from the produced metabolites. 
 A close to realistic approach (exposure to real-life chemical mixtures) is 
required to study the distribution, metabolism, clearance and toxicokinetics of 
emerging contaminants. 
 Investigating the human bioavailability and/or bioaccessibility of NBFRs via 
dermal contact. 
 Assessment of the environmental fate and behaviour of PPCPs post-water 
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